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Abstract 
The destruction of articular cartilage is a central feature of arthritis. The activity 
of collagenase enzymes, induced by pro-inflammatory cytokines, is a key step 
in this process. Collagenases have been targeted therapeutically but trials have 
not proven beneficial due to off-target effects. Understanding the signalling 
consequences which drive the expression of these proteolytic enzymes is 
therefore a major area of research. The aim of the present study was to 
elucidate the signalling events that regulate collagenase expression, focusing 
on the role of a small family of serine/threonine kinases termed protein kinase D 
(PKD). 
To understand the role of the individual PKD isoforms in the modulation of 
collagenase gene expression, each isoform was selectively silenced. Using a 
model of the pro-inflammatory milieu prevalent in arthritic disease, the 
consequences of isoform specific gene silencing on the expression of MMP-1 
and MMP-13 was studied in primary chondrocytes stimulated with IL-1 in 
combination with OSM. Data suggest PKD1 to be ‘anabolic’, with gene silencing 
leading to increased collagenase gene expression. PKD2 was shown not to 
significantly modulate the collagenase expression, whereas, PKD3 silencing 
markedly reduced the collagenase gene expression.  
To understand the signalling consequences orchestrated by each isoform of 
PKD, the role each isoform in the regulation of signalling pathways known to 
modulate collagenase gene expression was examined. PKD1 and PKD3 
silencing both abrogated the phosphorylation of the MAPK signalling pathways 
(ERK, JNK and p38). PKD3 silencing also led to decreased STAT-1 and STAT-
3 serine phosphorylation. This contrasted with the effects of PKD1 silencing, in 
which STAT-1 serine and tyrosine phosphorylation increased, as well as 
increased Akt and p65 phosphorylation being observed. These opposing roles 
may explain the differences in the regulation of collagenase gene expression 
between each isoform. To further understand this modulation the expression of 
the AP-1 components, Fos and Jun were examined, along with other recently 
identified post-AP-1 factors (ATF3, EGR2 NFATc1, and BMP-2). Data showed 
PKD3 silencing to reduce their expression, suggesting a potential mechanism 
by which PKD3 signalling can modulate MMP expression. In conclusion, this 
work identifies the distinct individual roles of PKD isoforms in the modulation of 
collagenase gene expression, illustrating the need to assess individual kinases 
within a family.  
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1 Chapter 1. Introduction 
1.1 The joint 
Arthritis is a progressive disease of load bearing joints. The main type of joint 
found within the body are synovial joints which are composed of a number of 
tissue types and fluids. These include articular cartilage, the capsule, the 
synovium, synovial fluid, tendon, ligament and subchondral bone. In addition, in 
joints such as the knee, the fat pad, menisci and patella are present. Joint 
homeostasis is crucial, with damage, changes in load bearing and the infiltration 
of inflammatory mediators all lead to changes in joint pathology. Imbalance in 
this homeostasis leads to arthritic disease which is seen to be detrimental to the 
joint (see Figure 1.3. for differences between diseased and healthy joints).    
1.2 Human articular cartilage 
Articular cartilage is a smooth friction-less surface that coats the articulated 
surfaces of bones. This tissue is unique in the fact that it is avascular, 
alymphatic and anerual. Embedded within this tissue is the sole cell type, the 
chondrocyte. These cells derive their nutrients and remove their waste products 
by diffusion through the extracellular matrix (ECM) to the synovial capsid and 
fluid (Rowan and Young, 2007). Articular cartilage derives its mechanical 
properties from its ECM (Buckwalter et al., 2005). Water contributes up to 70% 
of the wet weight of articular cartilage. Interactions between water and the many 
macromolecules which cartilage comprises of, influences the mechanical 
properties of the tissue. Collagens, proteoglycans, non-collagenous proteins 
and glycoproteins make up 20-40% of the wet weight (Pearle et al., 2005). The 
composition of these macromolecules gives the cartilage the ability to absorb 
and distribute high compressive forces.  
Collagen, the most widely expressed protein within the body, provides a fibrillar 
meshwork that gives form and tensile strength to the cartilage. Proteoglycans 
and non-collagenous proteins can bind or become mechanically entrapped 
within this mesh, while water fills the interstitial space. Type II collagen is the 
primary collagen within articular cartilage, accounting for around 90% of all 
collagen molecules (Pearle et al., 2005). Type II collagen is composed of 3 
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identical αI polypeptide chains that intertwine to form a triple helix. The triple 
helix align to form collagen fibrils; these fibrils provide the framework for the 
collagen meshwork (Shoulders and Raines, 2009). This is stabilised by internal 
crosslinking between molecules. Type XI collagen, another cartilage specific 
fibrillar collagen, covalently binds to type II collagen, aiding in the stability of the 
meshwork (Buckwalter et al., 2005). Type IX collagen is another cartilage 
specific collagen which does not form fibrils but binds to the surface of the type 
II/type XI fibril (Kuettner, 1992). Type X collagen is found in the zone of calcified 
cartilage and is synthesised only by hypertrophic cells. Type X collagen has 
been described as an indicator of chondrocyte differentiation to bone (Aigner et 
al., 1993).  
Proteoglycans resist compression and generate turgidity due to their affinity for 
water. Aggrecan is the predominant proteoglycan found within articular cartilage 
and is non-covalently bound to hyaluronic acid via a link protein. This provides 
the osmotic properties that are needed for articular cartilage to resist 
compressive loads (Martel-Pelletier et al., 2008). It has a high sulphated 
glycosaminoglycan (GAG) content, which is negatively charged, drawing water 
into the tissue. The osmotic properties of aggrecan, along with the meshwork of 
collagen fibrils, form the structure and provide the tensile properties of cartilage. 
Other molecules such as decorin, biglycan, laminin, tenascin, Cartilage 
oligomeric matrix protein (COMP) and fibromodulin assist in maintaining tissue 
structure through the spatial organisation of the ECM (Temenoff and Mikos, 
2000). Figure 1.1 is a representative diagram of the extracellular matrix of 
cartilage. 
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Figure 1.1. The extracellular matrix of cartilage. The extracellular matrix of cartilage consists 
of two major load-bearing macromolecules: collagen and proteoglycan. Of these; type II 
collagen and aggrecan are the major components. Smaller classes of macromolecules are 
present and aid in the tensile strength of cartilage. Embedded within the ECM is the sole cell 
type the chondrocyte, which aids in the synthesis and degradation of these macromolecules. 
Taken from (Chen et al., 2006).  
 
1.2.1 The layers of human articular cartilage 
Articular cartilage can be divided into five distinct zones (superficial, transitional, 
middle, deep and calcified), as depicted in Figure 1.2. Each zone has different 
morphological features, with the boundaries between each zone not being 
easily distinguishable. The superficial zone is in contact with the synovial fluid 
and provides a smooth surface for articulation. This zone represents 10-20% of 
the articular cartilage volume and can be divided into two layers. The first is an 
acellular sheet of fibrils, covering the joint surface. Below this is a second layer 
composed of flattened chondrocytes with a high collagen and water content, but 
low proteoglycan composition compared to the other zones (also known as the 
transitional zone) (Buckwalter et al., 2005). The middle zone consists of around 
40-60% of articular cartilage volume. This zone is less organised than the upper 
superficial zone due to the unorganised orientation of thicker collagen fibrils. 
The chondrocytes within this zone are more rounded, larger and less 
compacted. The deep zone (representing 30% volume) contains large diameter 
fibrils which orientate themselves in a perpendicular fashion to the articular 
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surface. This layer has the greatest proteoglycan content, but lowest water 
content, allowing for the greatest compression of any other zone. The 
chondrocytes within this zone align themselves parallel to the fibrils in long 
columns. The tidemark separates the deep cartilage zone from the calcified 
cartilage which lies directly on the subchondral bone (Pearle et al., 2005). This 
thin zone of calcified cartilage links the middle zone to the subchondral bone, 
with collagen fibrils extending from the calcified cartilage into the articular 
cartilage.  
 
 
 
 
 
 
 
Figure 1.2. The zones of articular cartilage. There are 5 distinct zones of the articular 
cartilage. These zones are known as superficial, transitional, middle, deep and calcified, with all 
have distinct characteristics. Changes in collagen, aggrecan and water content are seen 
between each zone, aiding in their distinct properties. See section 1.2.1 for full details. Adapted 
from (Buckwalter et al., 1994). 
 
1.3 Human articular chondrocytes (HAC) 
Human articular chondrocytes represent around 0.4-2% of the total volume of 
articular cartilage (Martel-Pelletier et al., 2008). Chondrocytes are vital in 
cartilage homeostasis as they are involved in both the synthesis and 
degradation of the cartilage matrix. Chondrocytes originate from mesenchymal 
stem cells (MSCs) which undergo chondrogenesis to produce mature 
chondrocytes (Goldring, 2012). During early development, MSCs undergo 
recruitment to correct loci, migration and proliferation. Then through cell-cell and 
cell-matrix interactions, as well as the secretion of differentiation factors, MSCs 
are differentiated into mature chondrocytes (Goldring et al., 2006). 
Differentiation begins with the synthesis of the ECM, rich in hyaluronan and type 
I collagen, aggregation of cells and finally the expression of chondrocyte 
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specific macromolecules such as type II collagen and aggrecan (Goldring et al., 
2006). These molecules are synthesised into an ordered and organised 
framework, providing structure for the articular cartilage.  
Proliferation of chondrocytes in normal conditions is limited with maintenance of 
the ECM regulated by low turnover of the ECM, and replacement of matrix 
proteins. If the synthesis and degradation of the ECM is disrupted, as in ageing 
and joint disease, then an imbalance in these processes occurs. Here the rate 
of collagen and proteoglycan degradation, by matrix metalloproteinases (MMPs) 
and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), 
exceeds synthesis, leading to destruction of the ECM (Cawston and Wilson, 
2006). Cartilage was originally believed to be an inert tissue, with chondrocytes 
unable to respond to external stimuli. This has been disproved with cartilage 
being shown to be able to respond to external stimuli and extrinsic factors, 
leading changes in gene expression and protein synthesis (Sandy et al., 1984, 
Muir, 1995). 
Two mechanisms of damage to cartilage have been described: the first of these 
is known as abnormal load on normal cartilage. This mechanism describes how 
chondrocytes can respond to changes in loading. Chondrocytes respond to 
these mechanical stresses, such as excessive load, inducing changes in the 
synthesis of cartilage matrix proteins (Fitzgerald et al., 2004). Injury to tissue 
can also lead to changes in load, leading to global gene expression changes 
(Kurz et al., 2005). The second of these mechanisms is described as normal 
load on abnormal chondrocytes. This describes changes in chondrocytes due to 
age or a genetic pre-disposition, leading to the imbalance of synthesis and 
degradation of ECM macromolecules. Chondrocytes can also respond to 
cytokines and growth factors leading to changes in gene expression which can 
alter the ECM of the cartilage.  
1.4 Arthritis 
Joint disease such as rheumatoid arthritis (RA) and osteoarthritis (OA) affect 
millions of people within the United Kingdom. Changes to the external factors 
surrounding the cartilage as well a genetic disposition can lead to alterations in 
the synthesis and degradation of the ECM; leading to disease. Deregulation of 
the anabolic and catabolic activity of the chondrocyte can lead to a diseased 
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tissue in which irreversible damage occurs. Arthritis is a disease which causes 
painful inflammation and stiffness of the joints. This disease comprises of many 
different arthritides in which different clinical markers and phenotypes are seen. 
OA and RA are the two major forms of the disease and although have different 
clinical phenotypes both have the same end result, albeit with different initiating 
factors. These are two of the major diseases of the 21st century, which are 
becoming increasingly more relevant due to an aging population. It is estimated 
that 8 million people within the UK have OA. With around 1 million of these 
seeking medical treatment (ARUK, 2011a). In 2010 an estimated £852 million 
was spent on total hip and knee joint replacements alone within the UK and is 
therefore a massive cost both socially and economically (Chen et al., 2012). RA 
on the other hand affects around 1.5% of all adult women and 0.5% of all adult 
men in the UK,(data from 2006) (ARUK, 2011b). It is estimated that 
approximately 690,000 adults have rheumatoid arthritis in the UK (NRAS, 
2013). Data has shown that arthritis and rheumatoid arthritis care led to a 
medical cost of around £689 million a year in the UK (NRAS, 2010). Together, 
the total cost of musculoskeletal conditions, due to loss of working hours and 
treatments, was believed to be around £5.7 billion in 2008 (ARUK, 2008), 
showing both the social and economic costs of the disease. Figure 1.3 
represents some of the pathological changes which occur to knee joints during 
the progression of RA and OA. 
Arthritis can be characterised by the progressive loss of the articular cartilage 
which surrounds articulated joints (Buckwalter et al., 2005). The removal of this 
cartilage leads to the loss of friction-less movement of the joint. Degradation of 
collagen is a key phenotype of cartilage destruction, as unlike other 
components of the ECM, collagen cannot be readily replaced (Goldring et al., 
2008). The turnover of collagen within the ECM is slow, with the collagen laid 
down during development having the ability to last for the duration of an 
individual’s life (Goldring and Marcu, 2009). Collagen cleavage is therefore 
known as the rate limiting step within cartilage breakdown. The chondrocyte is 
therefore crucial in this process, acting as a sensor within in the cartilage. The 
secretion of pro-inflammatory cytokines into the synovial fluid can lead to an 
increase in catabolic mediators leading to the production of cartilage lesions as 
well as cartilage remodelling (Yasuda, 2006). The induction of catabolic 
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mediators and the down regulation of anabolic mediators, leads to the 
progression of cartilage damage and disease. Healthy ECM is therefore 
maintained in a non-disease state by the balance between synthesis and 
degradation of the ECM macromolecules; in a disease state such as in RA and 
OA this balance is lost. Degradation exceeds synthesis and the irreversible loss 
of cartilage occurs.  
 
Figure 1.3. The pathological changes which occur in a knee joint due to rheumatoid 
arthritis and osteoarthritis. The cellular components and sites of destruction in rheumatoid 
and osteoarthritic knee joints. During rheumatoid arthritis an infiltration of proinflammatory 
cytokines enter the joint, these include dendritic cells, plasma cells, lymphocyte T and B cells 
and macrophages. This can then lead to an inflamed and thickened synovial membrane, the 
formation of a pannus and cartilage destruction. In an osteoarthritic joint, bone remodelling, 
meniscal damage, cartilage destruction, synovial hypertrophy and osteophytes can all be 
observed. Taken from (Buckley, 1997) and (Hunter and Felson, 2006). 
 
1.4.1 Rheumatoid arthritis  
Rheumatoid arthritis is a chronic autoimmune disease in which the body’s own 
immune system attacks the synovial joints. RA affects around 1% of the 
population, with a female to male ratio of around 3:1 (ARUK, 2011b). RA can be 
characterised by chronic inflammation of multiple joints causing synovitis. The 
aetiology of RA is not fully understood, but it is known to have an autoimmune 
element involving interplay between T and B cells, as well as cytokine networks 
(Choi and Brahn, 2010). Macrophages, neutrophils and synovial fibroblasts are 
also important in the mechanism of disease. Other contributory factors include: 
the environment, infection, hormonal factors as well as genetic pre-disposition.  
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RA is believed to be initiated by the infiltration and activation of immune cells 
such as T cells, B cells, macrophages and dendritic cells into the synovial lining 
of the joint. These activated immune cells secrete pro-inflammatory cytokines 
leading to further inflammation through self-activation and the stimulation of 
surrounding cells within the joint. B cells are responsible for antigen recognition 
and antibody production. The role of B cells in RA is poorly defined but B cell 
depletion treatments, such as Rituximab and Epratuzumab have highlighted the 
importance of B cells in RA (Edwards et al., 2004). B cells have been linked 
with the production of autoantibodies such as rheumatoid factor and other 
antibodies which target citrullinated proteins (Schellekens et al., 1998). The use 
of B cell depletion therapies has therefore been shown to be positive in 
improving patient health in people with RA.  
B cells have also been shown to present antigens to T cells, leading to their 
activation and further exacerbation of disease. T cell activation, as well as their 
migration is seen to occur as an early consequence of RA, adopting a 
proinflammatory phenotype (Firestein, 2003). T cells have been linked to RA 
due to the high numbers of T cells found within the synovium, a genetic link with 
MHC class II alleles and with the lymphoid-specific protein tyrosine 
phosphatase, non-receptor type 22 (PTPN22) mutation (Panayi, 2006). T helper 
1 cells are the T cells believed to drive RA, as they have the capabilities to 
produce the pro-inflammatory cytokines interferon-γ (IFN-γ) and tumour 
necrosis factor-α (TNF-α) (McInnes and Schett, 2007), which can potentiate the 
progression of the disease. As well as Th1 cells being important in RA, Th17 
cells have recently been linked with RA (Nakae et al., 2003) and are found to be 
elevated in the peripheral blood of patients with early onset RA (Leipe et al., 
2010). Th17 are thought to be important in RA as they produce then cytokine IL-
17. IL-17 plays is seen to have synergistic effects when induced with tumor 
necrosis factor (TNF) and IL-1, which can induce cartilage degradation 
(Lubberts et al., 2005). However, Th17 cells are not widely found within the 
synovium of RA patients (Hueber et al., 2010), with this work suggesting mast 
cells to be the prominent source of IL-17 in RA synovium. Macrophages have 
also been shown to play a key role in RA as they produce pro-inflammatory 
cytokines which exacerbate disease.  
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Inflammation caused by the infiltration of immune cells occurs within the 
synovium of the joint. The synovium lines the joint cavity and is the site of 
production of synovial fluid. Normal synovium consists of macrophages and 
fibroblast like cells known as synoviocytes. In RA the lining of the synovium 
swells, with increased numbers of macrophages and fibroblasts. The synovium 
proliferates and formation of a pannus (an abnormal layer of thickened synovial 
tissue which grows over the joint surface) occurs, extending over the articular 
cartilage. Currently, it is unclear as to whether inflammation and joint 
destruction are linked. Degradation of the ECM is believed to be driven by the 
infiltration of pro-inflammatory cytokines into the joint cavity, leading to the 
stimulation of the sole cell type, the chondrocyte (van den Berg and van Riel, 
2005). Cartilage destruction is then mediated through the increased expression 
and activity of proteolytic enzymes, resulting in cartilage degradation and 
erosion of the subchondral bone (Otero and Goldring, 2007, Sweeney and 
Firestein, 2004). 
1.4.2 Osteoarthritis 
Osteoarthritis (OA) is a disease of articular joints, and is affecting a third of 
people over the age of 45 in the UK (ARUK, 2011a). A total of 76,759 primary 
total hip replacements and 81,979 total knee replacements were performed I 
2010, showing the large numbers of patients with which treatment of the 
symptoms of disease is no longer a viable option (Registry, 2011). OA is one of 
the leading causes of chronic disability and is the most prevalent forms of 
arthritis. Symptoms include joint pain, stiffness, loss of mobility and non-
systemic inflammation. Both joint pain and stiffness are used for diagnosis, but 
clinically the use of X-rays, evidence of swelling and fluid in and around the joint 
is used. The uncertainty in diagnosis is due to there being no clear clinical 
markers for the disease, hindering early diagnosis. The aetiology of OA has not 
fully been resolved with further research required into the causes and 
development of the disease. It is believed that multiple factors can lead to the 
disease with numerous risk factors being flagged as contributors to the disease. 
These factors include genetics, age, weight, gender and other joint 
abnormalities.  
OA can be characterised by the softening, fibrillation and loss of articular 
cartilage, synovial inflammation as well as the formation of osteophytes and 
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subchondral cysts (Goldring and Goldring, 2007). Age is the major risk factor of 
OA, with normal quiescent chondrocytes changing phenotypically compared to 
healthy or normal cells (Price et al., 2002). OA can also develop due to damage 
to the cartilage, leading to further degradation of the cartilage surrounding the 
joint. OA has been seen as a ‘wear and tear’ disease compared to the 
inflammatory disease of RA. This view is becoming outdated as OA is now 
beginning to be shown to have an inflammatory phenotype. Patients with OA 
have been shown to have increased vascularity and inflammatory-cell infiltration 
of their joints (Smith et al., 1997), albeit these tend to be of lower grade than 
those observed in RA (Pessler et al., 2008). Inflammatory mediators, such as 
cytokines and chemokines are seen to be elevated within the synovial fluid of 
patients with OA. Interleukin-1β (IL-1β) and TNFα (tumor nercrosis factor α) 
have been shown to be elevated in OA, and these cytokines stimulate the down 
regulation of matrix synthesising genes as well as promoting cartilage 
catabolism (Goldring and Marcu, 2009). 
1.4.3 Chondrocytes and arthritis  
During the initial stages of OA, chondrocytes begin to divide leading to the 
formation of multicellular clusters. These chondrocytes begin to express 
hypertrophic markers such as type X collagen, Runt-related transcription factor 
2 (RUNX2), osteocalcin and alkaline phosphatase (van der Kraan and van den 
Berg, 2012). These markers are usually only found in terminally differentiated 
chondrocytes found within the growth plate (Aigner et al., 1993). Ossification 
can begin to occur with osteophyte boney growths protruding from the cartilage 
being observed. These hypertrophic-like chondrocytes also begin to express 
increased levels of the MMPs, specifically MMP-13 (Goldring and Goldring, 
2007). The increased expression of MMP-13 leads to the irreversible 
degradation of the main ECM component type II collagen, leading to the 
breakdown of the ECM.  
1.4.4 Treatment for arthritis 
Treatment for OA is limited with no preventative or progressive treatments 
available. Currently, only pain relief is offered, and in severe cases, total joint 
replacement is the only viable clinical option. Joint replacements have their 
limitations, with the duration of the replacement being around 10-15 years 
(Lucas, 2004). As well as their short life span, the surface of these 
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replacements does not provide the same frictionless surface that articular 
cartilage provides. RA on the other hand has many more viable treatment 
options. These include the disease-modifying anti-rheumatic drugs (DMARDs) 
which are designed to slow down the progression of the disease. DMARDs 
include Rituximab, the B cell targeting drug, as well as anti TNF-α therapy. 
These drugs though useful, do not work in all patients and only treat the 
symptoms of inflammation, they do not target the disease process itself directly. 
Further research is therefore needed into treatments which target the disease 
directly rather than only treating the symptoms. A key research aim is therefore 
to discover the mechanisms behind cartilage degradation, looking at the roles of 
both inflammation and the signalling consequences leading to disease.  
1.5 Proteinases and cartilage degradation 
The breakdown of the ECM of articular cartilage is one of the major processes 
involved in the progression of arthritis. This process is catalysed by proteinases, 
proteolytic enzymes which are up-regulated and activated in many arthritides. 
Proteinases cleave covalent peptide bonds within protein structures; this can 
lead to the inactivation and degradation of the target protein. Proteinases are 
synthesised and secreted from a number of cells found within the joint, including 
chondrocytes and synovial fibroblasts. The expression and activation of these 
enzymes is regulated by cytokines and growth factors secreted in the synovial 
fluid (Goldring et al., 2008). As mentioned previously, one of the key processes 
in arthritis is the irreversible cleavage of type II collagen found within the ECM 
of cartilage. This process is catalysed by these proteinases. The cleavage of 
type II collagen is preceded by further cleavage of other ECM components. The 
cleaved collagen cannot be readily replaced by the cells, due to its low turnover 
rate. The estimated half-life of type II collagen in healthy cartilage is over 100 
years (Verzijl et al., 2000). In the disease state the degradation of collagen 
therefore exceeds its synthesis.  
Proteinases can be classified into 5 main classes; this is dependent on the 
chemical group which participates in the hydrolysis of the peptide bond. 
Proteinases therefore belong to either the cysteine, aspartate, threonine, serine 
or metallo-proteinase groups. These 5 classes are shown in Figure 1.4. These 
proteinases work within different subcellular and extracellular locations, dictated 
by the pH at which the enzymes are active. Cysteine, aspartate and threonine 
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proteinases are active at acidic pH and therefore act intracellularly. This 
contrasts with the serine and metalloproteinases that act extracellularly at 
neutral pH (Rengel et al., 2007). All classes of proteinases are involved in the 
catalytic breakdown of connective tissues, with members of each family having 
the potential to activate themselves or other family members. The matrix 
metalloproteinase class of metzincin enzymes are strongly linked with the 
degradation of the ECM of cartilage and are believed to be the major 
collagenolytic enzymes (Ellis et al., 1994).  
 
 
 
 
 
 
 
 
 
Figure 1.4. The 5 main sub-divisions of the Proteinase family. The 5 main groups include; 
the collagenases, gelatinases, matrilysins, stromelysin and the membrane type MMPs, all of 
which work extracellularly at neutral pH. Further detail on family members and role in ECM 
degradation can be found in section 1.5. Adapted from (Rengel et al., 2007). 
 
1.5.1 Matrix metalloproteinases 
MMPs have been shown to cleave key components of the ECM, with the levels 
of MMPs being significantly raised in patients with RA and OA (Hembry et al., 
1995, Yoshihara et al., 2000, Davidson et al., 2006). Collagenase-1 (MMP-1), 
the first member of the MMP family to be identified (Gross and Lapiere, 1962), 
has the capability to specifically cleave triple helical collagen. MMPs can be 
either cell surface bound or secreted. MMPs require the neutral pH of the 
extracellular environment to become fully active. These family members have a 
similar amino acid sequence and all share a common structure and function, but 
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differ in their target sites. MMP-1, -8 and -13 form the ‘classic’ collagenases and 
degrade collagen, whilst MMP-2 (Aimes and Quigley, 1995) and MMP-14 
(Ohuchi et al., 1997) also have this capability in vitro. 
Currently, 23 members of the MMP family have been identified. All are divided 
into 5 traditional groups, dependent on their known catalytic target, sequence 
homology and cellular location (Clark et al., 2008). The 5 main groups include; 
the collagenases, gelatinases, matrilysins, stromelysin and the membrane type 
MMPs. In normal homeostasis of the cell, within healthy individuals, MMP levels 
and ECM degradation is low. In arthritis this balance changes and MMP levels 
rise, especially the collagenases (Kevorkian et al., 2004). 
1.5.1.1  MMP structure 
All MMPs consist of a propeptide of around 80 amino acids, a catalytic 
metalloproteinase domain of around 170 amino acids, a hinge region of variable 
length and a haemopexin domain of 200 amino acids (Murphy and Nagase, 
2008) as depicted in Figure 1.5. The propeptide domain contains a highly 
conserved PRCGXPD cysteine switch motif; this can ligate to a zinc ion within 
the active site, maintaining latency (Clark et al., 2008). The zinc ions bind to the 
HEXGHXXGXXH zinc-binding sequence within the catalytic domain (Clark et 
al., 2008). The catalytic domain also contains a conserved methionine, which 
forms a ‘Met-turn’, eight residues after the zinc binding motif. This forms a 
support structure around the catalytic zinc (Bode et al., 1993). The hinge region 
links together the C- and N- terminal domains. The hemopexin domain has 
various roles depending on the MMP. It plays a crucial role in substrate 
specificity, the binding of TIMP-2 (tissue inhibitor of matrix metalloproteinase 2) 
to proMMP2, as well aiding in the cleavage of collagen by MMP-1 (Lauer-Fields 
et al., 2009).  
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Figure 1.5. The domain structures of the MMPs. All MMPs have a catalytic domain 
containing the active site zinc (Zn). Some MMPs contain a furin recognition motif (Fu), allowing 
intracellular activation by furin-like proteinases. All MMPs (apart from MMP-7, -26 and -23) 
contain a haemopexin domain, which can determine substrate specificity. Other domains found 
include; the fibronectin-like domains (F), found in MMP-2 and -9 and the vitronectin-like domain 
(V) in MMP-21. Some MMPs contain a trans-membrane domain (TM) with cytoplasmic tail (Cyt) 
or via a glycosylphosphatidyl inositol (GPI) anchor which anchors them to the cell surface. 
MMP-23 is structurally unique compared to the others MMPs. MMP-23 contains an N-terminal 
TM domain, acysteine array (CA) and an immunoglobulin-like domain (Ig-like). Taken from 
Cawston and Young, (Cawston and Young, 2010). 
1.5.1.1.1 The collagenases 
The collagenases play a vital role in the turnover of collagen. This ability 
therefore makes the collagenases of great importance in the progression of 
arthritis. There are three classical collagenases; MMP-1 (collagenase-1), MMP-
8 (collagenase-2) and MMP-13 (collagenase-3). MMP-13 preferentially cleaves 
type II collagen (Knauper et al., 1996a) whereas MMP-1 preferentially cleaves 
type III and MMP-8 type I; they all have the capability to cleave type II collagen. 
Of the collagenases MMP-1 and MMP-13 are thought to be of greatest 
importance in relation to arthritis, due to their cleavage affinities and expression. 
MMP-13 is restricted in expression and in normal cartilage believed only to be 
expressed during development, fulfilling its role of removing type II collagen 
from the growth plate during bone formation (Johansson et al., 1997). MMP-1 is 
more abundant and expressed within more cell types (Vincenti and Brinckerhoff, 
2002). MMP-1 is described as the key collagenase in RA, whereas MMP-13 is 
thought to be the important collagenase in OA. MMP-8 is not well expressed in 
human articular chondrocytes (Stremme et al., 2003), and therefore is not 
thought to be as prominently involved in cartilage destruction in OA and RA. 
Both MMP-1 and -13 are shown to have a similar activity against type I collagen 
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but MMP-13 appears to have a 10-fold higher activity against type II (Knauper 
et al., 1996a). This inefficiency of MMP-1 is believed to be counteracted by 
increased expression of MMP-1 compared to MMP-13 (Vincenti and 
Brinckerhoff, 2002).  
Type II collagen is a major component of the ECM and its degradation is one of 
the major factors in both OA and RA. Collagen is resistant to degradation by 
most proteinases until digestion by MMPs (Visse and Nagase, 2003). MMPs 
cleave collagen fibrils at a single glycine-isoleucine/leucine bond (Visse and 
Nagase, 2003). This cuts the helical domain of the collagen into ¾ and ¼ 
fragments (Birkedal-Hansen et al., 1985), causing them to unwind and be 
susceptible to further proteolysis. The mechanism by which MMPs degrade 
collagen is not well established but data imply MMPs must first unwind the 
collagen chains before cleaving the chains individually (Chung et al., 2004). The 
loss of type II collagen leads to the degradation of the ECM as it exposes 
further cleavage sites for further proteolytic enzymes.   
1.5.1.1.2 Gelatinases 
The subgroup of MMPs known as the gelatinases consists of the MMP-2 
(gelantinase A) and MMP-9 (gelatinase B). The two gelatinases cleave 
denatured collagen, type IV and V collagen as well as elastin (Aimes and 
Quigley, 1995). MMP-2 and MMP-9 differ from other MMPs as they contain 
fibronectin-like inserts in their catalytic domain, enabling them to bind to 
denature collagen (gelatin). MMP-2 is the most widely expressed gelatinase 
and has the ability to activate proMMP-9 (Fridman et al., 1995) and -13 
(Knauper et al., 1996c). MMP-9 is expressed within transformed and tumour 
driven cells as well as in chondrocytes, neutrophils and monocytes (Matrisian, 
1992). Both gelatinases are seen to be elevated in RA (Ahrens et al., 1996). 
1.5.1.1.3 Stromelysins 
MMP-3 (stromelysin 1) and MMP-10 (stromelysin 2) both form the subgroup of 
MMPs known as the stromelysins. MMP-11 is called stromelysin 3 but because 
of sequence and substrate differences is not always placed within this group. 
Both MMP-3 and MMP-10 gene and protein expression can be induced by IL-1 
in both chondrocytes (Murphy et al., 1986), as well as in synovial fibroblasts 
(MacNaul et al., 1990). MMP-3 and MMP-10 have similar substrate specificities; 
MMP-3 however has a slightly greater proteolytic efficiency compared to MMP-
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10. Besides ECM degradation, MMP-3 can also activate growth factors, 
chemokines, cytokines and various receptors. MMP-3 is also able to activate 
proMMP-1, -3, -7, -8, -9 and -13 (Ito and Nagase, 1988). MMP-3 is also 
involved in a self-activation loop in which MMP-3 cleaves and induces its 
upstream activators plasminogen and urokinase-type plasminogen activator 
(Ogata et al., 1992, McCawley and Matrisian, 2001). MMP-10 also has the 
capability to activate various MMPs, including MMP-1 and -8 (Knauper et al., 
1996b). Both of these enzymes are therefore important in the degradation of the 
ECM and the activation of other MMPs needed to initiate degradation.  
1.5.1.1.4 Matrilysins  
MMP-7 and MMP-26 form the matrilysins. These differ from other MMPs as 
they contain no haemopexin domain. MMP-7 is synthesised by epithelial cells 
whereas MMP-26 is expressed in many different cell types such as those found 
in the endometrium, they are also found in some carcinomas (Murphy and 
Nagase, 2008). MMP-26 can digest a number of ECM products whilst MMP-7 
also has the capability to process cell surface molecules such as E-cadherin 
and pro-Tκ-α (Visse and Nagase, 2003).  
1.5.1.1.5 Membrane-type MMPs (MT-MMPs) 
There are 6 MT-MMPs: four are type I transmembrane proteins (MMP-14, 
MMP-15, MMP-16 and MMP-24), the two other MMPs are 
glycosylphosphotidylinositol (GPI) anchored proteins (MMP-17 and MMP-25) 
(Visse and Nagase, 2003). All MT-MMPs contain a furin-like pro-protein 
convertase recognition sequence and are activated intracellularly. All MT-MMPs 
except MMP-17 have the capability to activate proMMP2. They can all degrade 
ECM components, with MMP-14 having collagenolytic activity on type I, II and 
III collagen (Ohuchi et al., 1997). MMP-14 can cleave and activate MMP-13 on 
the cell surface and is thus important in arthritis due to its ability to activate this 
collagen degrading enzyme.  
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MMP Class Name Substrate 
MMP-1 Collagenases  Collagenase-1 Collagens (i–iii, vii, viii, and X), gelatin,  
aggrecan, MMP-2, MMP-9 and IL-1β 
MMP-8 Collagenases  
 
Collagenase-2/ 
neutrophil  
collagenase 
Collagens (i–iii, v, vii, viii, and X),  
gelatin, aggrecan, fibronectin 
MMP-13 Collagenases  Collagenase-3 Collagens (i–iv, iX, X, and Xiv),  gelatin, 
plasminogen, aggrecan, fibronectin,  
osteonectin, MMP-9 
MMP-2  Gelatinases Gelatinase-A Gelatin, collagen iv–vi, X, elastin, fibronectin 
MMP-9  Gelatinases Gelatinase-A Collagens (iv, v, vii, X, and Xiv), gelatin, aggrecan, 
elastin, fibronectin, plasminogen, IL-1β 
MMP-3  
 
Stromelysins Stromelysin-1 Collagens (iii–v, and iX), gelatin, aggrecan, , 
laminin, elastin,  plasminogen, MBP, IL-1β, MMP-
2/TiMP-2, MMP-7, MMP-8, MMP-9, MMP-13 
MMP-10 Stromelysins Stromelysin-2 Collagens (iii–v), gelatin, casein, aggrecan, elastin, 
MMP-1, MMP-8 
MMP-11  Stromelysins Stromelysin-3 Unknown (casein) 
MMP-7  
 
Matrilysins Matrilysin-1  
(PUMP) 
 
Collagens (iv, X), gelatin, aggrecan, decorin, 
fibronectin, laminin, elastin, casein, transferrin, 
plasminogen, MMP-1, MMP-2, MMP-9, TiMP-1 
MMP-26 Matrilysins Matrilysin-2 Collagen IV, fibronectin, fibrinogen, gelatin, α (1)-
proteinase inhibitor 
MMP-14  MT-MMP MT1-MMP  
(membrane type) 
Collagens (i–iii), gelatin, casein, fibronectin, laminin, 
proteoglycans, MMP-2, MMP-13 
MMP-15  MT-MMP MT2-MMP Fibronectin, entactin, laminin, aggrecan, MMP-2 
MMP-16  MT-MMP MT3-MMP Collagen iii, gelatin, casein, fibronectin, MMP-2 
MMP-17  MT-MMP MT4-MMP Unknown 
MMP-24  MT-MMP MT5-MMP Fibronectin, but not collagen type i or laminin 
MMP-25  MT-MMP MT6-MMP Progelatinase A 
 
Figure 1.6 MMPs and their substrates. A table containing the names and substrates of the 4 
major classes of MMPs. All MMPs contain a similar structure, with greatest homology beingn 
found within the catalytic domain. Differences in extracellular distribution, processing and 
substrate specificity are all found. For further detail see section 1.5.1.1. Adapted from (Sekhon, 
2010) 
 
1.5.2 Regulation of matrix metalloproteinases 
Due to their catabolic properties, MMPs are tightly regulated within healthy 
cells, at both the level of transcription and activation (Burrage et al., 2006). 
MMP activity is therefore regulated at 3 key stages; synthesis, proenzyme 
activation and inhibition. In diseases such as arthritis, this regulation is 
disrupted leading to increased MMP catalytic activity.  
1.5.2.1 Transcriptional regulation of MMPs within chondrocytes 
The transcription of MMPs is tightly regulated, with low expression of MMPs 
found within normal resting chondrocytes (Vincenti and Brinckerhoff, 2002). In 
disease, this regulation is disrupted, with increased MMP expression and 
secretion being observed (Hembry et al., 1995, Yoshihara et al., 2000, 
Davidson et al., 2006). 
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Expression of MMPs is dependent on the binding of transcription factors to the 
promoter of each MMP gene at numerous DNA binding regions known as cis-
elements. These elements vary between each MMP, allowing for gene specific 
regulation of each MMP, even under the same stimulus. The MMP-1 and MMP-
13 promoters both contain a TATA box approximately 30 base pairs (bp) 
upstream of the transcription start site as well as a proximal activator protein-1 
(AP-1) binding site approximately 40bp upstream of the TATA box (Goldring et 
al., 2008). Variation occurs between MMP-1 and MMP-13 through the binding of 
other transcription factors. As Figure 1.7 shows, MMP-1 and MMP-13 have 
varying cis-elements within their promoters, giving rise to different expression 
patterns. The key cis-elements found within the promoters of MMPs include 
nuclear factor kappa B (NFκB), signal transducer and activator of transcription 
(STAT), RUNX2 and specificity protein-1 (SP-1). 
In disease, an infiltration of pro-inflammatory cytokines into the joint activates 
signalling events which in turn activate numerous transcription factors. These 
cytokines include IL-1β, TNF-α and oncostatin M (OSM). The activation of cell 
signalling pathways by IL-1 in combination with OSM therefore leads to the 
phosphorylation and increased expression of numerous transcription factors 
involved in collagenase expression.  
Figure 1.7. Schematic of MMP-1 and MMP-13 promoter region. The consensus transcription 
factor binding sites and their approximate nucleotide position relative to the transcription start 
site of MMP-1 or -13. These binding sites include; SBE, the STAT-binding element; TIE, TGF-
beta inhibitory element; S, Smad-binding site; SAF-1, serum amyloid A-activating factor-1; 
OSE2, osteoblast-specific element 2 (Cbfa1/Runt binding site); TBP, TATA binding protein; 
RNAP, RNA polymerase II complex. Taken from (Rowan and Young, 2007) 
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1.5.2.2 Activation of proMMPs 
MMPs are first synthesised as pre-proenzymes. During translation the signal 
peptide is first removed forming the proenzyme. The zymogen must then 
undergo further cleavage and processing to become active. This latency is 
maintained until the pro-peptide sequence is cleaved, removing a bound 
cysteine residue from the catalytic zinc ion (Nagase et al., 2006).  
Thirteen MMPs are secreted from the cell as proMMPs. These contain a 
proteinase susceptible ‘bait’ region in the pro-peptide, which can be cleaved by 
multiple proteinases (Nagase et al., 2006). These MMPs can be activated by 
the proteolytic cleavage of their pro-domain via the action of serine proteinases 
such plasmin (Eeckhout and Vaes, 1977) or matriptase (Milner et al., 2010). 
This method is referred to as the ‘step wise method’ (Nagase et al., 1990). 
MMPs themselves also have the capability to cleave other MMP pro-domains, 
leading to further MMP activation. These MMPs may themselves be activated 
by serine proteinases in an activation cascade of pro-collagenases (Milner et 
al., 2001).  
Other MMPs are cleaved by the catalytic action of furin, a known pro-protein 
convertase (Cawston and Young, 2010). These MMPs contain a furin 
recognition site between the pro-peptide and catalytic domain. Once cleaved 
the inhibitory binding of the cysteine residue is removed. This can occur within 
the trans-Golgi Network (TGN) leading to the secretion of active proteinase 
capable of degrading the components of the ECM.  
1.5.3  Tissue inhibitors of metalloproteinases (TIMPs)  
Once synthesised and activated the proteolytic activity of MMPs can be 
regulated by the endogenous MMP inhibitors, TIMPs. TIMPs specifically inhibit 
MMP activity by binding to the MMP active site. The regulation of ECM turnover 
is dependent on a fine balance between MMPs and TIMPs, with alterations in 
the levels contributing to diseases such OA and RA (Bokarewa et al., 2005) 
(Cawston and Young, 2010). As well as active site inhibition, TIMPs can bind to 
the proMMPs inhibiting their activation (Bigg et al., 2001). 
There are 4 TIMPs; TIMP-1, TIMP-2, TIMP-3 and TIMP-4. All consist of around 
184-189 amino acids, sub-divided into N-terminal and C-terminal subdomains 
(Nagase et al., 2006). The N-terminal domain has the capability to fold as an 
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independent unit, inhibiting MMPs (Murphy et al., 1991). TIMPs are able to 
inhibit all MMPs, except for TIMP-1 which cannot inhibit MMP-14 (Will et al., 
1996). TIMPs bind to MMPs in a 1:1 stoichiometry; their wedge-like structures 
inserts itself into the active site of an MMP, in a similar manner to that of a 
substrate. They bind non-covalently via a cysteine within the N-terminal domain 
to the zinc ion within the active site; this dispels the water molecule bound to the 
zinc ion, rendering the enzyme inactive (Gomis-Ruth et al., 1997). Due to non-
covalent binding this process is reversible. Although all TIMPs are described as 
broad spectrum MMP inhibitors, their specificity for individual MMPs differs.  
TNF-α and IL-1 are both seen to induce MMP synthesis, but inhibit TIMP-1 
expression in chondrocytes. Conversely, IL-6 can promote TIMP-1 expression 
but not MMP expression (Lotz and Guerne, 1991) in synoviocytes. Since IL-6 is 
expressed under the control of IL-1 or TNF-α (Radtke et al., 2010), this could be 
a potential regulatory feedback loop which may try to counteract the catabolic 
effects of the MMPs under such pro-inflammatory conditions.  
Several other proteins are reported to inhibit MMPs. These include α-
macroglobulins, which are general endopeptidase inhibitors, which inhibit by 
entrapping the MMP within the macroglobulin (Cawston and Mercer, 1986). 
Tissue factor pathway inhibitor-2 is a serine proteinase inhibitor also capable of 
inhibiting MMPs. MMP homeostasis within the joint is a key process with 
inhibition of MMPs a tightly controlled process; changes within this balance can 
lead to degradation of the ECM and diseases such as OA and RA.  
1.5.4 Synthetic MMP inhibitors 
The use of broad spectrum MMP inhibitors in the treatment of both RA and OA 
has been tried as a potential therapeutic target. Early MMP inhibitors were 
broad specificity inhibitors, they were ineffective with many drugs causing 
musculoskeletal side-effects (Clark and Parker, 2003). Once available, the 
crystal structures of each MMP gave insight into the lack of specificity due to the 
catalytic domains of each MMP being structurally similar. Inhibition of MMPs for 
the treatment for arthritides has many challenges, such as; deciding on whether 
to use broad spectrum or MMP specific inhibitors as well as deciding on 
whether proteoglycan or collagen release should be the main focus. Also to be 
considered is the deleterious effects of inhibition of MMPs which are essential 
and beneficial for tissue integrity (Cawston and Young, 2010). Understanding 
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the signalling events that lead to the induction of individual MMPs may therefore 
lead to therapeutics capable of inhibiting the expression and synthesis of 
individual MMPs. This may avoid some of the side effects observed and lead to 
specificity against individual MMPs. 
1.6 Pro-inflammatory cytokines in arthritis 
Cytokines are small soluble proteins that regulate a variety of biological 
processes; most common of these is the regulation of immunomodulatory 
functions. Cytokines are produced in response to cellular stress, which includes 
infection, inflammation and injury. Their release leads to modulation of a target 
cell, leading to changes within transcription and protein expression. The 
complex milieu of cytokines released within inflammation includes both pro- and 
anti-inflammatory cytokines, which are designed to control cellular stress and 
minimise damage. However, disease can occur when this tightly controlled 
inflammatory response becomes deregulated. The dysregulation of cytokine 
networks leads to the pathology of multiple diseases and chronic inflammation.  
RA and OA differ in their pathology, but both are driven by the production of 
catabolic factors in response to a complex milieu of elevated pro-inflammatory 
cytokines. In RA, chronic inflammation is seen, with the infiltration of cytokine 
producing immune cells, including macrophages, T-cells and neutrophils into 
the synovium being observed (Smeets et al., 2003). This leads to the 
dysregulation of cytokine networks leading to chronic inflammation of the joint. 
OA, though not historically thought to be an inflammatory disease, due to low 
numbers of immune cells found within the synovial fluid of OA patients, is 
beginning to be re-evaluated in this context. The role of inflammatory cytokines 
in the pathogenesis of OA is now thought to be a key process in disease 
progression (Abramson and Attur, 2009). 
Inflammation and the release of pro-inflammatory cytokines stimulates the 
production of enzymes involved in the degradation of the ECM of cartilage, 
whilst also impairing the ability of the chondrocyte to repair the damage. 
Cytokines released by the synovium and the chondrocytes themselves lead to 
the activation of the normally quiescent chondrocyte. The chondrocytes, which 
usually promote low matrix turnover, become active and undergo phenotypic 
modulation due to the action of both anabolic and inflammatory cytokines 
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(Goldring and Otero, 2011). Two key pro-inflammatory cytokines implicated in 
the destruction of articular cartilage are IL-1β and TNF-α. Both cytokines have 
been found to be elevated in RA synovium and are detected in the synovial fluid 
of RA patients (Lubberts et al., 2000). The production of both IL-1 and TNF-α is 
also seen to be elevated in osteoarthritic articular chondrocytes (Pelletier et al., 
2001). IL-1 and TNF-α target the chondrocyte, leading to the expression of 
catabolic and anabolic genes, resulting in an imbalance in cartilage 
homeostasis. In addition to the up-regulation of catabolic and anabolic genes, 
both cytokines can suppress the expression of COL2A1, the collagen II gene, in 
vitro (Tyler and Benton, 1988, Goldring et al., 1988, Lefebvre et al., 1990). 
These cytokines can therefore increase degradation of the ECM as well as 
inhibit the synthesis of its key component.  
Other pro-inflammatory cytokines have been shown to be elevated within RA 
and OA joints, leading to the induction of catabolic factors capable of degrading 
cartilage. A key characteristic of these cytokines is their ability to synergise, 
leading to a greater than additive induction of gene expression than when used 
individually. One of these cytokines is OSM, a member of the IL-6 cytokine 
family. This cytokine has the capability to synergise with IL-1 and TNF-α leading 
to MMP induction (Cawston et al., 1998a, Rowan et al., 2001, Cawston et al., 
1998c, Cawston et al., 1998b).  
1.6.1 Interleukin-1 
The IL-1 family is a group of 11 pleiotropic cytokines which can regulate 
immune and inflammatory responses. The IL-1 family consist of; IL-1α, IL-1β, 
IL-1 receptor antagonist (IL-1Ra), IL-18, IL-33 andL-36, α, β and ƴ. IL-1 
activates multiple signalling pathways, acting as a mediator in the pathology of 
many diseases. IL-1α and IL-1β are the two major inflammatory cytokines within 
the family, while IL-1Ra exhibits anti-inflammatory effects (Dinarello, 1996, 
Dinarello, 2011). IL-1α and IL-1β have the same biological activities as both 
form the same complex with the IL-1 receptor. IL-1α and IL-1β are both 
synthesised as a 31kDa pro-IL-1 precursors (Dinarello, 1996, Dinarello, 2011). 
Pro-IL-1α is processed by the cleavage of the N-terminal domain, leaving an 
18kDa mature protein. Both pro- and mature IL-1α are biologically active. In 
contrast, pro-IL-1β is processed into a 17.5kDa (Black et al., 1988). The pro-IL-
1β is immature and therefore cleavage of the prodomain is needed for the 
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cytokine to be biologically active. IL-1α associates with the membrane and 
therefore acts locally whereas IL-1β is secreted and acts systematically.  
The IL-1 receptor (IL-R) consists of two major forms (IL-1RI and IL-1RII), of 
which there are 9 members (Daun and Fenton, 2000). All isoforms contain 
immunoglobulin-like domains within their own extracellular domain. IL-1RI is an 
80 kDa receptor which binds IL-1, aiding in inflammation. IL-1RII is a 60 kDa 
protein with considerable homology to that of IL-1RI (Daun and Fenton, 2000). 
IL-1RII binds IL-1 with the same affinity as IL-1RI but has no signal transduction 
capabilities, therefore acting as a signal transduction suppressor. IL-1RII is also 
enzymatically cleaved from the surface and acts a soluble IL-1 binding protein. 
The IL-1RII can therefore bind to circulating IL-1α and –β. The receptor is 
therefore known as a decoy receptor, competing with IL-1RI for IL-1.  
The IL-1RI does not work alone, for greater affinity binding of IL-1α and IL-1β to 
the receptor a an accessory protein is also needed, this is known as IL-1 
receptor accessory protein (IL-1R AcP) (Wesche et al., 1997). IL-1R AcP aids in 
the internalisation of the active IL-1R complex inducing intracellular signalling. 
Further recruitment of IL-1 receptor- associated kinase (IRAK) and TNF 
receptor associated factor (TRAF) accessory proteins aid in initiating 
downstream signalling (O'Neill and Greene, 1998). Active IL-1RI can therefore 
activate mitogen activated protein kinase (MAPK) signalling pathways, the 
NFκB pathway, as well as the tyrosine phosphorylation of STATs.  
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Figure 1.8. IL-1 signalling pathway. IL-1 binds to its receptor (IL-1R) and accessory protein IL-
1RAcP. This leads to the association and conformational changes in the further accessory 
proteins (cytosolic myeloid differentiation protein (MyD88), IRAK and TRAF proteins). 
Hyperphosphorylation of IRAK leads to its dissociation from the receptor, leading to its 
association with TARF6 (Takaesu et al., 2000).This complex binds TGF-beta activated kinase 
1/MAP3K7 binding protein 2 (TAB2) and Transforming growth factor-beta-activated kinase 1 
(TAK1). Phosphorylation and activation of TAK1 leads to further signal transduction, TAK1 
activates both the MAPK and NFκB pathways (Ninomiya-Tsuji et al., 1999). TAK1 activates the 
NFκB pathway via the phosphorylation of NFκB-inducing kinase (NIK). NIK phosphorylates the 
inhibitor of κB kinase (IKK) complex, leading to the phosphorylation of inhibitor of NFκB (IκB). 
IκB is then polyubiquinated and targeted for proteasomal degradation. This releases the 
transcription factor NFκB from its inhibitory state, allowing the translocation of the protein to the 
nucleus, in which it can initiate gene transcription. TAK1 can also activate all members of the 
MAPK signalling family. TAK1, also known as a member of the MAP3K family, phosphorylates 
its downstream substrates (members of the MAP2Ks), leading to activation of the MAPKs. 
Activation of these pathways leads to the induction and phosphorylation of numerous 
transcription factors involved in the induction of the MMPs. As well as the activation of TAB2 
and TAK1, TRAF6 can also associate with p62, this leads to the binding of atypical Protein 
Kinase Cs (aPKC) to TARF6. TARF6 then activates aPKC leading to their downstream 
signalling and activation of the ERK pathway. p62/aPKC have been shown to activate the NFκB 
pathway (Geetha and Wooten, 2002), but silencing of the aPKC had no effect on NFκb 
signalling (Litherland et al., 2010). Adapted from (Vincenti and Brinckerhoff, 2002) and 
(Litherland et al., 2010). 
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1.6.1.1  IL-1 and arthritis 
IL-1 was first identified within the synovial fluid of patients with RA in the early 
1980s (Fontana et al., 1982). IL-1 was later also seen to be elevated within the 
blood plasma (Eastgate et al., 1988), the cartilage (Goldring and Marcu, 2009, 
Towle et al., 1997) and the synovial membranes of RA patients (Rowan et al., 
2003). Raised levels of IL-1 within the synovial fluid and the sera are associated 
with disease activity and cartilage breakdown in RA. Chondrocytes from 
patients with OA display high levels of both IL-1α and IL-1β and have elevated 
membrane bound IL-1R1 (Martel-Pelletier et al., 1992). The levels of IL-RII are 
also down-regulated (Martel-Pelletier et al., 1992), indicating not only increased 
levels of IL-1 but also increased sensitivity.  
IL-1 stimulates cartilage degradation by inducing the expression and activation 
of proteolytic enzymes capable of cleaving ECM components, such as the 
MMPs and aggrecanases. Intra-articular injection of recombinant or highly 
purified IL-1 into the knee joints of adult rabbits led to infiltration of leukocytes 
into the synovial cavity as well as the loss of proteoglycan from the articular 
cartilage (Pettipher et al., 1986). This loss of proteoglycan was not due to the 
infiltration of leukocytes but instead, due to the activation of proteolytic 
enzymes. IL-1 had already been implicated in the induction of the collagenases 
within sites of inflammation when released by macrophages (Postlethwaite et 
al., 1983). As well as increasing the levels of catabolic enzymes, decreases in 
the synthesis of type II collagen were observed (Goldring et al., 1988). IL-1 has 
therefore a clear role in the progression of arthritis, with elevated levels being 
identified. This leads to the activation of cell signalling events, which cause the 
degradation of the ECM by proteolytic enzymes.  
1.6.2 Oncostatin M  
OSM is a secreted glycoprotein monomer of 28 kDa which belongs to the IL-6 
type cytokine family. OSM is synthesised and secreted by T cells and monocytic 
cells (Cawston et al., 1998b). This family of cytokines signal through a common 
gp130 receptor but differ in their second receptor component. OSM signals 
primarily through the OSM Receptor (OSMR), but also has the unique ability to 
signal through the leukemia inhibitory factor Receptor (LIFR) (Mosley et al., 
1996). However, in chondrocytes, data suggests that in the chondrocytic cell 
line T/C28a4 (Catterall et al., 2001) and in primary HAC (Litherland et al., 2008) 
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LIFR is not expressed, suggesting that OSM signals only through the 
OSMR/gp130 heterodimer in chondrocytes. 
Signalling through the receptor is initiated by the binding of OSM to the OSMR 
leading to the recruitment and hetero-dimerisation of the OSMR with gp130. 
gp130 receptors do not have an endogenous kinase activity within their 
cytoplasmic region. The receptor therefore has to recruit complementary factors 
to transduce their signal. On binding, gp130 interacts with members of the 
Janus kinase (JAK) family, maintaining a constitutive association with the 
receptor. JAK1, JAK2 and Tyk2 are all activated on OSM binding (Lutticken et 
al., 1994, Wang and Fuller, 1994). Following binding, JAKs are activated by 
autophosphorylation, leading to JAK mediated tyrosine phosphorylation of the 
gp130 receptor. These tyrosine residues act as docking sites for multiple 
accessory proteins which can aid in the activation of signalling cascades. 
Proteins containing a Src homology 2 (SH2) domains have the capabilities to 
bind to these phosphorylated tyrosine residues, leading to downstream 
signalling activation. 
The signal transducers and activators of transcription (STATs) are one such 
signalling proteins that can bind these phosphorylated tyrosine residues. JAKs 
phosphorylate 4 tyrosine residues, Y767, Y814, Y905 and Y915, within the 
cytoplasmic tail of the receptor (Lehmann et al., 2006). Binding of STATs to the 
receptor leads to JAK-mediated tyrosine phosphorylation in their SH2 domain. 
This causes the formation of STAT dimers. These active STAT dimers can then 
translocate to the nucleus to drive gene expression.  
OSM binding to the OSMR/gp130 heterodimer also has the capability to 
activate signalling cascades other than just the JAK/STAT pathway. 
Phosphorylated tyrosine 757 also has the capability to act as a phosphorylation-
dependent docking site for Src homology phosphotyrosyl phosphatase (SHP-2). 
SHP-2 is a ubiquitously expressed cytoplasmic tyrosine phosphatase (Hof et al., 
1998). Once active, SHP-2 phosphorylates and activates phosphatidyl inositol-3 
kinase (PI3K) signalling, leading to the activation of Akt, NFκB and other 
downstream signalling events.  
OSM signalling can also activate the MAPK pathways. As well as SHP-2, 
numerous other SH2 domain containing proteins can bind to the OSMR/gp130 
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receptor. One such example is Ras, a monomeric GTPase, which is recruited to 
the receptor by growth factor receptor-bound protein 2 (GRB2), SHC and the 
GTP exchange factor, son of sevenless homolog (SOS), which in turn activates 
downstream MAPKKKs and thus MAPK (Kolch, 2000). OSM therefore activates 
multiple signalling cascades which are known to be important in the 
transcription of MMPs. Figure 1.9 shows the potential signalling cascades which 
OSM induces, leading to collagenase gene expression in HAC. 
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Figure 1.9. OSM signalling cascade. The binding of OSM to its receptor subunits, OSM 
receptor (OSMR) and gp130, activates several signalling pathways. These pathways include 
the PI3K/Akt pathway, the JAK/STAT pathway and the MAPK pathway. The IL-6 family of 
receptors do not possess intrinsic kinase activity, therefore for signal transduction the 
recruitment and activation of the JAKs is required. JAKs phosphorylated numerous downstream 
targets leading to signal transduction. JAKs are seen to phosphorylate and activate SHP2, 
leading to PI3K signalling pathway, which results in the production of the signalling molecule 
phosphatidyl-3, 4, 5-trisphosphate (PIP3). PIP3 can then go onto to activate Akt leading further 
downstream phosphorylation. This includes the activation of GSK-3, which has recently been 
implicated in arthritis under OSM simulation(Litherland et al., 2014), and NFκB, a well-
established MMP transcription factor. As well as the activation of Akt, PIP3 can activate 
phosphoinositide dependent protein kinase-1 (PDK1). PDK1 can then activate PKC isoforms. 
OSM signalling through the receptor also induces the JAK/STAT signalling pathway. Activated 
JAKs recruit and activate STAT proteins. The STATs then dimerise, leading to their 
translocation to the nucleus. These STATs can further be phosphorylated by the MAPKs 
priming the STATs for transcription. The STATs then bind to regulatory elements in the 
promoter of OSM-responsive genes and leading to gene expression. SHC can also be activated 
by OSM, this signalling molecule initiates MAPK signalling via the phosphorylation of GRB2. 
Activate GRB2 binds the GTP-exchange factor SOS. SOS interacts with Ras, recruiting Ras-
related C3 botulinum toxin substrate 1 (Rac1) and Raf-1. Rac1 activates the MAP3K/MKK 
cascades resulting in the activation of p38 and JNK via. Raf-1 activates the MEK/ERK1/2 
cascade. The activation of all these downstream cascades leads to alterations in gene 
expression. Adapted from Heinrich et al., (Heinrich et al., 2003) 
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1.6.2.1 Oncostatin M and arthritis 
OSM is seen to be elevated in the synovial fluid of patients with RA, but not 
patients with OA (Hui et al., 1997). The role of OSM in both osteo- and 
rheumatoid arthritis is not as clear as that of IL-1, with contradictory evidence 
suggesting OSM to have both pro- and anti-catabolic functions. Stimulation of 
HACs with OSM increases the levels of TIMPs, suggesting OSM to promote 
MMP inhibition and protect against cartilage degradation (Nemoto et al., 1996). 
In contrast, murine models have shown OSM to be pro-inflammatory and 
catabolic, leading to synovial hyperplasia, ECM remodelling and cartilage loss 
(Langdon et al., 2000). OSM also increases the levels of MMP-1 within RA 
synovial cells and HACs, leading to increased proteoglycan degradation and 
GAG release, whilst an increase in TIMP-1 is also observed (Fearon et al., 
2006). OSM has been shown to synergistically induce MMP-13 gene 
expression as well as cartilage degradation of cartilage in both bovine and 
human models, suggesting OSM works in combination with other pro-
inflammatory cytokines (Hui et al., 2003b, Rowan et al., 2001, Koshy et al., 
2002a).  
1.6.3 The synergistic properties of IL-1 in combination with OSM 
Numerous cytokines and growth factors are found within inflamed joints (van 
den Berg, 1999). These cytokines have the capability to interact synergistically 
to promote marked collagenolyisis by inducing collagenase gene expression. 
One of the most marked inductions of collagenase gene expression is observed 
when cells are stimulated with both IL-1 in combination with OSM (Rowan et al., 
2001). The first observations of the synergistic effect of IL-1 in combination with 
OSM on cartilage degradation were observed in bovine nasal cartilage. Here, 
dramatic collagen release from bovine explant cultures was seen, when 
compared to stimulation with IL-1 alone (Cawston et al., 1995a, Cawston et al., 
1995b). This suggested that IL-1 in combination with OSM further stimulated 
chondrocytes than when used individually. Further studies in bovine, porcine 
and human cartilage showed IL-1 in combination with OSM to increase MMP-1 
expression, suggesting this collagen release was collagenase-dependent 
(Cawston et al., 1998b). A decrease in the levels of TIMP production was also 
seen compared to that of OSM alone. The adenoviral delivery of IL-1 and OSM 
into murine joints confirmed these findings in vivo (Rowan et al., 2003). 
Collagenase gene expression has been shown to be synergistically induced in 
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HAC grown in monolayer (Barksby et al., 2006), indicating a potential 
mechanism by which collagen release is being induced in cartilage models. 
Other IL-6 family members have also been studied to see if they share these 
synergistic properties. Apart from IL-6 in combination with its soluble receptor, 
no other IL-6 family members synergise with IL-1 (Rowan et al., 2001). IL-11 
also synergises with IL-1 to induce MMP gene expression (Rowan, personal 
communication). 
All of these data suggest that IL-1 in combination with OSM stimulates collagen 
release and the breakdown of the ECM of cartilage. However, there is little 
knowledge of the signalling mechanism by which IL-1 and OSM synergise to 
induce collagenase gene expression. Recent work on the signalling cascades 
which are activated by IL-1 and OSM, leading to collagenase gene induction are 
beginning to emerge {Litherland, 2008 #65;Catterall, 2001 #13;Litherland, 2010 
#66}. Understanding of the signalling pathways induced by both cytokines 
individually may therefore aid in the understanding of disease progression. 
Finding drug targets which inhibits chondrocyte production of MMPs under a 
complex stimulus is more likely to inhibit disease progression compared to 
targeting one factor. Further understanding is therefore needed to understand 
how IL-1 and OSM together regulate collagenase expression and the pathways 
at which this synergistic cross-talk occurs.  
IL-1 in combination with OSM has been shown to be the most prolific inducer of 
MMP gene expression in HAC grown in monolayer (Cawston et al., 1998b), with 
this synergistic stimulus also leading to the degradation of bovine nasal 
cartilage and the release of proteoglycan (Cawston et al., 1995b). For these 
reasons, this stimulus is often used as model of the cytokines elevated during 
arthritic disease. Many studies use one cytokine as a stimulus to examine cell 
signalling. However, multiple cytokines are released during disease, activating 
many pathways which exhibit cross-talk. Therefore understanding the effects of 
cell signalling in a complex stimulus gives a greater understanding of the 
pathways activated during a disease. This stimulus helps us to understand the 
signalling cascades activated during the progression of both OA and RA.  
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1.7 Signalling pathways regulated by IL-1 and OSM 
For pro-inflammatory cytokines to relay their inflammatory signal, inducing 
transcriptional changes, the cytokine must activate the internal signalling 
pathways of the cell. Binding of the cytokine to the receptor can lead to 
autophosphorylation events and signal transduction. IL-1 and OSM, on binding 
to their receptor, are known to activate multiple signalling pathways within 
chondrocytes. These pathways include the MAPKs, PI3K, STATs and the NFκB 
pathways. 
Signalling in inflammation is complex, with multiple signalling cascades being 
activated on cytokine stimulation within different cell contexts. Further 
complexity is due to interaction between different signalling pathways, leading 
to further induction of these cascades. This ‘crosstalk’ has a possible role in the 
synergy seen between various cytokines (Koshy et al., 2002a, Cawston et al., 
2003, Hui et al., 2003a). IL-1 and OSM can activate independent pathways, but 
in some cases both cytokines activate the same pathway. Cross-talk between 
signalling pathways activated by either cytokine can also occur. This cross-talk 
leads to further signalling activation and therefore the synergistic induction of 
MMP gene expression seen with these stimuli.  
Little is known about the signalling events which regulate collagenase gene 
expression within chondrocytes stimulated with IL-1 in combination with OSM. 
Some of this is due to the paradigm that inflammatory disease is synovium-
driven (Rowan and Young, 2007). However, this concept is changing, with more 
research being performed to understand inflammation-driven activation of 
proteinases within chondrocytes. Therefore, elucidating and understanding the 
signalling events which both cytokines activate is crucial in understanding how 
IL-1 and OSM regulate collagenase expression through these pathways within 
chondrocytes with an inflammatory context. 
1.7.1 The MAPK pathway 
The Mitogen-activated protein kinase cascade consists of multiple 
serine/threonine kinases. These kinases have the capability to transduce the 
cytokine signal from receptor into transcriptional changes within the cell. The 
signal transduction occurs by a series of phosphorylation cascades that 
culminate in the activation of effector proteins and as transcription factors. This 
leads to transcriptional changes within the cell, dictated by the cytokine. The 
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MAPK pathways consists of three distinct signalling cascades; extracellular 
signal-regulated kinase (ERK), Jun N-terminal Kinase (JNK) and p38 kinase 
(SAPK). MAPK signalling is a three tiered process in which upstream activation 
of a MAP kinase kinase kinase (MAPKKK) initiates the downstream signalling 
cascade. MAPKKK activation leads to MAP kinase kinase (MAPKK) 
phosphorylation which can then phosphorylate the MAPK itself. MAPKs share 
many upstream activating factors, therefore to ensure signal specificity, scaffold 
proteins are used. These scaffolds bind to components of the signal cascade in 
specific modules, forming complexes, ensuring correct signal transduction. 
These scaffolds include, β-arrestin, MEK partner-1, kinase suppressor of Ras 
as well as the tribbles (Brown and Sacks, 2009) (Kiss-Toth et al., 2004). All of 
these measures ensure that the signal is transduced from receptor into 
transcriptional changes. IL-1 and OSM individually and in combination have 
been shown to activate all three MAPK pathways within chondrocytes (Liacini et 
al., 2002, Li et al., 2001, Geng et al., 1996).  
1.7.1.1  ERK pathway 
The ERK pathway is well established in regulating collagenase gene expression 
within chondrocytes. Under the stimulation of IL-1 and OSM, ERK can be 
activated by the phosphorylation of the MAPKKK RAF, which in turn 
phosphorylates the MAP2K MEK, leading to the phosphorylation and activation 
of ERK (Vincenti and Brinckerhoff, 2002). Once active, ERK can play numerous 
roles in regulating collagenase expression. The inhibition of ERK using siRNA 
and ERK inhibitors shows a clear loss of collagenase gene expression within 
chondrocytes and collagen release from explant cultures (Litherland et al., 
2010). The mechanism by which ERK induces collagenase expression has not 
been fully elucidated. It is however believed that ERK can induce MMP-1 gene 
expression via the phosphorylation of a CCAAT enhancer-binding protein 
(C/EBP) (Raymond et al., 2006). IL-1 stimulation of ERK is seen to 
phosphorylate C/EBP at threonine 235 within chondrocytes, leading to 
activation. This transcription factor is then seen to bind to the C/EBP binding 
site found within the MMP-1 promoter, leading to transcription. ERK may also 
work indirectly, activating Elk-1, leading to the transcription of Fos, a known 
member of the AP-1 transcription factors (Gille et al., 1995).  
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1.7.1.2  JNK pathway 
JNK consists of 3 individual isoforms (JNK1, JNK2 and JNK3), which are all 
expressed within chondrocytes. JNK is regulated by several MAPKKK, which 
phosphorylate the MAP2Ks, MAPKK4 or MAPKK7 leading to the 
phosphorylation and activation of JNK. Jun is a downstream target of JNK. This 
key member of the AP-1 transcription factor is seen to be directly 
phosphorylated at serine residues 63 and 73 (Pulverer et al., 1991), increasing 
the transcriptional activity of Jun. JNK also plays a role in the priming of STAT-1 
and STAT-3 by phosphorylating these at the serine residue 727, leading to 
greater transcriptional activity (Lim and Cao, 1999). Through inhibitor and 
siRNA mediated gene silencing, JNK has been shown to regulate collagenase 
gene expression within chondrocytes and other tissues of the joint (Mengshol et 
al., 2000, Han et al., 2001).  
JNK inhibition in the human chondrosarcoma cell line SW1353, by the 
overexpression of the inhibitory scaffold protein JNK-interacting protein (JIP), 
led to reduced MMP-13 gene expression by 60%. The levels of phosphorylated 
Jun were also seen to be reduced (Mengshol et al., 2000). Isoform specific 
gene silencing of each isoform of JNK in HAC showed down-regulation of MMP-
1 and MMP-13 gene expression when stimulated with IL-1 in combination with 
OSM (Litherland and Rowan, unpublished data). JNK inhibition within synovial 
fibroblasts also causes a decrease in the phosphorylation of Jun and the 
transcription of collagenase genes (Han et al., 2001). Adjuvant-induced arthritic 
rats, when treated with the JNK inhibitor SP600125, had reduced swelling as 
well as a decrease in bone and cartilage damage (Han et al., 2001). JNK has 
therefore a clear involvement in the regulation of collagenase gene expression, 
and inhibition within the joint leads to a reduction in the progression of disease.  
1.7.1.3  p38 pathway 
p38, named so after its size of 38 kDa, consists of 4 distinct isoforms; p38α, 
p38β, p38γ and p38δ. p38 can be activated under stress and inflammatory 
conditions. p38 again follows the three-tiered kinase cascade of the MAPK 
pathway. In general, p38 is phosphorylated and activated by several MAP2Ks 
including MAPKK3, 4 and 6, these are in turn activated by MAP3K, such as 
MEKK1-4 (Cuadrado and Nebreda, 2010). The p38 Kinases contribute to MMP-
1 (Mengshol et al., 2000, Ridley et al., 1997) and MMP-13 (Mengshol et al., 
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2001, Mengshol et al., 2000) gene expression in direct response to 
inflammatory mediators. In chondrocytes, p38 is seen to recruit the AP-1 
complex and the chondrocyte/osteoblast-specific transcription factor RUNX2 to 
the promoter of MMP-13, leading to increased transcription (Mengshol et al., 
2001). p38 also increases the stability of MMP-1 mRNA, although the 
mechanism by which this occurs has not been elucidated (Reunanen et al., 
2002). Treatment of rat and mouse models with the p38 inhibitor SB 203580 led 
to decreased bone resorption and paw inflammation, implicating p38 in 
regulating the arthritic phenotype (Badger et al., 1996).   
1.7.2  The PI3K pathway 
PI3Ks are a family of enzymes that catalyse the phosphorylation of the 3-
position of the inositol ring of phosphoinositides (Hawkins et al., 2006). 
Phosphorylation of phosphatidylinositol (PtdIns) by PI3K leads to the production 
of phosphatidylinositol 3, 4 bisphosphate (PtdIns 3, 4, P2) and 
phosphatidylinositol 3, 4, 5 trisphosphate (PtdIns 3, 4, 5, P3), two important 
signalling molecules. These two signalling molecules can be further processed 
into diacylglycerol (DAG) and inositol trisphosphate (IP3). PI3K have the 
capability to bind to receptors which bind growth factors, hormones, antigens 
and inflammatory stimuli, leading to the activation of signalling pathways which 
regulate cell growth, survival, proliferation and movement. (Rodriguez-Viciana 
et al., 2004). Three major classes of PI3Ks have been described: Classes I, II 
and III. PI3K is divided into these groups based on structure and functional 
homologies (Hawkins et al., 2006).  
In chondrocytes class IA PI3Ks have been implicated in the regulation of 
collagenase gene expression (Litherland et al., 2008). Class IA consist of 
dimers of either p110α, p110β or p110δ catalytic subunits and either p50-
55/p85 regulatory subunits. Class IA PI3Ks are activated by binding to 
phosphotyrosine receptors such as the OSMR. Phosphorylated tyrosine 
residues within the receptor act as binding ligands for SH2 domains found 
within the regulatory subunits of PI3Ks. The mechanism by which activation 
occurs is still unclear; it may be down to conformation changes within the 
regulatory domain. PI3K signalling was first shown to regulate collagenase 
expression through OSM stimulation of chondrocytes. PI3K activation led to 
increased MMP-13 expression. Blocking PI3K using the PI3K inhibitor 
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LY294002 lead to a decrease in MMP-13 mRNA and protein levels within HACs 
(El Mabrouk et al., 2007). Litherland et al., (2008) further showed that the PI3K 
subunit p110α was required for MMP-1 and MMP-13 gene expression, whereas 
p110δ was required for MMP-13 gene expression (Litherland et al., 2008). This, 
for the first time, specifically implicated the PI3K IA class of PI3Ks as the 
regulators of collagenase expression; this activation occurred via the known 
PI3K substrate Akt. 
1.7.2.1  AKT 
One of the major kinases activated by PI3K is Akt (otherwise known as protein 
kinase B). This is a serine/threonine kinase known to be phosphorylated and 
activated by OSM stimulation (Litherland et al., 2008). Activation of the OSM 
receptor leads to tyrosine autophosphorylation and PI3K activation. PtdIns 3, 4, 
P2 is then phosphorylated and converted to PtdIns 3, 4, 5, P3, which binds Akt 
leading to a change in confirmation. This exposes the amino acid threonine 308 
within the activation loop of Akt. This is a known phosphorylation site of PDK1. 
Phosphorylation leads to Akt activation. Within chondrocytes, isoform specific 
roles of Akt were observed (Litherland et al., 2008). Here, Akt1 was required for 
MMP-1 and MMP-13 mRNA expression, whereas PDK-1 and Akt3 induced 
MMP-13 collagenase expression. The mechanism by which Akt regulates 
collagenase expression has not been fully elucidated. It is though proposed that 
Akt regulates collagenase expression through regulation of the NFκB pathway 
(Chen et al., 2013), a known downstream substrate of PI3K-PDK1-Akt.  
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Figure 1.10 PI3K signalling. OSM stimulation leads to the phosphorylation and activation of 
the PI3K signalling pathway. This leads to the induction of PKC isoforms that contain an AGC 
loop, as well as Akt activation, this is meditated by PDK1. PTEN dephosphorylated PIP3, 
reducing the amounts of this secondary messenger. Induction of both pathways in chondrocytes 
has been shown to induce collagenase gene expression in HAC (Litherland et al., 2008, 
Litherland et al., 2010). However, the precise mechanism by which Akt regulates MMP gene 
expression in chondrocytes is currently unknown; this may be via GSK-3 modification as 
suggested by (Litherland et al., 2014) or NFκB regulation. 
 
1.7.3 Transcription factors induced by IL-1 and OSM 
1.7.3.1  AP-1 
One of the major transcription factors involved in MMP gene expression is the 
activator protein-1 (AP-1). This transcription factor complex consists of 
homo/heterodimers made up of multiple proteins from major proto-oncogene 
families; these include the major family members, Jun (c-Jun, Jun B and Jun D) 
and Fos (c-Fos, Fos B). AP-1 members can also bind to Fos-related antigen 
(Fra)-1 and Fra-2), as well as activating transcription factor (ATF), ATF1, ATF2, 
ATF3, ATF4, ATF5, ATF6, and ATF7 to form the AP-1 transcription factor. The 
composition of these factors determines their transcriptional activity.  
AP-1 binding elements found within the promoters of MMP-1 and MMP-13 are 
well established as important transcription factor binding sites involved in 
collagenase gene expression within chondrocytes. The main AP-1 site or TPA 
responsive element (TRE) (5’-TGAG/CTCA-3’) sits approximately -70bp 
upstream of the transcription start site (Benbow and Brinckerhoff, 1997) and 
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binds dimers of Fos and Jun. Several other AP-1 sites are found throughout the 
MMP promoter and may aid in transcription. Induction of Fos and Jun protein 
expression is therefore crucial in the expression of the MMPs. Signalling 
pathways known to activate MMP gene expression are seen to induce the 
expression of these two family members. IL-1 stimulation of numerous cell 
types, leads to the AP-1 dependent transactivation of many MMPs via the 
activation of the MAPK signalling pathways. JNK and ERK are of particular 
relevance to MMP transcription as they phosphorylate and activate Jun (Karin, 
1995, Leppa et al., 1998). The ERK pathway also regulates the activity of 
erythroblastosis twenty-six (Ets) which can cooperate with AP-1 proteins in the 
promoter of multiple MMP promoters (Vincenti and Brinckerhoff, 2002). p38 
signalling is seen to increase the protein expression of Fos and Jun, 
contributing to collagenase gene expression indirectly through AP-1 regulation 
(Vincenti and Brinckerhoff, 2002). Protein Kinase C (PKC) has been implicated 
in regulating Fos mRNA and protein levels within chondrocytes stimulated with 
IL-1 in combination with OSM (Litherland et al., 2010), and the silencing of Fos 
led to a decrease in mRNA expression of MMP-1 and MMP-13 under the 
stimulation of IL-1 in combination with OSM (Litherland et al., 2010). All of these 
signalling cascades have the potential to increase the transcription and stability 
of Fos and Jun protein, leading to their binding of the AP-1 binding site in the 
promoters of MMPs, leading to increased transcription. Increased Fos 
expression is seen in the mid- and calcified zones of cartilage from 
inflammatory arthritis (Tsuji et al., 2000). All of these data indicate signalling 
pathway induced transcription and activation of Fos and Jun leading to 
increased expression of MMPs within chondrocytes.  
1.7.3.2 STATs 
As previously mentioned, the JAK/STAT pathways can be activated by OSM 
binding to the OSMR, leading to STAT phosphorylation and transcriptional 
activation. Currently seven STATs have been identified: STAT-1, STAT-2, 
STAT-3, STAT-4, STAT-5a, STAT-5b and STAT-6. STATs are transcription 
factors which must form homo- or hetero-dimers to become transcriptionally 
active. JAK-dependent phosphorylation leads to dimer formation and 
translocation to the nucleus. Further modification occurs by serine 
phosphorylation within the transactivation domain, increasing their transcription 
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potential. Phosphorylation at this site is dependent on the MAPK signalling 
pathways. STAT signalling has been implicated in both RA and OA, with STAT3 
being shown to regulate MMP-1 gene expression under the stimulation of IL-1 
in combination with OSM in HAC. STAT3 was shown to not directly bind to the 
promoter of MMP-1 but instead bind to a hSIE (sis-inducible element) binding 
site (Catterall et al., 2001). It was therefore proposed that STAT3 was binding to 
the SIE in the c-fos promoter leading to increased transcription, increasing the 
levels of this AP-1 protein. This work showed STAT3 to indirectly led to 
increased transcription of MMP-1 via c-fos gene induction (Catterall et al., 
2001). The role of STAT3 was later confirmed by Litherland et al., 2010 in which 
STAT3 gene silencing led to reduced MMP-1 and MMP-13 gene expression 
when under the stimulation of IL-1 in combination with OSM in chondrocytes. 
Silencing also led to a decrease in Fos protein levels which was shown to down 
regulate collagenase expression (Litherland et al., 2010). Electrophoretic 
mobility shift assay (EMSA) data also confirm that STAT-1, -3 and -5 all have 
the potential to bind to the c-fos promoter under synergistic conditions in HAC 
(Rowan, unpublished data).  
The importance of STAT signalling in arthritis is further implicated by the 
development of JAK inhibitors which are in circulation and undergoing clinical 
trials. Tofacitinib, is a JAK3 inhibitor which is clinically available to treat patients 
with moderate to severe RA (Rakieh and Conaghan, 2013). It is currently 
available in the United States, Japan and Russia. The activation of STAT 
signalling is therefore crucial in the progression of both RA and OA and further 
understanding of this pathway has the potential to lead arthritic drugs. 
1.7.3.3  Nuclear factor κB 
NFκB is a family of transcriptional factors which regulate the expression of 
multiple genes involved in controlling both innate and adaptive immunity. 
Canonical NFκB signalling and transcription occurs through tightly regulated 
protein complexes. NFκB transcriptional control arises from the assembly of 
homo- and heterodimers of 5 different NFκB proteins (RelA/p65, RelB, c-Rel, 
NFκB1/p105, NFκB2/p100) (Marcu et al., 2010). Inhibitory proteins known as 
IκB (IκBα, IκBβ, IκBε) sequester these homo/heterodimers within the cytoplasm, 
inhibiting their transcriptional activities. Upon stimulation, dimers are activated 
by the amino-terminal phosphorylation of IκB by the IκB kinase (IKK) 
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signalosome complex (IKKα, IKKβ and NEMO) (Scheidereit, 2006). 
Phosphorylation of IκB within conserved destruction boxes targets the protein 
for polyubiquitination and proteasomal degradation. NFκB is freed from its 
inhibitory protein exposing a nuclear localization sequence, this targets the 
dimer to the nucleus; binding to the specific NFκB binding site then occurs, 
leading to active transcription. The binding and activation of NFĸB binding sites 
also stimulates IĸB to bind NFκB and translocate to the cytoplasm acting as a 
negative feedback loop. 
IL-1 signalling is well established as an activator of NFκB, with IL-1 receptor 
activation stimulating the canonical pathway (Bonizzi and Karin, 2004, 
Wickremasinghe et al., 1999, Fan et al., 2006, O'Neill and Greene, 1998). IL-1 
activation of NFκB signalling has been shown to lead to MMP gene induction 
within chondrocytes (Fan et al., 2006). NFκB has therefore been implicated in 
the progression of OA, with a clear role in the regulation of collagenase gene 
expression. NFκB binding sites are found with the proximal promoters of many 
MMPs (Clark et al., 2008); both MMP-1 and MMP-13 contain NFκB binding 
sites. MMP-1 is shown to contain a non-canonical NFκB binding site (Vincenti et 
al., 1998), whereas MMP-13 is shown to contain a canonical site. Studies in 
mice with experimental arthritis immunised with collagen have also showed 
NFκB expression to correlate with MMP-13 and MMP-3 levels, indicating NFκB 
to regulate the expression of both MMPs (Han et al., 1998). 
1.8 Protein Kinase C  
The PKC family consists of 10 serine/threonine kinases. These kinases are 
divided into three distinct groups, dependent on their domain structure and 
activation. These groups consist of; the conventional (cPKC), atypical (aPKC) 
and novel PKCs (nPKC). The PKC family belongs to the AGC family of protein 
kinases, which includes over 70 proteins including PKA, PKC and PKG; all are 
grouped together as share a similar structure (Roffey et al., 2009). Figure 1.11 
shows the domain structures for each of the three PKC groups and the isoforms 
which belong to these groups, defining their individual differences. 
Phosphatidylserine acts as an essential co-factor for all 3 PKC groups aiding in 
PKCs activation, with each individual group of PKCs needing additional 
allosteric factors. The cPKCs comprise of α, β׀, β׀׀ and γ, with all requiring both 
DAG and calcium (Ca2+) for activation. nPKCs consist of δ, θ, ε and η, all lack 
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the Ca²+ binding domain but still require DAG for activation. The aPKC consist 
of both ζ and ι isoforms. These isoforms lack both the ability to bind DAG and 
Ca2+ as they contain no C2 domain and have an atypical C1 domain; they still 
require PIP3 and/or ceramide (Steinberg, 2008). PKC structural and cellular 
diversity allows the family to differentially regulate various cellular signalling 
pathways. 
All PKC isoforms contain a conserved catalytic or kinase domain, as well as an 
N-terminus or regulatory domain. The regulatory domain in the inactive form 
acts as a pseudosubstrate, binding the active site and inhibiting the catalytic 
domain (Steinberg, 2008). The pseudosubstrate positions itself within the 
catalytic domain of the PKC and positions an alanine in the serine/threonine 
phospho-acceptor site preventing activation of the protein (Steinberg, 2008). 
For PKC activation, PKC must translocate and bind to the cell membrane. 
Phosphorylation of PKC by phosphatidylserine, DAG or Ca2+, causes PKC to 
translocate to the cell membrane. Further phosphorylation of PKC, via upstream 
allosteric factors, leads to a conformational change within the protein, causing 
the expulsion of the N-terminal pseudosubstrate from the catalytic region, 
activating the protein (Roffey et al., 2009). PKC is then primed for activity via 
phosphorylation initiated by PDK-1 (Steinberg, 2008). This protects PKC from 
degradation, stabilising it, for further phosphorylation by allosteric factors. Once 
activated the catalytic domain of PKC can then bind ATP, hydrolyse and 
transfer one phosphate group to either a serine or threonine of its downstream 
substrate. 
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Figure 1.11. Diagram showing the domain structures of each individual PKC group. PKC 
has 2 major conserved domains, the kinase domain and less conserved regulatory domain. The 
C2 domain acts as a calcium dependent phospholipid binding domain, except in the novel 
isoforms which are calcium independent. The C1 domain acts to bind PMA and DAG in all 
isoforms except in the atypical isoforms, which bind PIP₃ or ceramide. Taken from Steinberg et 
al (Steinberg, 2008) 
 
1.8.1 Protein kinase C in arthritis 
PKCs can regulate multiple cellular processes including proliferation, apoptosis 
and migration (Griner and Kazanietz, 2007). PKC has mainly been studied in 
relation to cancer, with PKC signalling being implicated in tumor invasion and 
metastasis, with the regulation of the MMPs being a major area of focus 
(Beliveau et al., 2010). Altered gene expressions of PKC isoforms are observed 
within tumour cells, suggesting PKC to play an important role in tumor 
progression and growth. Because of the downstream consequences of PKC 
signalling, PKC has been implicated in the progression of arthritis. PKC is 
known to be activated by numerous pro-inflammatory cytokines leading to the 
induction of multiple downstream signalling events which can lead to disease 
progression. 
In relation to arthritis and cartilage biology, PKC has been implicated in cartilage 
homeostasis. PKC is seen to regulate the differentiation of mesenchymal cells 
into chondrocytes, implicating PKC in producing the foundations of cartilage 
(Chang et al., 1998). PKC can also maintain the phenotype of the chondrocyte, 
with the dedifferentiation of chondrocytes in monolayer being linked with PKC 
regulation (Yoon et al., 2002). The regulation of this pathway is therefore 
important in the maintenance of healthy chondrocytes.  
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PKC is also shown to regulate the remodelling of the ECM of cartilage, 
specifically via the regulation of MMP gene expression.  Research into the role 
of PKC in the regulation of MMP gene expression began with broad spectrum 
inhibition. PMA (a DAG homologue known to activate PKC) stimulation of 
chondrocytes was the first link between MMP gene induction and PKC. Tardif et 
al., showed chondrocytes stimulated with PMA led to increased MMP-13 
production (Tardif et al., 1999). Inhibitor studies were then performed to further 
understand PKC role in chondrocyte homeostasis and MMP gene induction. 
Broad spectrum PKC inhibition by the PKC inhibitor bisindolylmaleimide, led to 
a decrease in MMP-13 expression, indicating PKC involvement in MMP gene 
regulation. The PKCδ isoform was then implicated in MMP-13 regulation with 
inhibition using Rotterlin (now seen as a poor, unselective PKC inhibitor (Davies 
et al., 2000) leading to decreased expression. PKC is also implicated in 
collagen breakdown, with bovine nasal cartilage explant cultures stimulated with 
IL-1 and OSM showing reduced collagen breakdown when PKC was inhibited 
using Gӧ6983, Gӧ6976 and Cal C (all three of these inhibitors are pan-PKC 
inhibitors) (Litherland et al., 2010). Individual PKC isoform gene silencing led to 
the atypical PKCs being implicated in the regulation of MMP-1 and MMP-13 
gene expression. Silencing of PKCζ led to decreased MMP-1 and MMP-13 
gene expression, whereas PKCɩ silencing led to reduced MMP-13 gene 
expression only, in HAC stimulated with IL-1 in combination with OSM 
(Litherland et al., 2010). PKC was seen to regulate STAT and ERK signalling 
leading to increased gene expression of c-fos. Isoform specific roles for the 
PKCs where therefore shown in chondrocytes, illustrating the importance of 
isoform specific study.  
PKC signalling is involved in the transduction of the inflammatory signals 
observed within RA. PKC regulates T-cell production of IL-2 (Isakov and 
Altman, 2002), implicating PKC in the regulation of the inflammation seen within 
RA. T-cells deficient of PKC are seen to have reduced proliferation, 
differentiation and survival (Chand et al., 2012). PKC in inflammatory arthritis is 
implied through gene KO studies in antigen-induced arthritis. Here PKCθ KO 
mice are protected from Th1-dependent antigen induced arthritis (Healy et al., 
2006).  
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Studies have therefore shown PKC to regulate chondrocyte and cartilage 
homeostasis as well as the induction of inflammatory mediators associated with 
arthritis. PKC therefore has the potential as a therapeutic target, with the 
understanding of further downstream signalling via this kinase aiding in the 
understanding of the signalling events activated during disease.  
1.9 Protein kinase D 
PKD is a family of three closely related serine/threonine kinase isoforms. PKD is 
a downstream substrate of PKC, a known modulator of MMP gene expression 
within chondrocytes stimulated with pro-inflammatory cytokines (section 1.8). 
PKD has not previously been studied in the context of arthritis, but has been 
shown to be a potential therapeutic target in other diseases such as breast and 
prostate cancer (Biswas et al., 2010, Eiseler et al., 2009). PKD has already 
been shown to modulate multiple signalling pathways and shown to be involved 
in cell survival/proliferation, apoptosis, plasma membrane-directed transport, 
metastasis and inflammation (Kim et al., 2010, McEneaney et al., 2010, Eiseler 
et al., 2009). The isoforms of PKD therefore have the potential to be signalling 
kinases involved in the induction of MMP gene expression within HAC in a pro-
inflammatory context.  
Most of the current work studying PKD has been referred to PKD as a kinase 
‘entity’, with no consideration of isoform specificity. This situation is beginning to 
change, with data now emerging in which each individual isoforms of PKD has 
been studied (Bernhart et al., 2013, Biswas et al., 2010). In this thesis when 
work refers to ‘PKD’ no specific isoform is being referred to.  
1.9.1 The structure of PKD 
PKD comprises of 3 isoforms (PKD1, 2 and 3), all of which share a similar 
domain structure, with greatest homology found within the catalytic domains. 
PKD was first described as a novel member of the aPKC family, and named 
PKCμ, in humans (Johannes et al., 1994). A murine form of PKCμ had 
previously been described and was known as PKD (Valverde et al., 1994). The 
two other isoforms of PKD were described later; PKD2 described by Sturany et 
al in 2001 and PKD3/PKCν by Hayashi et al in 1999.  
PKD was first classified as belonging to the AGC family of serine/threonine 
kinases, with a unique molecular architecture distinct to other members (Van 
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Lint et al., 2002). Once further studied, PKCμ was re-classified as a novel 
serine/threonine kinase and renamed PKCμ/PKD, a new family of proteins. This 
was due to differences in domain structure compared to that of PKC. The 
isoforms of PKD were then re-classified as members of the calcium/calmodulin 
(CAMK) family based on sequence similarity in the kinase domain and substrate 
specificity.  
Each isoform of PKD has a molecular weight of around 115 kDa (Johannes et 
al., 1994) and range from 875-918 amino acids in length, depending on isoform 
(Avkiran et al., 2008). These proteins consist of an N-terminal regulatory 
domain consisting of two cysteine-rich zinc finger-like motifs and a pleckstrin 
homology (PH) domain. This domain is then linked to a C-terminal catalytic 
domain (Avkiran et al., 2008). The N-terminus of PKD comprises of many apolar 
amino acids, consisting mainly of alanines and prolines (Lint et al., 2002). This 
is linked by the tandem repeats of cysteine rich zinc finger-like motifs named 
Cys1 and Cys2. Deletion studies of both the zinc fingers showed activation of 
the protein suggesting these to have inhibitory affects (Iglesias and Rozengurt, 
1999). These are linked by long Zn finger-linker region ranging from 64-76 
amino acids in length. This linker region is much longer than the PKC isoform 
linkers which also link two Zn finger-like motifs. Both of the cysteine-rich 
domains allow PKD to bind to DAG and phorbol esters with great affinity, aiding 
in the regulation of the protein (Van Lint et al., 1995). Figure 1.12 shows the 
structure of each PKD isoform. 
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Figure 1.12. PKD isoform domain structures. Each PKD isoform has a molecular weight of 
close to 115 kDa and around 875-918 amino acids in length. Each isoform contains two 
cysteine rich domains (cys1 and cys2) which are known to bind to DAG. These are joined by a 
long linker region. Next is a pleckstrin homology domain which acts as an autoinhibitory domain, 
as well as being able to bind PKC and other phospholipids. This is followed by the catalytic 
domain of the protein which contains key PKC phosphorylation sites which vary between each 
isoform. Also found within PKD1 and PKD2 is an autophosphorylation domain which is known to 
represent PKD activity when phosphorylated. 
 
Following this region is a PH domain. The PH domain within PKD has also an 
autoinhibitory function, with deletion of the PH domain causing the protein to be 
constitutively active (Iglesias and Rozengurt, 1998). The PH domain therefore 
keeps the protein in a state of low basal activity due to its intramolecular 
autoinhibitory interactions (Rybin et al., 2009). The PH domain also aids in the 
binding of PKD to phosphatidylinositol as well as other components of signalling 
pathways: PKC binds to PKD via the PH domain of PKD, which aids in signal 
transduction (Brandlin et al., 2002).  
Following the PH domain is the catalytic domain of the protein. The catalytic 
region of the protein is regulated by phosphorylation of specific amino acids 
within and around the catalytic domain. These specific phosphorylation sites 
vary between isoform but are within a short distance of each other. Within the 
catalytic domain is the PKC phosphorylation site, which once phosphorylated 
can activate the protein. 
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PKC phosphorylates PKD at serine residues found at 744/748 in PKD1, 
706/710 in PKD2 and 731/735 in PKD3. These amino acids are found within the 
activation loop of the protein. Phosphorylation leads to the stabilisation of the 
activation loop such that it is in the optimal conformation for catalysis (Rybin et 
al., 2009). In addition to the 744/748 phosphorylation site PKD contains an 
autophosphorylation site, found at ser916 in the carboxy-terminal of PKD1, and 
found at ser876 in PKD2. This site has not been identified in PKD3. 
Phosphorylation modifies the conformation of the protein and is an important 
marker of activity (Vertommen et al., 2000). The phosphorylation site itself is not 
required for activity in vivo or in vitro (Vertommen et al., 2000). Ser203 is also 
another known autophosphorylation site for PKD1 and is located within the 
regulatory domain. Phosphorylation is also seen at Ser255 which is also located 
in the regulatory domain of the protein; this protein is shown to also be 
phosphorylated by members of the PKC family. Ser255 mutations showed a 
decrease in the Kcat of the protein suggesting that this phosphorylation site 
regulates protein kinase activity (Vertommen et al., 2000). 
PKD and its isoforms though structurally similar, are though to have different 
roles within individual cell types. Each isoform may therefore interact within 
multiple signalling pathways in a cell-specific manner. 
1.9.2 Protein Kinase D activation 
PKD is activated in a multi-step process. Three major events can cause this 
activation; the direct binding of DAG, phosphorylation and caspase-mediated 
proteolytic cleavage, all of which lead to activation of the catalytic domain of 
PKD.  
1.9.2.1  Protein kinase C phosphorylation 
PKD is a well-known substrate of PKC, with PKC directly phosphorylating PKD 
within its activation loop. Phosphorylation occurs at Ser744 leading to the 
autophoshorylation of Ser748, activating the protein. Upon Ser744/Ser748 
phosphorylation, in PKD1, Ser916 autophosphorylates, this is a known indicator 
of PKD activation. PKC inhibitors block the activation and phosphorylation of 
these sites, showing PKC to be playing a crucial role in the activation of PKD 
(Waldron et al., 2004). In relation to arthritis, PKC delta (Im et al., 2007) and the 
atypical PKCs are the only isoforms to be shown to regulate MMP gene 
expression (Litherland et al., 2010) and therefore these isoforms may initiate 
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PKD activation in HAC. This contrasts to many findings within numerous other 
cells types in which the phosphorylation of PKD is initiated by the novel PKCs. 
PKD phosphorylation at the serine744/748 site was first identified by the 
Rozengurt group (Iglesias et al., 1998). The Rozengurt group showed that 
PKCε and η were both capable of stimulating PKD to comparable levels to that 
of stimulation with phorbol esters (Zugaza et al., 1996). However, they showed 
that PKD could not be phosphorylated by atypical PKCζ. This suggested that 
the novel PKC had specific roles in the stimulation of PKD. This may be cell 
specific, with different isoforms of PKC activating PKD within different cell types. 
1.9.2.2  Diacyl glycerol activation 
DAG is generated by the hydrolysis of phosphatidlyinositol 4, 5-bisphosphate by 
Phospholipase C (PLC). PLC breaks down PIP2 to produce two secondary 
messengers; IP3 and DAG (Fukami et al., 2010). IP3 triggers the release of 
calcium from intracellular stores (Fukami et al., 2010), while DAG can activate 
PKC and PKD directly (Rozengurt, 2011). DAG can regulate PKD in two ways; 
firstly it can directly bind to PKD by binding the C1 domain in PKD, activating 
the protein, secondly DAG can bind and activate PKC which can then activate 
PKD by phosphorylation. DAG can also recruit PKC and PKD to the plasma 
membrane, ensuring both are in close enough proximity, enabling PKC to 
phosphorylate PKD (Rozengurt, 2011). 
1.9.2.3  Caspase mediated activation in oxidative stress 
PKD can also be activated through caspase-mediated proteolytic cleavage in 
cells induced by reactive oxygen species (Vantus et al., 2004). PKD cleavage 
by caspase-3 leads to increased kinase activity. Cleavage leads to the 
production of two PKD catalytic fragments which are thought to be produced via 
two capase-3 cleavage sites found within PKD. Cleavage occurs between the 
catalytic and regulatory domain of the protein, suggesting the loss of the 
regulatory zinc finger motifs can cause activation of the protein (Vantus et al., 
2004). 
1.9.2.4 Activation by tyrosine phosphorylation  
PKD can also be activated by phosphorylation events other than PKC mediated 
phosphorylation. PKD can be activated by the phosphorylation of tyrosine 
residues found within the PH domain, when the cell is under oxidative stress. 
PKD has been shown to be phosphorylated at Tyr432, Tyr463, and Tyr502 
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leading to PKD activation (Vertommen et al., 2000). Further study showed that 
Tyr463 phosphorylation is a crucial event in the activation of PKD. Mutation and 
siRNA silencing studies showed that, via the Src–Abl pathway, PKD could be 
activated, independent of PKC (Storz et al., 2003). Tyrosine phosphorylation 
may allow the binding of PKC isoforms to the PH domain causing further PKD 
phosphorylation and activation PKD (Storz et al., 2003, Waldron et al., 1999). 
1.9.3 PKD activation via IL-1 and OSM 
The potential mechanism by which PKD is activated and phosphorylated by IL-1 
and OSM in HAC is unclear. However, data from the literature has shown PKD 
to be downstream of the IL-1 receptor, with direct and indirect activation via IL-1 
stimulation (Song et al., 2007). PKD1 has been shown to be phosphorylated by 
PKC in a IL-1 dependent mechanism, suggesting PKD to be phosphorylated 
and activated by this mechanism. PKD has also been shown to bind to the 
TLR9/MyD88 receptor complex via an interaction with IRAK4, IRAK1 and 
TRAF6 (Park et al., 2009). This suggests a mechanism by which PKD could 
bind to the IL-1 receptor through IRAK and TRAF6 binding. OSM, on the other 
hand, has not been shown to previously phosphorylate and activate PKD. OSM 
has, however, been shown to activate PKC signalling (Litherland et al., 2010), a 
known upstream activator, as well as stimulating the PI3K signalling cascade, a 
further upstream activator of PKC and also PKD (Lynch et al., 2013).  
1.9.4 PKD cellular distribution 
PKD is known to shuttle between numerous compartments within the cell in 
response to cellular stimulation. The localization of PKD is dependent on 
isoform and stimuli. PKD can translocate from the cytosol to DAG containing 
environments upon stimulation by G-protein couple receptor (GPCR) (Rey et 
al., 2001). PKC stimulation on the other hand has shown to cause PKD3 to 
translocate from the cytosol to the nucleus (Rey et al., 2006). PKD can also be 
seen to accumulate and localise at the Golgi apparatus, as well as the 
mitochondria. Not only does this show the diverse compartments within the cell 
that PKD can be found but also suggests how different stimuli can cause 
different responses of the protein, aiding in its multiple regulatory processes. 
1.9.5 Protein kinase D signalling 
Protein kinase D has numerous roles within multiple cellul types, with the 3 
different isoforms having more predominant roles in distinct cell types. PKD has 
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a consensus substrate sequence of LXR(Q/K/E/M)(M/L/K/E/Q/A)S*XXXX with 
greatest specificity found for a leucine residue found at the 5 position (Wang, 
2006, Doppler et al., 2005). PKD activation by cytokine or ligand binding to a 
receptor complex leads to upstream signalling activation, which drives PKD 
phosphorylation and activation. PKD lies at a crucial crossroad between DAG 
and PKC signalling, with both regulating PKD activity. PKD has not been 
studied in relation to arthritis; but as a downstream substrate of PKC and known 
activator of MMP gene expression, PKD has the potential to be of great interest. 
PKD has been shown to be involved in the activation of the ERK pathway, 
modulation of the JNK pathway and stimulation of NFκB (Storz and Toker, 
2003, Sinnett-Smith et al., 2007b, Hurd et al., 2002). Figure 1.13 illustrates the 
signalling pathways which PKC and PKD are believed to modulate.  
 
 
 
Figure 1.13. PKC/PKD signalling cascade. PKD can be directly activated by DAG generated 
by Phospholipase C (PLC). GPCRs are known activators of PLC. DAG can also activate PKC 
which leads to the phosphorylation of PKD on key serine residues leading to PKD activation. 
PKD can then via its catalytic domain activate multiple signal pathways and phosphorylate key 
proteins. These include members of the ERK pathway, JNK pathway, phosphorylation of 
HDACs and stimulate NFκB activity. Adapted from (Rozengurt, 2011) 
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1.9.5.1  ERK pathway 
The ERK pathway is well established in the regulation of collagenase 
expression. As mentioned earlier, ERK can regulate collagenase expression via 
the regulation of the gene transcription and phosphorylation of the AP-1 
transcription factor component Fos. Litherland et al., have shown ERK 
dependent transcription of c-fos in chondrocytes stimulated with IL-1 in 
combination with OSM (Litherland et al., 2010). Activation of ERK via PKD has 
the potential to be either PKC dependent or independent. PKC mediated 
activation of ERK through PKD occurs via the trans-phosphorylation of 
Ser744/748 leading to PKD activation and signal transduction (Sinnett-Smith et 
al., 2009). PKD1 has already been implicated in the increased activation of the 
ERK pathway leading to MMP-3 and MMP-9 expression in prostate cancer cells 
(Eiseler et al., 2009). This suggests that a similar process could occur within 
chondrocytes. The PKD-ERK-Fos signalling pathway has the potential to have a 
crucial role in the progression of arthritis, due to the regulation of AP-1 activity.  
PKD2 has recently been implicated in the prolonged activation of the ERK 
pathways, leading to increased Fos accumulation via GPCR activation. 
Bombesin, a potent GPCR activator, stimulates GPCR signalling leading to the 
activation of PLC. This breaks down PIP2, producing DAG. DAG can then 
activate PKD directly via interaction with the protein or indirectly through PKC 
phosphorylation. PKD2 overexpression was seen to increase the duration and 
activation of ERK signalling, as well as increasing Fos accumulation. This was 
seen in the presence of Bombesin, suggesting that PKD2 regulated ERK 
signalling when activated by GPCR (Sinnett-Smith et al., 2007a). The activation 
of PKD by Bombesin appears to lead to phosphorylation and activation of the 
MEK-ERK-RSK signalling pathway leading to Fos phosphorylation, stabilising 
Fos (Sinnett-Smith et al., 2007a). 
PKD also regulates the ERK pathway through the phosphorylation of Ras and 
Rab interactor 1 (RIN1), a protein that when unphosphorylated inhibits Ras/Raf 
interaction, preventing ERK activation (Wang et al., 2002). RIN1, in its 
unphosphorylated state binds to RAS and is shown to bind in a way which is 
competitive with RAF. PKD can directly phosphorylate RIN1 at Ser351 inducing 
the binding of the 14-3-3 protein. This restricts RIN1 to the cytosol, preventing 
its ability of blocking Ras/Raf-1 interaction at the plasma membrane (Wang et 
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al., 2002). 14-3-3 is a known negative regulator of RIN1 membrane localization 
and its association with Ras (Wang et al., 2002). This leads to the activation of 
the ERK signalling cascade allowing signal transduction. All this data implies 
PKD may directly phosphorylate RIN1 leading to the Ras-Raf-MEK-ERK 
signalling. ERK is therefore shown to be a major downstream substrate of PKD, 
and has the potential to be a mechanism by which PKD regulated collagenase 
gene expression in chondrocytes.  
1.9.5.2  JNK and Oxidative stress 
Oxidative stress is a process in which an imbalance between the production 
and removal of reactive oxygen species (ROS) occurs; the cell is not able to 
detoxify or resolve this imbalance leading to cellular damage. ROS and H2O2 
are known activators of gene expression via the JNK pathway (Zhang et al., 
2005). H2O2 is shown to cause the activation of PKD leading to activation of the 
JNK pathway (Zhang et al., 2005). This is believed to occur via apoptosis 
signal-regulating kinase 1 (ASK1). In H2O2 stimulated cells PKD is activated 
leading to its translocation from the plasma membrane to the cytoplasm (Zhang 
et al., 2005). This then leads to the dephosphorylation of ASK1 by PKD via an 
unknown mechanism (it is suggested a phosphatase 2A family-like 
phosphatase may be involved (Zhang et al., 2005)). This causes the 
dissociation of 14-3-3 enabling ASK1 to activate JNK (Zhang et al., 2005). PKD 
has also been shown to regulate AP-1 signalling via JNK in response to ROS. 
Increased toxicity is found when PKD is inhibited using Gö6976, leading to 
sustained activation of JNK/AP-1 signalling. The activation of the JNK pathway 
leading to AP-1 accumulation could therefore potentially be an area of interest 
in regards to PKD signalling and arthritis.   
1.9.5.3  p38 
p38 has not been widely studied in relation to PKD signalling. Inhibition of PKD 
by the pan-PKD inhibitor CRT0066101 (Bernhart et al., 2013) and the PKC/PKD 
inhibitor Gö6976, in two different cell lines, led to reduced p38 phosphorylation 
(Lemonnier et al., 2004), suggesting PKD to be an upstream activator of p38. 
Overexpression of PKD1 has shown conflicting results, with a decrease in 
phosphorylation of p38 being seen (Song et al., 2009). p38 has also been 
shown to directly phosphorylate PKD leading to inhibition (Sumara et al., 2009). 
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These data suggest that the role of PKD in p38 signalling is still unclear, but this 
discord may have a stimulus and cell-specificity.  
1.9.5.4 Nuclear factor κB 
Numerous studies have indicated that PKD activates the NFκB pathway when 
cells are exposed to GPCR agonists or oxidative stress (Chiu et al., 2007, Storz 
and Toker, 2003, Mihailovic et al., 2004). NFκB has also been shown to be 
involved in IL-1-dependent MMP regulation in chondrocytes (Fan et al., 2006). 
Cells stimulated alone with IL-1 are seen to activate NFκB signalling through 
phosphorylation and degradation of the inhibitory protein IκB (O'Neill and 
Greene, 1998). IκB is bound to NFκB transcription factor components and upon 
phosphorylation IκB is released, exposing the nuclear localisation signal, 
causing the transcription factor to translocate to the nucleus, allowing NFκB to 
bind to its consensus sequence on target genes (O'Neill and Greene, 1998). 
Two kinases have been identified as the kinases responsible for 
phosphorylation of IκB, named IκB kinase 1 and 2 (DiDonato et al., 1997, 
Woronicz et al., 1997). PKD therefore may be acting upstream of these proteins 
leading to their activation, inducing MMP expression in chondrocytes. 
1.9.6 The regulation of AP-1 via PKD signalling 
Many of the signalling pathways activated by PKD induce the transcription and 
stabilisation of the transcription factor AP-1. As previously mentioned, AP-1 
plays a key role in the induction of the MMPs. It has been shown that under the 
stimulation of IL-1 in combination with OSM, Jun and Fos form the major AP-1 
heterodimers in chondrocytes (Litherland et al., 2010, Richards et al., 2001, 
Catterall et al., 2001). Through the regulation of the signalling pathways 
mentioned above, PKD has been shown to regulate these major components of 
AP-1. 
Within the literature there is much conflicting data in relation to how PKD 
regulates Jun at both the transcriptional and protein level. Phosphorylation of 
Jun is known to increase the stability and transcriptional activity of the 
transcription factor. PKD has been shown to directly bind to JNK, leading to a 
loss of JNK dependent phosphorylation of Jun, indicating PKD to decrease the 
stability and activity of Jun (Hurd et al., 2002). However, conflicting data indicate 
Jun to be phosphorylated by PKD in a JNK independent manner (Yamashita et 
al., 2010), suggesting a different mechanism of Jun phosphorylation. PKD is 
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also shown to directly phosphorylate Jun at a PKD specific phosphorylation site, 
Ser58 (Waldron et al., 2007). The phosphorylation of Jun in a PKD dependent 
manner is shown to increase nuclear Jun levels, indicating increased 
transcriptional activity (Bernhart et al., 2013). Although conflicting, all of these 
data implicate PKD in the regulation of the stability of Jun. The manner in which 
regulating Jun is still under debate but it appears to play a crucial role. The role 
of PKD in the phosphorylation of Jun could be isoform, cell and stimuli 
dependent.  
Fos, the other main component of the AP-1 transcription factor in chondrocytes, 
is also regulated by PKD signalling. Overexpression of PKD2 led to increased 
duration of MEK-ERK phosphorylation. ERK then phosphorylates its 
downstream substrate RSK, which together, phosphorylated Fos stabilising the 
protein and promoting its cellular accumulation (Sinnett-Smith et al., 2007a, 
Sinnett-Smith et al., 2007b). PKD1 is also shown to regulate the protein levels 
of Fos, with silencing leading to decreased levels (Sinnett-Smith et al., 2011).  
PKD acts as an upstream regulator of multiple signalling cascades which are 
seen to regulate AP-1 components. Manipulation of the cellular levels of PKD 
leads to dysregulation of these pathways and impaired Fos and Jun levels. As 
AP-1 is a key transcription factor in the regulation of the collagenases, PKD 
may regulate their expression through these transcription factors.  
1.9.7 The regulation of MMPs via PKD signalling 
PKD has not previously been studied within the context of arthritis or within 
chondrocytes. PKD has however been studied in relation to cancer. Here, PKD 
has been shown to be a regulator of metastasis in invasive cancers, via the 
regulation of MMPs (Biswas et al., 2010, Eiseler et al., 2009). In initial studies 
the majority of this work focussed on the role of PKD1. This was because, at the 
time, PKD1 was the most characterised isoform of the family. PKD1 was also 
found to be epigenetically suppressed in many cancer tissues and cell lines 
(Eiseler et al., 2009, Jaggi et al., 2003, Kim et al., 2008). Hypermethylation of 
the PKD1 promoter in these cells compared to healthy tissue led to reduced 
expression. These same changes were not observed for PKD2 and PKD3 
(Eiseler et al., 2009). The decreased expression of PKD1 in these tumour cells 
was shown to benefit tumour progression. Active PKD1 in breast cancer cell 
lines was shown to down regulate the expression of MMP-2, -7, -9, -10, 11, -13, 
Chapter 1. Introduction 
 
54 
 
-14 and 15, leading to a reduction in metastasis (Eiseler et al., 2009). Similar 
results are found in osteosarcoma cells, with PKD1 being down regulated and 
PKD1 overexpression leading to decreased MMP-2 expression (Onishi et al., 
2012). These data therefore support the idea that PKD1 is a negative regulator 
of MMPs in cancer tissues.  
Conflicting data in the regulation of MMP gene expression via the regulation of 
PKD1 are observed within different cellular contexts. In prostate cancer cells, 
pan-PKD inhibition prevented JunD recruitment to the AP-1 binding site within 
the MMP-1 promoter, preventing gene expression. This appeared to be 
modulated by PKD activation of the JNK pathway (Yamamoto et al., 2010). Also 
in prostate cancer, overexpression of constitutively active PKD1 led to 
increased secretion and activation of MMP-2 and MMP-9. This was shown to be 
mediated by the MEK-ERK signalling (Biswas et al., 2010). PKD1 is also shown 
to regulate the subcellular localisation of HDAC7 relieving its inhibitory effects 
upon MEF2 mediated MMP-10 and MMP-14 gene expression (Ha et al., 2008). 
Although not a cancer cell, osteoblasts stimulated with basic calcium phosphate 
(BCP) crystals, which are known to occur in patients with OA, activate PKD 
leading to ERK activation, which induces MMP-1 and MMP-3 gene induction 
(Reuben et al., 2004). All these data implicate that the regulation of MMP gene 
expression by PKD is cell specific and dependent upon cell stimulation. 
Although most of the initial data focused upon PKD1 signalling and regulation of 
MMPs, data are now emerging on how PKD2 and PKD3 regulate gene 
expression. Zou et al., showed PKD2 and PKD3 silencing lead to decreased 
expression of MMP-9 and MMP-14 through regulation of the NFκB pathway 
(Zou et al., 2012), whilst Bernhart et al., showed PKD2 silencing lead to 
impaired ERK, JNK and p38 signalling, which inhibited Jun protein expression 
and phosphorylation, reducing subsequent MMP-1 gene expression (Bernhart 
et al., 2013). 
PKD therefore needs to be studied as the three individual isoforms it comprises 
to fully understand the role of each in regulating collagenase expression within 
chondrocytes. Studying PKD as an entity or only one of the three isoforms is 
insufficient. Therefore, understanding the roles of each isoform of PKD in the 
regulation of collagenase gene expression stimulated by IL-1 in combination 
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with OSM will give greater insight into the signalling mechanisms involved in 
collagenase induction in HAC within an inflammatory context.  
1.9.8 Protein kinase D in skeletal development 
Currently there has been no research into the roles of PKD signalling within 
chondrocytes, but data are emerging on the role of PKD is skeletal 
development. All isoforms of PKD are identified in limb buds during early 
embryogenesis (Oster et al., 2006). Recently, the development of mouse 
models has begun to further implicate PKD in the regulation of skeletal 
development. PKD1 knockout mice are shown to be embryonic lethal (Fielitz et 
al., 2008), whereas PKD2 and PKD3 knockout mice are seen to be viable 
(Matthews et al., 2010, Rogers et al., 2005). Currently no data are available on 
the role of PKD1 and PKD2 in skeletal development is available as only tissue 
specific roles have been identified. PKD3 however has been shown to be 
expressed during skeletogenesis in mice, most notably in the cartilage 
primordia of bones (Ellwanger et al., 2008) which are areas of active ECM 
degradation during cartilage remodelling prior to mineralization. A mutant 
mouse strain of PKD3, harbouring a gene-trap deletion of PKD3, revealed a 
mild skeletal abnormality, which included a decrease in the mean trabecular 
bone volume and thickness (Rogers et al., 2005). These data implicate the PKD 
family in the regulation of skeletal development and thus may play a role in the 
arthritic phenotype. 
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1.10 Aims 
The aims of this thesis are to examine the individual roles of each PKD isoform 
in the regulation of collagenase gene expression in HAC stimulated with IL-1 in 
combination with OSM. Experiments will focus on the role of each isoform in the 
regulation of MMP-1 and MMP-13 gene expression, as well as the signalling 
pathways which are known to regulate their expression. Work will also focus on 
the AP-1 transcription factor family members and how each isoform of PKD 
regulates their expression and stabilisation. Therefore the main aims of this 
thesis are to:- 
 Establish the individual role of each PKD isoform in the regulation of 
MMP-1 and MMP-13 gene expression in HAC 
 Determine the signalling pathways which each isoform of PKD regulates 
under the stimulation of IL-1 and OSM alone as well as IL-1 in 
combination with OSM. 
 Understand whether the individual isoforms of PKD regulate the 
expression of AP-1 family members.  
 Examine the effects of PKD on novel post-AP-1 collagenase regulating 
cytokines and transcription factors.  
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2 Chapter 2. Material and methods 
2.1 Materials 
2.1.1 Antibodies 
All antibodies used were rabbit polyclonal and diluted 1:1000 in bovine serum 
albumin (BSA) in TBS-T (Sigma-Aldrich, Poole, UK), unless otherwise stated. 
Antibodies, PKCζ (#9372), PKCι (#2998), PKD3 (#5655), PKD*S916 (#2051), 
PKD*S744/748 (#2054), ERK1/2*T202/Y204 (#9101), JNK (#9252), JNK*T183/Y185 
(#9251), p38*T180/Y182 (#9211), Akt*S473 (#4060), c-Fos (#4384), STAT-1*S727 
(#9177), STAT-1*Y701 (#9171), STAT-3*S727 (#9134), STAT-3*Y705 (#9131), 
caveolin-1 (#3238) p65*S536 (#3033) and lamin A/C (#2032) were purchased 
from Cell Signalling Technology (Danvers, MA, USA). MEK2 (#04-377) 
monoclonal antibody, anti-HA tag (ab18181), PKD2 (#1969-1) and β-tubulin 
polyclonal antibodies (#1799-1) were purchased from Epitomics (Insight 
Biotech, Wembley). PKD1 (L905) antibody was purchased from Bio-world 
(Dublin, USA). GAPDH (mouse) (MAB374) was purchased from MerckMillipore 
(Watford, UK) (Diluted 1:4000). Jun H-79 (sc-1694) and c-Jun*T93 (sc-101722) 
(both diluted 1:500) antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Polyclonal goat, anti-rabbit immunoglobulin HRP and 
polyclonal goat, anti-mouse immunoglobulin HRP secondary antibodies were 
purchase from DAKO (Cambridge, UK). All secondary antibodies were diluted 
1:2000, except when used for GAPDH when diluted 1:10,000 in 5% (w/v) non-
fat dry milk in TBS-T.  
2.1.2 Cell lines 
Two different cell lines were used in this thesis. The human chondrosarcoma 
cell line, SW1353, generated from cells taken from the humerus of a 72 year old 
female Caucasian, and the Human Embryonic Kidney cell line HEK293T. Both 
were purchased from the American Type Culture Collection (ATCC) (Manassas, 
VA, USA). Cells were routinely passaged. SW1353 cells were used up to a 
passage of 20 to ensure they maintained their responsiveness. 
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2.1.3 Cell culture reagents 
Dulbecco’s modified Eagle’s medium (DMEM), Dulbecco’s modified Eagle’s 
medium: Hams F12 medium (DMEM-F12), Hank’s balanced salt solution 
(HBSS), and foetal bovine serum (FBS) were purchased from Invitrogen 
(Paisley, UK). Phosphate buffered saline (PBS) was from Lonza (Wokingham, 
UK). Penicillin-streptomycin solution (10 000 U/ml and 10 mg/ml, respectively), 
L-glutamine solution (200 mM), nystatin suspension (10,000 U/ml), trypsin-
EDTA (ethylenediaminetetraacetic acid) solution (0.5 g porcine trypsin and 0.2 
g/L EDTA), hyaluronidase (from bovine testes, 439 U/mg), trypsin (from porcine 
pancreas, 1020 U/mg), collagenase (from Clostridium histolyticum type II) and 
dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich. Centrifuge tubes, 
50 ml and 15 ml were obtained from Corning/Costar UK Ltd. (High Wycome, 
UK). 50 ml syringes were obtained from Scientific Laboratory Supplies Ltd. 
(Nottingham, UK). Syringe filters (0.2 μm) were purchased from Pall Life 
Sciences (Portsmouth, UK). Syringe filters made of polyethersulfone (PES) 
(0.45 μm) were purchased from Alpha Laboratories (Hampshire, UK). Cell 
strainers (100 μm) were from BD Biosciences, (Oxford, UK).  
2.1.4 Cytokines 
All cytokines were recombinant human. IL-1α was a generous gift from Dr Keith 
Ray (GlaxoSmithKline, Stevenage, UK) and was stored at -20°C until use. OSM 
was prepared in-house using expression vectors kindly provided by Prof. J. 
Heath (University of Birmingham, UK) and methods described in (Staunton et 
al., 1998). OSM was prepared at a concentration of 60 μg/ml in Dulbecco’s 
phosphate buffered saline (DPBS) (with 0.1% bovine serum albumin (BSA)) and 
stored at -80°C. Immediately prior to use all cytokines were dilute to working 
concentrations in cell culture medium. 
2.1.5 Commercially available kits 
Qiaprep Spin Maxi Kit was purchased from Qiagen (Crawley, UK). Pierce 
Cytoplasmic and Nuclear Fractionation and the Subcellular Protein 
Fractionation Kit were purchased from Thermo Fisher Scientific (Loughborough, 
UK). Lenti-X™ Concentrator and Lenti-X™ qRT-PCR Titration Kit were both 
purchased from Takara Bio Europe/Clontech (Paris, France).  
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2.1.6 Immunoblotting reagents 
BSA (2 mg /ml) standards, Ammonium peroxodisulphate (APS), b-
mercaptoethanol, N,N,N’N’-tetramethylenediamine (TEMED), 1,10-
phenanthroline and polyoxyethylenesorbitan monolaurate (Tween 20) were 
obtained from Sigma-Aldrich. 40% (w/v) acrylamide/bis-acrylamide (37.5:1) 
solution was obtained from Amresco (OH, USA). Bradford ULTRA was 
purchased from Novexin (Invitrogen). PageRulerTM prestained protein ladder 
was purchased from Thermo Fisher Scientific. Enhanced chemiluminescence 
(ECL), ECL prime or Advanced Western Blotting Detection systems were 
obtained from Amersham ™ GE Healthcare UK Ltd, (Buckinghamshire, UK). 
ECL plus was obtained for MerckMillipore. Reagents for the iBlot gel Transfer 
System were all purchased from Invitrogen.  
2.1.7 Molecular Biology reagents 
Cells to cDNA lysis buffer was purchased from Ambion (Huntington, UK). 
SidestepTM Lysis and Stabilization Buffer was purchased from Agilent 
Technologies, Stratagene Product Division (CA, USA). Polybrene 
(hexadimethrine bromide), doxycycline hyclate (D9891), RNase- and DNase-
free H2O, real-time reverse transcriptase polymerase chain reaction primers 
and probes were purchased from Sigma-Aldrich. Moloney Murine Leukamiea 
Virus (M-MLV) reverse transcriptase and RNaseOut recombinant ribonuclease 
inhibitor were purchased from Invitrogen. Random hexamers were purchased 
from IDT (Coralville, IA, USA). RQ1 RNase-free DNase was purchased from 
Promega (Southampton, UK). DNTPs were purchased from Bioline (London, 
UK). Taqman Fast Universal PCR Master MIX (2x) and Taqman Universal 
Master Mix II were purchased from Applied Biosystems ((Life techonlogies) 
Foster City, CA, USA). DharmafectTM 1 lipid reagent, ON-TARGETplus Non-
targeting siRNA #2 (catalogue number 001210-02) and PKCζ and PKCɩ 
SMARTpool® small interfering RNA siRNAs were purchased from Dharmacon 
(a Thermo Fisher Scientific company) (Cramlington, UK). PKD1, PKD2, PKD3, 
JNK1 and JNK2 siRNAs were all purchased from Sigma-Aldrich and were 
originally identified from the Sigma-Aldrich MISSION™ siRNA Human Kinase 
Panel. GIPZ and TRIPZ short hairpin RNAs (shRNAs) for PKD1 were 
purchased from Open Biosystems (a Thermo Fisher scientific company) 
(Pittsburgh, PA, USA). The expression vector pcDNA-PKD1 was purchased 
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from Addgene (plasmid; 10808) (Storz et al., 2003). pcDNA3.1 was used as the 
empty vector control. The packaging plasmid pCMV-dR8.91 and the envelope 
plasmid pMD2.G were a kind gift for Martina Elias (Newcastle Univeristy). For 
plasmid maps of all expression plasmids see section 7.9 in the appendices 
2.1.8 Inhibitors  
The PKC inhibitor Gö6983 and the PKD inhibitor kb NB 142-70 were both 
purchased from Tocris Bioscience (Bristol, UK). The STAT3 inhibitor S3I-201 
was purchased from Stratech Scientific Ltd (Suffolk, UK). All inhibitors were 
reconstituted in sterile DMSO at appropriate concentrations. All inhibitors were 
screened for cytotoxicity in all cell types used, using the ToxiLightTM Bioassay 
Kit (Lonza). 100x protease inhibitors were made from dissolving one complete 
miccrococcal protease inhibitor mini tablet (Roche products limited, Welwyn 
Garden City, UK) in RNase- and DNase-free H2O. 
All other biological chemicals were purchased from Sigma-Aldrich (unless 
otherwise stated) and were of the highest purity availability.  
2.2 Methods  
2.2.1 Isolation of Human articular chondrocytes (HACs) 
Background 
Human articular cartilage samples were acquired from osteoarthritis patients 
undergoing total knee or hip replacement surgery at the Freeman hospital, 
Newcastle upon Tyne. Ethical approval and informed consent were obtained 
prior to surgery. All subjects gave informed consent and the study was 
approved by the NRES Committee North East - Newcastle & North Tyneside 1; 
REC reference 09/H00906/72. Post-surgery joint were kept at 4oC in HBBS 
supplemented with penicillin, streptomycin and nyastatin. All joints were 
assessed for tissue viability within 24 hours post-surgery. 
The extracellular matrix of human articular cartilage was digested to release 
embedded chondrocytes. These chondrocytes were used for in vitro 
experiments. Sequential enzyme digestion of the ECM using hyaluronidase (for 
hyaluronan), trypsin (for aggrecan) and collagenase (for collagen) released 
chondrocytes for monolayer culture.  
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Reagents 
 HBSS containing 100 IU/ml penicillin, 100 μg/ml streptomycin and 40 
IU/ml nystatin  
 DMEM medium containing 10% (v/v) FBS, 2 mM L-glutamine, 100 IU/ml 
penicillin, 100 μg/ml streptomycin and 40 IU/ml nystatin. 
  PBS containing 100 IU/ml penicillin, 100 μg/ml streptomycin and 40 
IU/ml nystatin. 
 Hyaluronidase (1 mg/ml in PBS)  
 Trypsin (2.5 mg/ml in PBS)  
 Collagenase (2.0 mg/ml in DMEM)  
Method 
HAC were extracted from the cartilage by enzymatic digestion of 
macroscopically normal articular cartilage from OA patients. Cartilage was 
dissected from the joint and cut into small pieces to increase the surface area. 
The cartilage was then enzymatically digested using hyaluronidase (bovine 
testes) (1 mg/ml, 4 ml/g of cartilage) at 37°C for 15 minutes in PBS, then trypsin 
(porcine pancreas) (2.5 mg/ml, 4 ml/g) at 37°C for 30 minutes in PBS, then 
finally collagenase (Clostridium histolyticum) (2.0 mg/ml, 3 ml/g) in serum 
containing DMEM, for 12-14 hours. Following digestion, cells were passed 
through a 100 μm cell strainer to remove undigested cartilage. Cells were then 
centrifuged at 217 x g for 10 minutes. The pellet was re-suspended in PBS and 
centrifuged again at 217 x g for 10 minutes. Cells were re-suspended in DMEM 
containing serum and counted. 3 million cells were plated per T75 cm2 for 
passage 1 (P1) chondrocytes or plated at a density of 10,000 per well for 96 
well plate or 500,000 per well for 6 well plate for P0 cells. Cells were maintained 
in culture conditions of 37°C, 5% (v/v) CO₂ for around 10 days till ~70% 
confluent. Passage (P0) cells grown in flasks were then trypsinised and plated 
24 hours prior to use for transfection or transduction at same densities as P0, 
these became known as P1 cells. P0 cells were serum starved overnight prior 
to stimulation or inhibitory studies. For serum deprivation, identical conditions 
were maintained except FBS was excluded. 
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2.2.2 Cell Line culture 
Background 
The cell line SW1353 was used for optimisation, subcellular fractionation and 
over-expression experiments. The cell line HEK293T was used as a packaging 
cell line for the production of lentiviral particles.  
Reagents  
 For SW1353 cells:- DMEM-F12 medium containing 10% (v/v) FBS, 2mM 
L-glutamine, 100 IU/ml penicillin, 50 μg/ml streptomycin 
 For HEK293T cells:- DMEM medium containing 10% (v/v) FBS, 2mM L-
glutamine, 100 IU/ml penicillin, 50 μg/ml streptomycin 
 
Methods 
SW1353 cells and HEK293T were maintained in culture conditions of 37°C, 5% 
(v/v) CO₂. Cells were cultured in T75cm2 flasks (Corning) until they were 70-
80% confluent. Cells were routinely passaged. Cells were washed 3 times in 
PBS and then 1.5 ml of trypsin added for 5 minutes. Cells centrifuged at 217 x g 
for 10 minutes, re-suspended in serum containing medium and counted using 
haemocytometer. SW1353 cells were plated at a density of 4,500 per well for 96 
well plate or 125,000 per well for 6 well plates for experimental procedures. 
HEK 293T cells were plated at a density of 25 million in 500 cm2 plates for 
lentiviral production.  
2.2.3 Lentivirus generation 
Background  
Recombinant retroviruses are widely used as gene therapy vectors due to their 
ability to integrate a transgene into the genome of a target cell. Retoviruses can 
therefore be utilised for basic science, allowing the stable integration of a target 
gene into the genome of the infected cell. Lentiviral delivery of both over-
expression and shRNA plasmids into a target cell has many benefits over 
transient transfection. Lentiviral transduction of an overexpression or shRNA 
plasmid into a target cell leads to the incorporation of the gene of interest into 
the host genome, allowing this to be constitutively expressed. Lentiviruses can 
also transduce both dividing and non-dividing cells allowing increased chance of 
delivery. The incorporation and constitutive expression of the gene or shRNA 
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increases the chance of over-expression or gene silence as the inserted gene is 
constantly expressed. 
Lentivirus can transduce a cell by binding to the host cell membrane. This is 
instigated by the glycoprotein of the vesicular stomatitis virus (VSV-G) proteins 
found on the surface of the viral particle. This binding leads to the endocytosis 
of the viral machinery and RNA into the target cell. Once incorporated, the viral 
reverse transcriptase converts the over-expression gene or shRNA transcript 
into DNA, the enzyme integrase then incorporates this into the host genome. 
This is then constitutively expressed by the host, leading to the production of 
the gene of interest or shRNA. The constant production increases the chance of 
gene silence or increases the chance of increased protein synthesis. Multiple 
modifications to the gene the human immunodeficiency virus (HIV-1) genome 
have been made to ensure biological safety and prevent the production of 
replication competent lentiviruses (RCLs).  
In this work a second generation lentiviral generation system was used. Here 
three plasmids were transfected into the packaging cell line HEK293T. These 
plasmids consisted of an envelope, packaging and vector plasmid. These 
contained the essential machinery needed to generate transducible lentiviruses 
which were unable to re-replicate. 
Class 2 biosafety approval was received from the Health and safety executive 
(HSE) for the generation and use of lentiviruses within our laboratory; HSE 
reference: GM540 
Reagents 
 HEK293T cells 
 Heat inactivated FBS 
 DMEM medium containing 2mM L-glutamine, 100 IU/ml penicillin, 50 
μg/ml streptomycin 
 500 cm2 square cell culture plate (Corning) 
 JetPEI transfection reagent 
 150 mM NaCL  
 Lenti-X™ Concentrator kit 
 Lenti-X™ qRT-PCR Titration Kit 
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Method 
Lentiviruses were produced on a large scale to ensure continuity between 
experiments. 25 million HEK293T cells were plated into a 500cm2 cell culture 
dishes 24 hours prior to transfection. On day of transfection FBS was heat 
inactivated by heating to 56°C for 30 minutes. This was then added to 
supplemented DMEM medium. HEK293T medium was then replaced with this 
heat inactivated FBS containing medium. In separate tubes equal amounts of 
150 mM NaCl were added. To the first tube, the shRNA plasmid, envelope 
(pMD2.G) and packaging plasmid (pCMV-dR8.91) were added and vortexed. 
To the next tube, the JetPEI transfection reagent was added at a ratio of 2:1 to 
plasmid DNA. These were combined by adding the DNA to the JetPEI, this was 
then vortexed and left for 20 minutes to allow complex formation. The 
DNA/JetPEI complexes were then added to the HEK293T cells in a drop wise 
manner. The cells were left for 8-10 hours before the medium was changed. 
The cells were left for a further 72 hours for viral production. After 72 hours the 
medium was harvested and cells discarded. The medium was then passed 
through a 0.45 μm polyethersulfone low protein binding filter to remove cell 
debris. Viral supernatant was also centrifuged at 1600 × g at 4 °C for 10 
minutes to ensure all debris removed. Once viral supernatant was clarified the 
viral was then concentrated. Figure 2.1 shows the production of lentiviral 
particles using a second generation packaging system. 
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Figure 2.1. Schematic of lentiviral production using the transient transfection of the 
packaging cell line HEK293T. The envelope plasmid contains the entire components needed 
to produce the viral envelope. Our envelope plasmid contains the vsv-g gene, which encodes 
the G-glycoprotein of the vesicular stomatitis virus. This allows the lentivirus generated to 
transduce a wide range of cell types. The packaging plasmid contains the key genes gag and 
pol. gag encodes the p24 protein as well as other protomers. These are the major components 
of the oligomeric viral capsid. The pol gene encodes the two key enzymes involved in 
incorporation of the viral RNA into the host genome. The third plasmid contains the gene of 
interest be it an overexpression plasmid or shRNA plasmid. These are all transfected in to the 
packaging cell HEK293T, which have been modified by the addition of the T antigen of SV-40 to 
increase replication.  
 
 
To concentrate the viral supernatant the Lenti-X™ Concentrator kit was used. 
This kit allows the concentration of lentiviral particles without the need for 
ultracentrifugation. Supernatant was combined with the Lenti-X™ Concentrator 
kit solution at a 3:1 ratio of supernatant to concentrator solution. This was left to 
incubate for up to 1 hour. Once incubation had occurred the solution was 
centrifuged at 1,500 x g for 45 minutes at 4°C. A viral pellet formed and the 
supernatant was removed. This pellet was then re-suspended in native DMEM 
medium at a 1:50 concentration, aliquoted into small volumes and stored a -
80°C until use. Repeated freeze thawing reduces viral viability. 
Viral supernatant removed 
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To calculate the Multiplicity of Infection (MOI) of SW1353 cells and HACs the 
number of viral particles generated in each viral prep was calculated. To 
achieve this, the Lenti-X™ qRT-PCR Titration Kit was used. This kit utilises 
SYBR Green technology to calculate the copy number of viral sample, using a 
known viral RNA control. An aliquot of viral supernatant was lysed and viral 
RNA purified, using the NucleoSpin RNA Virus Kit that forms part of the Lenti-
X™ qRT-PCR Titration Kit. As the viral particles were produced from a transient 
transfection rather than stably expressing cell lines, a DNase step was 
performed to remove any residual plasmid DNA. A one-step reverse 
transcription-real-time PCR experiment was then performed. Both control and 
viral RNA undergo 10 fold serial dilutions in dilution buffer. These are then 
added to a real time PCR plate in duplicate and the enzyme reaction mix added 
(see Table 1). A non-template control was also added to the RT-PCR plate. The 
plate was then centrifuged at 1200 x g (4°C) for 1 min to remove any bubbles. 
The samples then underwent the following PCR cycles within the real time PCR 
machine: 
RT Reaction- 42°C 5 min followed by 95°C 10 sec 
qPCR x 40 Cycles- 95°C 5 sec followed by 60°C 30 sec 
Dissociation Curve- 95°C 15 sec followed by 60°C 30 sec which was followed 
by (60°C–95°C) 
The dissociation curve confirmed that no primers dimers or secondary non-
specific PCR artefacts formed in the reaction. Figure 7.8 (in appendices) shows 
an example of the dissociation curve of one of the experiments performed. 
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Table 1. Components, concentrations and volume of viral titre real time PCR master mix. 
Table indicating the components which made up the reaction mix used for the viral titre 
calculation.  
 
From the Ct values obtained, the quantity of viral RNA could be calculated. This 
was achieved by forming a standard curve from the average Ct values of the 
diluted viral RNA control. This was plotted on a graph with average Ct vs. copy 
number (log scale). The average Ct values for each duplicate sample dilution 
were read and the corresponding copy number value from the standard curve 
was calculated. Then using the equation below, for each dilution, the copy 
number was calculated. This generated a mean value to determine the RNA 
genome content of the sample. 
          
(                           )(      )(             )
(             )(                      )
  
Once the number of copies per ml was calculated the MOI could be calculated. 
To do this a known number of cells were plated into a 96 well plate and fold 
dilutions of the viral supernatant was added to each well. From this, using the 
red fluorescent protein (RFP) or green fluorescent protein (GFP) expressed by 
the shRNA, the volume needed to transduce all cells plated in one well could be 
calculated. RFP and GFP were quantified using a Zeiss Axiovert 200M confocal 
microscope. This volume could then be used to calculate the number of viral 
particles needed to transduce all cells. An MOI of 30 was calculated for HAC 
cells. An MOI of 15 was calculated for SW1353 cells. Understanding the MOI 
allows to correct for any differences between viral preparations and ensure the 
right volume of viral supernatant is added to the cells to get maximal 
transduction. 
Reagent Volume (μl)/ well 
RNase-Free Water   8.0 
Quant-X Buffer (2X) 12.5 
Lenti-X Forward Primer (10 μM) 0.5 
Lenti-X Reverse Primer (10 μM) 0.5 
Reference Dye LSR 0.5 
Quant-X Enzyme 0.5 
RT Enzyme Mix 0.5 
RNA 2 
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2.2.4 RNA interference 
Background 
Small interfering (si) and Short hairpin (sh) RNA mediated gene silencing is a 
robust and well defined method for blocking gene expression. Both methods 
can be used to silence the expression of a target gene, leading to reduced 
mRNA expression, which can lead to reduced protein expression. siRNAs can 
be chemically synthesised as double-stranded RNA and are transfected into the 
cell in this manner. shRNAs on the other hand can be transfected into the cell in 
the form of a expression vector or a short hairpin structure. siRNAs and 
shRNAs can both achieve similar outcomes in gene silencing but are 
intrinsically different molecules.  
siRNAs are double-stranded RNA sequences which are around 20-25 
nucleotides in length, these bind through complementarity to the mRNA of a 
target gene, leading to its degradation. To achieve this, the siRNA must partake 
in the RNA interference pathway. For this to occur, the dsRNA is transfected 
into the cell, in this case using a lipid-based vesicle. The dsRNA is unwound 
and processed into a single stranded 20-25 nucleotide siRNA containing a 2-
nucleotide overhang at the 3' end, known as the guide strand. This process is 
catalysed by the ribonuclease Dicer. Once cleaved, Dicer aids in the 
translocation of the guide strand and its association with the RNA-induced 
silencing complex (RISC), which assembles onto the siRNA. The complex is 
targeted to the complementary gene by sequence complementarity of the 
siRNA. Once bound the RISC complex cleaves the complementary target gene 
through its endonuclease activity found within the argonaute protein (Elbashir et 
al., 2001). This cleavage leads to a reduction in the amount of mRNA of the 
target gene. A reduction in the levels of mRNA can therefore lead to reduced 
protein translation and thus reduced protein levels within the cell; this is 
dependent on protein stability and mRNA transcription rate. The downstream 
effects of the target gene can then be assessed.  
shRNA differs to siRNAs in the manner in which they enter the cell and the form 
that they are in (Rao et al., 2009). For these reason shRNA undergo different 
processing within the cell. shRNAs are usually found within an expression 
vector and enter the cell in this form. Two methods can be utilised in the 
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expression of the shRNA. These include, transient transfection using a 
transfection reagent or transduction via viral based incorporation. In this work 
lentiviral mediated gene delivery was utilised. Here, the shRNA is incorporated 
into the viral particle and is transduced into the cell as a shRNA rather than an 
expression vector. Once inserted into the cell, the shRNA must be first 
converted into a mature siRNA. To this the shRNA must undergo processing 
within the nucleus of the target cell. The shRNA must undergo cleavage of its 
short hairpin structure by the RNase III enzyme Drosha (Rao et al., 2009). This 
converts the shRNA into a dsRNA similar to that of the transfected immature 
siRNA. This is then exported from the nucleus into the cytoplasm by exportin 5. 
The dsRNA then enters the RNAi pathway described above.  
Reagents 
siRNA transfection: 
 For SW1353 cells- DMEM-F12 medium containing 10% (v/v) FBS, 2mM 
L-glutamine, 100 IU/ml penicillin, 50 μg/ml streptomycin. FBS was 
excluded for serum free conditions. 
 For HAC- DMEM medium containing 10% (v/v) FBS, 2mM L-glutamine, 
100 IU/ml penicillin, 100 μg/ml streptomycin and 40 IU/ml nystatin. FBS 
was excluded for serum free conditions. 
 Dharmacon ON-TARGET plus SMARTpool siRNA or Sigma MISSION™ 
siRNA. 
 Dharmacon ON-TARGETplus Non-targeting control siRNA 
 DharmaFECT 1 Transfection reagent 
 For a list of siRNAs used see Table 2 and Table 3 
 
shRNA transduction: 
 For SW1353 cells- Native DMEM-F12 medium or DMEM-F12 medium 
containing 20% (v/v) FBS, 4 mM L-glutamine, 200 IU/ml penicillin, 100 
μg/ml streptomycin. 
  For HAC- Native DMEM medium or DMEM medium containing 20% 
(v/v) FBS, 4 mM L-glutamine, 200 IU/ml penicillin, 200 μg/ml 
streptomycin and 80 IU/ml nystatin.  
 Polybrene 8 μg/ml 
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 Doxycyline 3 μg/ml 
 For a list of shRNA used see Table 4 
Methods 
Transfection of siRNA 
96 well plate format: 
Flasks of SW1353 cells or P0 HACs were trypsinised and cells plated out into 
96 well plates, 24 hours prior to experiment start point. Several hours prior to 
transfection, all medium was removed from the HAC or SW1353 cells and 
replaced with 50 μl of fresh FBS-containing DMEM or DMEM-F12, respectively. 
For each well, 100 nM siRNA in a total volume of 15 μl FBS-free DMEM or 
DMEM-F12 was prepared. Separately, 0.26 μl of DharmaFECT 1 lipid reagent 
in a total volume of 15 μl of FBS-free DMEM or DMEM-F12 was also prepared. 
These were both combined and incubated at room temperature for 20 minutes 
before addition to cells, allowing for complex formation. Cells were transfected 
for 48 hours and serum starved for 12 hours prior to the addition of cytokines for 
a further 24 hours. Total RNA was isolated and reverse-transcribed as 
described in section 2.2.10. Expression of genes of interest was measured by 
real-time PCR as described in section 2.2.11. Changes in gene-specific mRNA 
levels were calculated by comparison of expression levels with cells transfected 
with 100 nM siCONTROL (siCON). 
6-well plate format: 
Flasks of SW1353 cells or P0 HACs were trypsinised and cells plated into 6 well 
plates, 24 hours prior to experiment start point. Several hours prior to 
transfection, all medium were removed and replaced with 500 μl of serum-
containing DMEM or DMEM-F12. For each well, 100 nM siRNA in a total 
volume of 250 μl serum-free DMEM/DMEM-F12 was prepared. Separately, 3.25 
μl of DharmaFECT 1 lipid reagent in a total volume of 250 μl of DMEM/DMEM-
F12 was also prepared. These were both combined and incubated at room 
temperature for 20 minutes before addition to cells, allowing for complex 
formation. Cells were transfected for 48 hours and serum starved for 12 hours 
prior to the addition of cytokines for varying time points. Total cell lysates were 
prepared as described in section 2.2.14 and proteins were separated by SDS-
PAGE as described in section 2.2.16 and identified using western blotting 
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(section 2.2.17). Silencing of specific genes was then assessed using 
antibodies against each protein.  
Isoform  Sequence 1 (5’-3’) Sequence 2 (5’-3’) Sequence 3 (5’-3’) Sequence 4 (5’-3’) 
PKC ζ  CGUCAAAGCCUCCC
AUGUU  
GCAGGACUUUGACC
UAAUC  
GACCAAAUUUACGCC
AUGA  
GAGUAUAUCAACCCA
UUAU  
PKC ι AGAAAUCAGUCUAG
CAUUA  
 
CAAGUGUUCUGAAG
AGUUU 
 
GAGGAGACCUAAUGU
UUCA 
GCAAUGAACACCAGG
GAAA 
 
Table 2. Dharmacon ON-TARGET plus™ SMARTpools® siRNA target sequences for PKC 
isoforms. 25 nM of four siRNA sequences make up each individual smartpool siRNA.  
Isoform siRNA (1) (5’-3’) siRNA (2) (5’-3’) siRNA (3) (5’-3’) 
PKD1 CAAGGAAAUUCCUUUAUCU 
 
GUGUAUGUUUGAGACGCCU 
 
GACCAAUUCACCUUGACAA 
 
PKD2 GCUUCUACGGCCUUUACGA 
 
GCUAUACACGGCCCACCGU 
 
CGAUACAUCACGCAUGAGA 
 
PKD3 GGAAGAAGAUCCUUAAUCA 
 
CAUAAACGCUGUGCAUCAA 
 
CCGUAAUGAAGUGGCUAUU 
 
JNK 1 GUUCUUAUGAAAUGUGUUATT 
 
  
JNK 2 CUGUAACUGUUGAGAUGUATT 
 
  
 
Table 3. Sigma MISSION™ siRNA Human Kinase Panel sequences. Each sequence were 
used as individual siRNAs to try and silence each gene of interest at both the protein and 
mRNA level. 
 
Transduction of shRNA 
For both 96 and 6-well plate format: 
P0 flasks containing HACs were trypsinised and cells plated out at a density of 
10,000 per well in a 96 well plate or 500,000 per well for 6 well plate. SW1353 
cells were passaged and plated at a density of 4,500 per well for 96 well plate 
or 125,000 per well for 6 well plates. For each well of a 96 well plate viral 
particles were added to native DMEM for HAC or DMEM-F12 for SW1353 cells, 
at a MOI of 30 for HAC and 15 for SW1353 cells, volumes were made up to 100 
μl. Polybrene at a concentration of 8 μ/ml was added to each well. For 6 well 
plates viral particles were added to native DMEM for HAC or DMEM-F12 for 
SW1353 cells, at an MOI of 30 and 15 for SW1353 cells, volumes were made 
up to 1 ml. In some experiments (see chapter 3, section 3.3.2.4 ) spinoculation 
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(the centrifugal inoculation of cell cultures) was performed. For this cells were 
centrifuged at 1,200 x g for 60 minutes at room temperature immediately after 
the addition of viral supernatant. Cells were left for 8 hours for transduction. 
Medium containing twice the normal supplements was then added to each well. 
If TRIPZ inducible shRNAs were used then this medium was supplemented with 
doxycycline at varying concentrations. The medium was then changed the 
following day to normal supplemented medium for GIPZ non-inducible shRNAs 
or doxycycline containing if TRIPZ based shRNAs. Cells were left for a further 
48 hours. Cells were lysed to assess gene silencing by either real-time PCR or 
western blotting or cells were serum starved for cytokine stimulation. The 
transduction of cells was assessed by analysing RFP expression for TRIPZ 
based shRNAs and GFP for GIPZ based shRNAs. Fluorescence was detected 
using an inverted confocal Zeiss Axiovert 200M confocal microscope, using live 
cells. 
 
Table 4. Open Biosystems TRIPZ and GIPZ shRNA sequences. Two different expression 
vectors were used in this study. Displayed are the sequences for the TRIPZ inducible 
expression vectors based shRNAs and the non-inducible GIPZ expression vector based 
shRNAs. 
 
2.2.5 Bacterial transformation 
Reagents 
 SOCs media 
 Mach1TM-T1® chemically competent E.coli  
Methods 
All reagents and glassware were autoclaved prior to use. Antibiotics were 
added at a final concentration of 100 μg/ml in filter-sterilised water for selection. 
Standard aseptic technique was used throughout the cloning procedure. 
Mach1TM-T1® chemically competent E.coli (30 μl) and 0.5 μg of plasmid were 
added to an eppendorf tube. Cells/DNA mixed by gentle flicking of tube. Agar 
plate, with appropriate antibiotic, was placed in incubator to warm to 37°C. The 
shRNA type shRNA (1) (5’-3’) shRNA (2) (5’-3’) shRNA (3) (5’-3’) 
TRIPZ (PKD1) TTGTTGATAAGATCAATGG TTCGAAACAATGAGGATTG TTGAGGTCACAGTGAACGA 
GIPZ (PKD1) AATAGCTACATCTCTTCCT TTCGAAACAATGAGGATTG  
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cell/DNA mixture was then placed on ice for 30 minutes. Cells were heat 
shocked by placing the tube into a 42°C water bath for 30-60 seconds. The tube 
was incubated on ice for 2 minutes before the addition of 500 μl pre-warmed 
SOCs (37°C). Tubes were incubated for 1 hour in a 37°C water bath. 50 μl of 
cell solution was streaked out on pre-warmed antibiotic plates. Plates were 
allowed to dry for 5 minutes before incubation at 37°C overnight. 
2.2.6 Purification of Plasmid DNA by MaxiPrep  
Background 
To acquire large quantities of plasmid DNA a single transformed bacteria must 
first be grown in large scale. The bacteria are then lysed and DNA extracted. 
This was achieved using the Qiagen plasmid MaxiPrep kit.  
Reagents 
 Plasmid Maxiprep Kit 
 Isopropanol  
 RNase and DNase free H2O 
Method 
Prior to plasmid transfection, large quantities of purified plasmid DNA were 
prepared. Bacterial stocks were first streaked onto agar plates containing 
ampicillin (sigma Aldrich) (100 μg/ml) and incubated overnight at 37°C. 
Individual colonies were first picked and added to 5 ml of LB broth (Sigma 
Aldrich) containing ampicillin (100 μg/ml) and incubated at 37°C with shaking for 
4 hours. The culture was then transferred to a 500 ml conical flask containing 
250 ml LB broth supplemented with ampicillin and incubated at 37°C with 
shaking overnight. The culture was then centrifuged at 6,000 x g for 15 minutes 
at 4°C. All buffers described are part of the Qiagen Maxiprep Kit (Qiagen). 
Pellets were re-suspended in 10 ml of P1 and RNase, followed by 10ml P2, 
incubated for 5 minutes, and then 10 ml chilled P3 and incubated for 20 minutes 
on ice. The lysate was then centrifuged at 20,000 x g for 30 minutes at 4°C, and 
the supernatant transferred to a new tube and centrifuged under the same 
conditions for a further 15 minutes. A QIAGEN-tip 500 gravity column was 
equilibrated with 10 ml of Buffer QBT; supernatant was then allowed to drip 
through the column. The column was subsequently washed twice with 30 ml of 
Buffer QC, and plasmid DNA eluted using 15 ml of Buffer QF into a fresh 
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centrifuge tube. DNA was precipitated following the addition of 10.5 ml of 
isopropanol and the sample was then centrifuged at 15,000 x g for 30 minutes 
at 4°C. The supernatant was then removed and residual isopropanol 
evaporated. The pellet was re-suspended in 500 μl of RNase- and DNase- free 
H2O. 1250 μl (2.5x volume) of 100% ethanol was added and after mixing the 
solution was incubated on ice for 15-20 minutes. Following a final centrifugation 
of 17,900 x g for 10 minutes at room temperature, the pellet containing DNA 
was air dried for 10 minutes prior to re-suspension in 300 μl of RNase- and 
DNase-free H2O and quantified using a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies). 
2.2.7 Over-expression plasmid transfection 
Background 
Transient over-expression of a target gene can lead to increased protein 
expression. The over-expression of the target gene can then be compared to 
cells expressing the vector backbone only. Changes on downstream signalling 
pathways and gene expression can be assessed.  
Reagents 
 JetPEI transfection reagent 
 150 mM NaCl 
 For SW1353 cells- DMEM-F12 medium containing 10% (v/v) FBS, 2mM 
L-glutamine, 100 IU/ml penicillin, 50 μg/ml streptomycin. FBS was 
excluded for serum free conditions. 
 For HAC- DMEM medium containing 10% (v/v) FBS, 2mM L-glutamine, 
100 IU/ml penicillin, 100 μg/ml streptomycin and 40 IU/ml nystatin. FBS 
was excluded for serum free conditions 
Method 
HAC and SW1353 cells were prepared and cultured as described in section 
2.2.2 and 2.2.1. For over-expression plasmid transfections, cells were 
trypsinized and re-seeded at approximately ~70% confluency, 24 hours prior to 
transfection. PKD1 over-expression plasmids were used to transfect HAC and 
SW1353 cells in combination with JetPEI transfection reagent.  
96-well plate format: 
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For all transfections a ratio of 2:1 of transfection reagent to DNA was used. In 
separate tubes 0.2 μg of plasmid DNA was added to 10 μl of 150 mM NaCl. 0.4 
μl of JetPEI was added to 10 μl of 150 mM NaCl in a separate tube. Contents of 
both tube were added together and vortexed. The mix was then incubated at 
room temperature for 20 minutes, to allow complex formation. Cells were 
transfected for 24 hours and serum starved for 12 hours prior to the addition of 
cytokines for a further 24 hours. Total RNA was isolated and reverse-
transcribed as described in section 2.2.10. Changes in gene expression of 
genes of interest were measured by real-time PCR as described in section 
2.2.11. Changes in expression of downstream targets of over-expressed gene 
were assessed by analysing changes in the mRNA levels of the downstream 
gene compared with cells transfected with the empty vector, pcDNA3.1. 
6-well plate format: 
For all transfections a ratio of 2:1 of transfection reagent to DNA was used. In 
separate tubes 1 μg of plasmid DNA was added to 10 μl of 150 mM NaCl. 2 μl 
of JetPEI was added to 10 μl of 150 mM NaCl in a separate tube. Contents of 
both tube were added together and vortexed. The mix was then incubated at 
room temperature for 20 minutes, to all complex formation. Cells were 
transfected for 24 hours and serum starved for 12 hours prior to the addition of 
cytokines for varying time points. Total cell lysates were prepared as described 
in section 2.2.14 and proteins were separated by SDS-PAGE as described in 
section 2.2.16 and detected by western blotting as described in section 2.2.17. 
Over-expression of specific genes was assessed using antibodies against the 
over-expressed protein or their specific tag.  
2.2.8 Cytotoxicity Assay 
Background 
Biological inhibitors are useful tool to understand the downstream events 
regulated by signalling molecules. Many inhibitors have been shown to have 
toxic effects on certain cell types. Therefore to assess whether the inhibitors 
used in section 2.2.8 and 2.2.9 were toxic to cells the ToxiLight Bio Assay was 
performed. This kit utilises bioluminescence to evaluate cell death. The kit 
works on the principle that on cell damage and cell death the cell will lose 
plasma membrane integrity. In such case, the cell will release the enzyme, 
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adenylate kinase (AK), a phospho-transferase. This is released from the cell 
into the medium. AK converts ADP to ATP; the produced ATP is then used to 
catalyse a bioluminescent reaction which can be measured and quantified using 
a luminometer. ATP aids in luciferases conversion of luciferin to oxyluciferin, 
with light being emitted as a by-product of this. As a consequence, the emitted 
light intensity is linear in relation to the released AK concentration in the 
medium and thus the cell death. The intensity of light emitted from the medium 
and total cell death can then be calculated and a percentage of cell death 
caused by the inhibitor calculated. All inhibitors were screened for cytotoxicity in 
HACs and bovine nasal cartilage. 
Reagents 
 ToxiLight BioAssay Kit: Non-Destructive Cytotoxicity Assay 
Method 
10 ml of Assay Buffer was first added to the vial containing the lyophilized AK 
detection reagent. This was mixed gently and was left at room temperature for 
15 minutes to equilibrate. SW1353/HACs were grown in 96 well plates; bovine 
nasal cartilage was plated in 96 well plates. Experiments were performed as 
though a normal experiment. 100 μl of medium was removed from each well 
and added to a fresh 96 well plate. The cells in the remaining 100 μl of medium 
were subjected to multiple freeze-thaw cycles. Freeze-thawing leads to the loss 
of cell membrane integrity and thus was used as a control for complete cell 
death. The cell death medium and normal medium was then raised to room 
temperature. 10 μl of each sample was taken from each sample and transferred 
to a luminescence-compatible 96 well plate. To each sample, 50 μl of the 
reconstituted AK detection reagent was added and incubated for 5 minutes. The 
plate was then placed into the luminometer and light quantified at immediate 1 
second integrated readings. From this a percentage cell death was calculated 
from the released AK in the normal medium compared to total cell death from 
adding both normal and cell death medium.  
2.2.9 Monolayer inhibition 
To assess broad-spectrum PKD and STAT3 inhibition on collagenase gene 
expression, as well as PKC inhibition on PKD phosphorylation broad-spectrum 
inhibitors were used. Cell grown in monolayer were treated with these inhibitors 
prior to cytokine stimulation. 
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Reagents 
 DMEM culture medium containing 2 mM L-glutamine 200 IU/ml penicillin, 
200 μg/ml streptomycin, 40 IU/ml nystatin. 
 NB 142-70  
 S3I-201 
 DMSO 
 
Method 
P0 HACs were used. Cells were used when they reached 70-80% confluency, 
usually 10 days post-digest. SW1353 cells were plated out 24 hours prior to 
experiment start point. Cells were serum starved overnight prior to inhibition. 
The following day, 1 hour prior to stimulation, serum free medium was replaced 
with serum free medium containing inhibitor or for controls; the vehicle inhibitor 
was reconstituted in (in all cases DMSO). After 1 hour cells were then stimulate 
with cytokines as normal. Cells were then lysed and lysates stored at -80°C until 
used in downstream experiments.  
2.2.10 RNA extraction and reverse transcription 
Background 
Prior to PCR, mRNA was extracted from cultured cell lines and primary 
chondrocytes grown in monolayer. Quantification of gene expression could then 
be partaken on the conversion of mRNA to cDNA. RNA was extracted from 
HACs grown in 96 well plates using the SideStepTM Kit. RNA was extracted 
from SW1353s cells grown in 96 well plates using the Cells-to-cDNA kit. Both 
kits inactivate RNases in one single step allowing reverse transcription to occur 
directly from lysates without any further processing. 
Reagents 
 SideStepTM Kit 
 Cells-to-cDNA kit 
 DNase 
 RNase- and DNase-free water  
 5x First Strand Synthesis Buffer 
 DTT 
 RNaseOut 
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 Moloney Murine Leukemia Virus-Reverse Transcriptase (MMLV) 
 Ice-cold PBS 
Method  
RNA extracted using SideStepTM Kit: 
HAC were seeded into 96-well plates at a density of 10,000 cells per well and 
grown until 70-80% confluent. Cells then underwent experimental conditions. 
The cell culture medium was removed and cells were washed three times in ice-
cold PBS on ice. 20 μl/well of SideStepTM Lysis and Stabilisation Buffer was 
added to each well and the plate was then vortexed for 2 minutes to ensure 
complete cell lysis. At this point lysates could be stored at -80°C. Lysates were 
then diluted 4-fold in RNase- and DNase-free water. 4 μl of the diluted cell 
lysate was transferred to a new 96-well plate for reverse transcription. To each 
well of the 96-well plate 1 μl random hexamers (pd(N)6) (0.2 μg/ml) and 3 μl 
deoxyribonucleotides (dNTPs) (2.5 mM) and 4 μl of Rnase- and DNase-free 
water were added and the plate heated at 70°C for 5 minutes. The plate was 
immediately placed on a cold block where 4 μl 5x First Strand Synthesis Buffer, 
2 μl Dithiothreitol (DTT) (0.1 M), 0.125 μl RNaseOut (40 U/μl) and 0.5 μl MMLV 
(200 U/μl) were added to each well. The plate was incubated at 37°C for 50 
minutes, followed by 70°C for 15 minutes. cDNA was diluted by adding 30 μl of 
RNase- and DNase-free water. All cDNA was stored at -20°C until required. 
RNA extracted using cell to cDNATM Kit: 
SW1353 cells were seeded into 96-well plates at a density of 4,500 cells per 
well and grown until 70-70% confluent. Cells then underwent experimental 
treatments. The cell culture medium was removed and cells were washed once 
in ice-cold PBS on ice. 30 μl cells to cDNATM Kit was added to each well and 
the lysates were transferred to a PCR plate. The lysates were then heated to 
70°C for 10 minutes to ensure samples were lysed. At this point lystates could 
be stored at -80°C. For certain experiments a DNase step was performed. If so, 
1 μl of RQ1 DNase was added. Lysates were then heated to 37°C for 30 
minutes and then heated to 70°C for 10 minutes to inactivate the enzyme. After 
the DNase step, 8 μl of the cell lysate was transferred to a new 96-well plate for 
reverse transcription. To each well 3 μl of dNTPs (2.5 mM) and 1 μl Pd(N)6) (10 
ng/μl were added and the plate was heated to 70°C for 5 minutes. The plate 
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was immediately placed on a cold block where 4 μl 5x First Strand Synthesis 
Buffer, 2 μl DTT (0.1 M), 0.125 μl RNaseOut (40 U/μl), 0.5 μl MMLV (200 U/μl) 
and 1.375 μl of RNase- and DNase-free water were added to each well. The 
plate was incubated at 37°C for 50 minutes, followed by 70°C for 15 minutes. 
cDNA was diluted by add 30 μl of RNase- and DNase-free water. All cDNA was 
stored at -20°C until required.  
2.2.11 Taqman Probe-Based Real-Time PCR 
Background 
This method for real time quantification of mRNA expression within cells 
cultured in monolayer relies on the use of a gene specific probe. This lends this 
method a high degree of specificity. The fluorescent probe is gene specific and 
binds to a region between both gene-specific primers. The probe contains a 5’ 
prime fluorophore and 3’ prime quencher. As real time synthesis of the primer 
takes place, the 5’-3’ endonuclease activity of the Taq polymerase cleaves the 
5’ fluorophore. The dissociated fluorophore is spatially distanced from the 
quencher allowing its fluorescence to be emitted. The levels of fluorescence 
detected are therefore directly proportionate to the amount of product produced 
by the PCR reaction (Bustin, 2000). Once a threshold level of fluorescence is 
detected a Ct value is given which indicates the number of PCR cycles taken to 
reach this threshold. This is inversely proportional to the levels of mRNA 
expression. The quantification of the gene should have no interference from 
non-specific binding or primer dimers. To normalise each sample for differences 
in total RNA present the levels of RNA from a housekeeping gene is used. In 
these experiments the house keeping gene 18S ribosomal RNA (rRNA) was 
used. Oligonucleotide probes and primers were designed using Primer Express 
1.0 (Applied Biosystems) or Universal ProbeLibrary Assay Design Centre for 
probe library probes and primers (Roche diagnostics Ltd, West Sussex, UK). All 
primers were designed to be intron spanning to ensure no genomic DNA was 
amplified. The exception to this was c-jun in which a DNase step was always 
performed prior to reverse transcription. Probes were either FAM-TAMRA or 
FAM conjugated. A list of all primers and probes used can be seen in Table 5.  
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Reagents 
 TaqMan Universal PCR Master Mix (2x) 
 TaqMan Fast Universal PCR Master Mix (2x) 
Method 
For housekeeping genes cDNA was diluted 1:25 for HAC and 1:100 for 
SW1353 lysates. 5 μl of cDNA was pipetted into either MicroAMP Fast or 
normal Optical 96-well reaction plates; this was dependent on the type of assay 
used. To this 4.5 μl of TaqMan Universal PCR Master Mix (2x) or TaqMan Fast 
Universal PCR Master Mix (2x) was added dependent on the assay type; these 
contain Taq polymerase, dNTPs and ROX normalisation dye. To this 0.2 μl of 
forward and reverse primers were added (final concentration of 300 nM) and 0.1 
μl of probe (final concentration of 150 nM). For the TaqMan Universal PCR 
Master assays, samples were subjected to an initial denaturation stage of 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. For TaqMan Fast Universal PCR Master assays, samples were 
subjected to an initial denaturation stage of 95°C for 10 minutes, followed by 40 
cycles of 95°C for 1 second and 60°C for 20 seconds. All assays were 
performed using the ABI prism 7900HT system (Applied Biosystems). 
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Table 5. List of primers and probes used for Taqman PCR. Oligonucleotide probes and primers were designed using Primer express 1.0 (Applied Biosystems) or 
Universal ProbeLibrary Assay Design Centre for probe library probes and primers. The c-fos assay is an ABi designed assay on demand.
Gene Forward primer 5’-3’ Reverse Primer 5’-3’ Probe 5’-3’ 
MMP-1 AAGATGAAAGGTGGACCAAAATT CCAAGAGAATGGCCGAGTTC CAGAGAGTACAACTTACATCGTGTTGCGGCTC 
MMP-2 TGGCGATGGATACCCCTTT TTCTCCCAAGGTCCATAGCTCAT CTCCTGGCTCATGCCTTCGCCC 
MMP-8 CACTCCCTCAAGATGACATCGA ACGGAGTGTGGTGATAGCATCA CAAGCAACCCTATCCAACCTACTGGACCAA 
MMP-9 CCTGGGCAGATTCCAAACCT GCAAGTCTTCCGAGTAGTTTTGGAT CTCAAGTGGCACCACCACAACATCACC 
MMP-13 AAATTATGGAGGAGATGCCCATT TCCTTGGAGTGGTCAAGACCTAA CTACAACTTGTTTCTTGTTGCTGCGCATGA  
MMP-14 AGGCCGACATCATGATCTTCTTT AAGTGGGTGTCTCCTCCAATGTT CCATGGCGACAGCACGCCCTT 
18S rRNA CGAATGGCTCATTAAATCAGTTATGG TATTAGCTCTAGAATTACCACAGTT
ATCC 
TCCTTTGGTCGCTC GCTCCTCTCCC 
PRKD1 TGTATTACCCTCTTTCAGAATGACA CCAGAGACAAAATTTCAGATAAAGG Human Probe library (Roche) # 38 
PRKD2 AGATGCTCTTCGGCCTAGTG AGCGCTTGTGGTAGTTCAGC Human Probe library (Roche) #46 
PRKD3 TGATTTAAAGCCAGAAAATGTGC CGTGCAAATCCAAAGTCACA Human probe library (Roche) #21 
jun CCAAAGGATAGTGCGATGTTT CTGTCCCTCTCCACTGCAAC Human probe library (Roche) #19 
c-fos ABi Assay on demand  
# Hs00170630_m1 
  
ATF3 TTTGCCATCCAGAACAAGC CATCTTCTTCAGGGGCTACCT Human probe library (Roche) #53 
NFATc1 CCAAGGTCATTTTCGTGGAG GGTCAGTTTTCGCTTCCATC Human probe library (Roche) #45 
BMP-2 GACTGCGGTCTCCTAAAGGTC AGCCCGCTTCAGGATAGAC Human probe library (Roche) #57 
AXUD1 CCTGCCTGACCGTGACTT GGAAGCAGCAACGCTAGAAG Human probe library (Roche) #49 
EGR2 TGGTTTCTAGGTGACGAGACG TGGTTTCTAGGTGCAGAGAGACG Human probe library (Roche) #3 
Interferon-α CCCTCTCTTTATCAACAAACTTGC TTGTTTTCATGTTGGACCAGA Human probe library (Roche) #69 
Interferon-ϒ TGCTCAGCTTTCACTATTGTTG TTTCTGGGGGCTTACATGAG Human probe library (Roche) #34 
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2.2.12  Cytoplasmic and nuclear extraction 
Background 
The NE-PER Nuclear and Cytoplasmic Extraction kit from Thermo Fisher 
Scientific was used to separate cytoplasmic and nuclear fractions. The first two 
(CER I and CER II) reagent within the kit enables the stepwise lysis of cell 
membrane and the separation of the cytoplasmic protein from the intact nuclei. 
The second reagent allows the extraction of nuclear proteins from genomic 
DNA and mRNA. 
Reagents 
 Ice cold PBS 
 Protease inhibitor  
 Nuclear and cytoplasmic extraction kit containing  
 Cytoplasmic Extraction Reagent I (CER I) 
 Cytoplasmic Extraction Reagent II (CER II) 
 Nuclear Extraction Reagent (NER) 
Method 
HACs were cultured as described in section 2.2.1 with 1 million P0 HACs being 
plated into 6 cm dishes. Following siRNA gene silence and cytokine stimulation, 
cells were washed twice with ice-cold PBS on ice. Cells were removed from the 
plastic using a Corning® cell lifter (Sigma Aldrich) in 1 ml of ice-cold PBS and 
centrifuged at 500 x g for 3 minutes to pellet. The supernatant was discarded. 
Protease inhibitors were added to each reagent. Amounts of reagent used were 
dependent on pellet volume, as indicated in Table 6. 
Ice cold CER I containing protease inhibitors was then added to cell pellet and 
vortexed for 15 seconds (all vortexing performed at the highest setting) and 
incubated on ice for 10 minutes. Ice-cold CER II was added and sample vortex 
for 5 seconds. This was then incubated on ice for 1 minute. The pellet was then 
vortexed for a further 5 seconds before being centrifuged at 16,000 x g for 5 
minutes. The supernatant (cytoplasmic fraction) was then transferred to a clean 
pre-cooled eppendorf and kept on ice. The insoluble pellet was then re-
suspended in ice-cold NER and vortexed for 15 seconds. The sample was then 
placed on ice for 10 minutes. The Eppendorf was repeatedly vortexed every 10 
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minutes for 40 minutes. The tube was then centrifuge for 10 minutes at 16,000 x 
g. The supernatant (nuclear fraction) was then transferred to a clean pre-chilled 
eppendorf. Fractions were snap-frozen using dry ice and stored at –80oC until 
required. 
 
Packed cell 
volume (μl) 
CER I (μl) CER II (μl) NER (μl) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
 
Table 6. Volumes of cytoplasmic and nuclear extraction reagents used in relation to 
pellet size. Volumes of reagents used varied upon size of cell pellet extracted from scraping 
cell culture dish.  
2.2.13 Subcellular protein fractionation 
 
Background 
The subcellular protein fractionation kit from ThermoScientific was used to 
separate the cytoplasmic, membrane, soluble nuclear, chromatin-bound nuclear 
and cytoskeletal fractions. The first reagent (CEB) added to the cell pellet 
causes lysis of the cell membrane, releasing soluble cytoplasmic contents. The 
second reagent (MEB) dissolves the remaining plasma, mitochondria and 
ER/golgi membranes. This reagent does not dissolve the nuclear membranes. 
Intact nuclei are recovered by centrifugation and the third reagent (NEB) lyses 
the nuclear membrane releasing soluble nuclear extracts. NEB is reused in the 
extraction of chromatin-bound nuclear protein but with the addition of 
micrococcal nuclease inhibitor and calcium chloride. Finally PEB is used to 
extract cytoskeletal proteins.  
 
Reagents 
 Ice-cold PBS 
 Subcellular Protein Fractionation Kit containing: 
 Cytoplasmic Extraction Buffer (CEB) 
 Membrane Extraction Buffer (MEB)  
 Nuclear Extraction Buffer (NEB)  
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 Pellet Extraction Buffer (PEB)  
 Micrococcal Nuclease (≥ 100 units/μl) 
 CaCl2 (100 mM) 
 HaltTM Protease Inhibitor Cocktail (100X) 
Method 
HACs and SW1353 cells were cultured as described in sections 2.2.1 and 
section 2.2.2 in 10 cm dishes, with 3 million HAC and 1 million SW1353 cells 
being plated. Following cytokine stimulation, cells were washed twice with ice-
cold PBS. Cells were scraped into 1 ml ice-cold PBS and centrifuged at 500 x g 
for 3 minutes to pellet. The supernatant was discarded. Protease inhibitors were 
added to each reagent. Amounts of reagent used were dependent on pellet 
volume. 
Ice-cold CEB buffer containing protease inhibitors was added to the cell pellet 
and the tube incubated at 4oC for 10 minutes with gentle mixing. The tube was 
centrifuged at 500 x g for 5 minutes at 4oC and the supernatant (cytoplasmic 
extract) transferred to a clean pre-chilled tube on ice. Ice-cold MEB buffer 
containing protease inhibitors was then added to the pellet and vortexed for 5 
seconds on highest setting. The tube was then incubated at 4oC for 10 minutes 
with gentle mixing and centrifuged at 3000 x g for 5 minutes at 4oC. The 
supernatant (membrane extract) was transferred to a clean pre-chilled tube on 
ice. Ice-cold NEB containing protease inhibitors was then added to the pellet 
and vortexed for 15 seconds on the highest setting. This was then incubated at 
4oC for 30 minutes with gentle mixing. The tube was centrifuged at 5000 x g for 
5 minutes at 4oC and the supernatant (soluble nuclear extract) transferred to a 
clean pre-chilled tube on ice. The chromatin-bound extraction buffer was 
prepared by adding 5 μl 100 mM CaCl2 and 3 μl of Micrococcal Nuclease (300 
units) per 100 μl of room temperature NEB and added to the pellet. The tube 
was vortexed for 15 seconds on the highest setting, incubated at room 
temperature for 15 minutes and centrifuged at 16000 x g for 5 minutes at 4oC. 
The supernatant (chromatin-bound nuclear extract) was transferred to a clean 
pre-chilled tube on ice. Room temperature PEB containing protease inhibitors 
was added to the pellet, vortexed at the highest setting for 15 seconds and 
incubated at room temperature for 10 minutes. The tube was centrifuged at 
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16000 x g for 5 minutes at 4oC and the supernatant (cytoskeletal extract) 
transferred to clean tube. Fractions were snap frozen and stored at –80oC until 
required. 
2.2.14  Whole cell lysis 
Background 
To extract cellular proteins for western blotting, cells membranes were lysed to 
extract all cellular proteins. Numerous protease inhibitors were used to prevent 
protein degradation and protein modifications. 
Reagents 
 Lysis buffer : 50 mM Tris, pH 7.5, 10% (v/v) glycerol, 1 mM EGTA, 1 mM 
EDTA, 1 mM Na3VO4, 10 mM 2-glycerophosphate, 50 mM sodium 
fluoride, 5 mM sodium pyrophosphate, 1% (v/v) Triton X-100, 1 μM 
microcystin-LR; 0.1% (v/v) 2-mercaptoethanol, 1x protease inhibitor 
cocktail (Roche).  
 Ice cold PBS 
Method 
Cells were harvested after stimulation at appropriate time points. Cells were 
washed 2x in ice cold PBS on ice. 120 μl of lysis buffer was added and cells 
scraped using Corning® cell scrapers (Sigma Aldrich) and added to 
Eppendorfs. Cells were vortexed at highest setting for 20 seconds and then left 
on ice for 20 minutes for complete lysis. Cells were then centrifuged for 3 
minutes at full speed to remove cytoskeletal debris. Total cell protein lysate 
were then snap frozen on dry ice and stored at -80°C until use.  
2.2.15  Protein Quantification  
Background 
The Bradford Assay is a colorimetric protein assay which measures protein 
concentration based on an absorbance shift in the Coomassie protein dye when 
bound to protein. A standard curve is generated by diluting BSA stock solution 
in the lysis buffer used for extraction; this is used to estimate the protein 
concentration of cellular lysates. 
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Reagents 
 2 mg/ml stock of BSA protein standard  
 Bradford assay reagent 
Method 
A BSA protein standard curve was generated by diluting the BSA stock solution 
in lysis buffer, with concentrations ranging from 0-4 mg/ml, with 0.4 mg/ml 
incremental increases. To the diluted BSA or extracted proteins 150 μl of 
Bradford Ultra (Expedeon, UK) was added to each sample in a 96 well plate. 
Following a 5 minute incubation, absorbance was read at 595 nm using a Tecan 
Sunrise microplate absorbance reader (Tecan, Reading, UK). Protein 
concentration was calculated using the standard curve generated from the BSA 
standards. All protein samples were then normalised using lysis buffer.  
2.2.16  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Background 
Protein containing samples, generated from cell lysates that were left whole, 
subjected to subcellular protein fractionation or nuclear and cytoplasmic protein 
extraction were separated based on size by SDS-PAGE. This was performed 
under reducing conditions. Acrylamide was polymerised by the addition of 
ammonium persulphate (APS) and the base TEMED. TEMED promotes the 
release of persulphate ions from the APS, allowing the free radicals to initiate 
the polymerisation of acrylamide. Samples were prepared by boiling in Laemmli 
loading buffer. This contained β-mercaptoethanol, SDS and the tracking dye 
Bromophenol blue. β-mercaptoethanol reduces disulphide bonds and prevents 
the oxidation of cysteines, reducing any tertiary or quaternary structures within 
the protein samples. SDS is an anionic detergent that denatures protein by 
disrupting non-covalent bonds, wrapping around the polypeptide backbone at a 
ratio 1.4 g SDS/g protein. SDS masks any positive charge from the protein and 
as SDS is an anionic detergents that gives the protein a net negative charge per 
unit mass. Samples are then separated by utilising two different gel types; the 
stacking and resolving gels. The stacking gel is the upper gel and this gel 
concentrates the protein into a sharp band before entering the lower separating 
gel. This is achieved by utilising the differences between pH and ionic strength 
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of the different gels as well as the electrophoresis buffer. The pores size of the 
stacking gel is large allowing free movement of all protein. When charge is 
applied across the gel, negatively charge glycinate ions, within the 
electrophoresis buffer, move away from the cathode towards the sample and 
stacking gel. As they enter the stacking gel the pH reduces so that their velocity 
decreases. Inside the stacking gel, negatively charged chloride atoms are also 
moving away from the cathode, these have a higher velocity then the slowed 
glycinate ions. This creates a tight band in which the sample is concentrated 
within the glycinate and chloride boundaries. This tight, negatively charged 
band then moves towards the anode. When this band enters the higher pH of 
the resolving gel the glycine becomes deprotonated and the mobility of the 
glycinate ions increase. The protein mobility decreases due to no longer being 
within this tight negatively charged band. The protein can then be separated 
upon size, due to changes in mobility due to protein size.   
Reagents 
 4 x Lower gel buffer (LGB): 1.5 M TrisHCl pH 8.8, 0.4% (w/v) SDS. 
 4 x Upper gel buffer (UGB): 0.5 M TrisHCl pH 6.8, 0.4% (w/v) SDS. 
 Stacking gel: 40% bis/acrylamide diluted to 4.5% with water and 4 x 
UGB. 
 5 x Laemmli Final sample buffer (FSB): 0.625 mM Tris HCl pH 6.8, 40% 
(v/v) glycerol, 10% (w/v) SDS, 0.5% (w/v) bromophenol blue, 5% (v/v) -
mercaptoethanol. 
 10 x Running Buffer: 250 mM Tris, 2 M glycine, 10% (w/v) SDS. 
 PageRuler pre-stained protein standards (Thermo Scientific) 
Method 
Cells were lysed as described in sections 2.2.12, 2.2.13 and 2.2.14. The protein 
concentration was then quantified as described in section 2.2.15. Samples were 
then normalised so that maximal amount of protein was ran on each gel. 
Samples were made to 100μl using DNAse/RNAse free water if required. 20μl 
of 5x FSB was added to samples and then heated at 105°C for 5 minutes. 
Electrophoresis was performed in a Bio-Rad Mini-PROTEAN® Tetra Cell using 
1.0 mm separator plates. For resolving gel, polyacrylamide-bis-acrylamide 40% 
(w/v) (37.5:1 acrylamide:bis) solution, was diluted with water and 4 x LGB to the 
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required percentage. Volumes dependent on number of gels required and 
percentage volume (gels cast at 10% unless otherwise stated). For one 10% gel 
3 ml of dH2O, 1.5 ml of acryl/bis and 1.5 ml of LGB was used. Gel mixture was 
polymerised by the addition of TEMED and APS 0.2% (w/v) at a ratio of 1:3 
prior to plate pouring (5 μl: 15 μl per gel). A spacer plate and short plate were 
combined within a casting frame and checked to ensure a seal had formed. The 
gel was then poured. The lower gel was then overlaid with isopropanol ensure a 
flat gel surface is achieved and oxygen is expelled, due to oxygen inhibiting 
polymerisation of the gel. Once set, the isopropanol was washed off using 
deionised water. The 4.5% bis/acrylamide stacking gel was then polymerised, 
again using TEMED and APS at a ratio of 1:3. This was laid on top of resolving 
gel and combs inserted. Once set the gel kit was assembled into the tank and 
combs removed. The tank and wells were then filled with 1x Running Buffer. 
Wells were washed in buffer to remove any waste gel. 3.5μl of the molecular 
weight marker PageRuler pre-stained protein standards was loaded in one well 
of each gel. 20μl of boiled sample was then added to the wells of the gel as 
appropriate. Proteins were electrophoresed at 100 mV through the stacking gel, 
to ensure proteins stacked. The voltage was then increased to 150 mV when 
proteins entered the resolving gel. Proteins were electrophoresed until the dye 
front reached the end of the resolving gel.   
2.2.17  Western blotting 
Background  
Following SDS-PAGE, proteins which had been separated by electrophoresis 
were transferred onto polyvinylidene fluoride (PVDF) membrane. Proteins 
embedded within the polyacrylamide gel are transferred from the gel onto the 
PVDF membrane by applying a current across both. The current draws the 
negatively charged proteins onto the membrane and the proteins bind the 
membrane through electrostatic and hydrophobic interactions. PVDF is more 
robust and easier to manipulate compared to nitrocellulose membranes. PVDF 
membranes can also be stripped, allowing the membranes to be re-probed 
later. To ensure that specific bind of the primary antibody occurs, the membrane 
must first be ‘blocked’. This consists of incubating the membrane in skimmed 
milk protein; this blocks any pores that are not occupied by protein, ensuring 
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specific binding on the primary antibody. Once blocked, the blot is incubated 
with a primary antibody that has affinity for the protein of interest. A secondary 
antibody conjugated to horseradish peroxidase (HRP) is then added; this has 
high affinity for the primary antibody. The conjugated HRP can then cleave a 
chemi-luminescent substrate found within a developing solution. This emits light 
which can be detected, indicating protein levels.  
Reagents 
 Tris Buffered Saline- Tween (TBS-T): 10 mM TrisHCl pH 7.4, 0.15 M 
NaCl. 0.2% Tween-20  
 Blocking buffer: TBS-T and 5% (w/v) non-fat dry milk 
 Stripping buffer: 0.2 M glycine and 2% (w/v) SDS, pH 2.5 
 ECL/ ECL prime or Advanced Western Blotting Detection systems 
according to manufactures instruction (Amersham ™ GE Healthcare UK 
Ltd) 
 ECL plus (MerckMillipore) 
 
Method 
The semi-dry iBlot gel transfer system (Life Technologies, Paisley, UK) was 
used to transfer protein onto PVDF membrane. The kit was used as 
manufacturer’s instruction, at a voltage 25 V of for 7 minutes. Here, the 
polyacrylamide gel was placed on the lower PVDF containing component. This 
contained a bottom buffer membrane and copper anode. On top of this was 
placed filter paper which had been dampened in deionised water. On this was 
placed the upper buffer membrane which contained a copper cathode. After 
transfer the membrane was placed in methanol and then deionised water to 
ensure membrane integrity.  
After protein transfer the PVDF membranes were then blocked for 1 hour at 
room temperature in blocking buffer, with agitation. Blocking solution was then 
removed and membrane was washed for 5 minutes in TBS-T to remove excess 
blocking solution. The membrane was then incubate with the primary antibody 
which had been diluted in TBS-T containing 5% BSA, overnight at 4°C with 
agitation. The membrane was then washed 3 x 15 minutes and incubated with 
secondary antibody diluted in TBS-T containing 5 % (w/v) non-fat dried milk for 
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1 hour at room temperature with agitation. The secondary antibody was 
discarded and the membrane was washed 3 x 15 minutes in TBS-T. Proteins 
were then visualised using western blotting detection systems according to 
manufacturer’s instruction. Membranes were visualised using a Syngene G-box 
detection system. Membranes were stripped and re-probed with antibodies that 
differed in size to original target, as well as a house keeper gene to determine 
equal protein loading. 
2.2.18 Statistical analysis 
Relative levels of gene expression were normalised to the housekeeping gene 
18S rRNA gene expression. Data were normalised and plotted as fold induction 
of target gene expression over basal levels. Data analysed using the ΔΔCt 
method. Values are pooled from at least 3 experiments and given as a mean of 
these data. Standard error of the mean was used (SEM). ANOVA (analysis of 
variance) with a post hoc Bonferroni was used to analyse significance between 
independent sample groups. Student one-tailed t-test were used to analyse 
optical density of western blots, standard deviation (STD) was used. Levels of 
statistical significance are shown as * p≤0.05, ** p≤0.01 and ***≤0.001. 
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3 Chapter 3: The characterisation of lentiviral-mediated gene 
silencing and optimisation of the over-expression and 
siRNA-mediated gene silencing of PKD in human articular 
chondrocytes 
3.1 Introduction 
The techniques of RNA interference (RNAi) and over-expression are two 
powerful molecular biological tools which can be utilised to alter the expression 
of endogenous mRNA and protein. Both methods can be used to help 
understand the role of a gene of interest in a particular system. These 
techniques have been applied for a number of years to understand the role of 
protein kinases within signalling cascades under cytokine stimulation (Dorsett 
and Tuschl, 2004). In this chapter I set out to utilise these techniques within 
primary chondrocytes so that the role of each isoform of PKD can be studied, 
specifically in the regulation of MMP gene expression under the pro-
inflammatory cytokine stimuli of IL-1 in combination with OSM.  
In this study two major types of RNAi have been deployed; siRNA- and shRNA- 
mediated gene silencing. As described in section 2.2.4 , siRNA and shRNA both 
exploit the same intrinsic machinery to decrease the expression of a target 
gene, but differ in the manner in which they are synthesised and introduced into 
the cell.  
siRNAs are double-stranded RNA sequences which are around 20-25 
nucleotides in length. siRNAs can be chemically synthesized as double-
stranded oligos, which can be transfected into the cell in this form. Design of the 
siRNA so that it is specific and has no off-target effects is crucial, with many key 
rules to be followed to enhance specificity (Reynolds et al., 2004). shRNAs on 
the other hand are hairpin structures, consisting of a stem region of paired 
antisense and sense strands connected by 7-9 unpaired nucleotides, which 
form a loop structure. shRNAs can be modified to increase their expression and 
processing, by making similar to that of a microRNA (miRNA). Modelling them 
on miRNA adds an additional Drosha processing site to the hairpin construct; 
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this can increase the gene silencing efficiency of the shRNA (Boden et al., 
2004). Adding miRNA flanking sequences either side of the hairpin has also 
been shown to lead to a 10-fold increase in Drosha and Dicer processing of the 
expressed hairpins when compared with conventional shRNA design (Silva et 
al., 2005). All these additions lead to increased chances of gene silencing as 
increased processing of the shRNA into a siRNA is observed.  
To achieve insertion of the siRNA or shRNA into the cell, different techniques 
can be utilised. siRNA and shRNAs can be directly transfected (non-viral 
method of insertion) into the cell using multiple methods. These include the use 
of calcium phosphate, electroporation, cationic polymers, liposomes and other 
transient transfection methods. This transient transfection directly inserts the 
siRNA or shRNA into the cell, allowing the RNA to be processed into a single 
stranded siRNA.  
shRNAs on the other hand can be introduced into a cell using two different 
methodologies. Firstly, they can be transiently transfected into a target cell by a 
method as described above. Secondly, shRNA can be incorporated into the cell 
by viral transduction. Recombinant retroviruses are widely used as gene 
therapy vectors due to their ability to integrate a transgene into the genome of a 
target cell (Buchschacher and Wong-Staal, 2000). This allows the stable 
integration of a shRNA into the genome of the infected cell. The expressed 
shRNA can then be processed by the cell into an active siRNA.  
Lentiviruses are one genus of the retroviridae family. One of the many benefits 
of using lentiviruses over other family members is that lentiviruses have the 
ability to transduce non-dividing cells (Freed and Martin, 1994), allowing greater 
transduction capabilities. Lentiviral mediated gene silencing utilises the ability of 
the virus to encompass a shRNA transcript. The virus can then integrate the 
gene of interest into the host genome, leading to stable expressing of the 
shRNA (Sakuma et al., 2012). This results in the long term expression of the 
transgene. siRNAs can therefore be produced from the shRNAs under the 
control of Pol III promoters (Brummelkamp et al., 2002); a U6 promoter is most 
commonly used. The benefit of this method over transient siRNA transfection, is 
that the cell constantly expresses the shRNA.  
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Lentiviral-mediated shRNA transduction had not previously been conducted 
within this laboratory and has only been assessed by a handful of other 
researchers when trying to transduce HAC (Miot et al., 2010, Li et al., 2004, 
Gouze et al., 2002). Development of this technique was therefore needed.  
As well as the use of RNAi and gene silencing to study the function of a gene of 
interest, the effect of over-expression of a gene can also be studied. Over-
expression of a mutated or native gene can give a similar insight into gene 
function as that of gene silencing. This method can be utilised by studying the 
effects of over-expressing a protein on downstream effector molecules and 
comparing this data to cells expressing normal protein levels. These data can 
be used by themselves or used to validate data seen with gene silencing, as the 
opposite effect should be observed. In this study I use the over-expression of 
native genes to understand their role in the signalling cascade which induces 
MMP gene expression through the stimulation of IL-1 in combination with OSM.  
In this chapter I therefore developed the molecular biological techniques 
capable of either reducing or increasing the expression of each individual 
isoform of PKD. This would ensure that any further findings within this thesis 
could be seen to be specific to each individual PKD isoforms.  
3.2 Aims 
 Optimisation of gene specific siRNA-mediated PKD isoform silencing 
 Optimisation of production of lentiviral particles 
 Optimisation of lentiviral transduction and PKD1 gene silencing 
 Optimisation of PKD1 over-expression in SW1353s and HAC 
3.3 Results 
3.3.1 Optimisation of PKD gene silencing using multiple siRNAs 
siRNA-mediated gene silencing is a well-established technique for reducing the 
expression of the mRNA and protein of a target gene. In this work I set out to 
understand the role of each isoform of PKD in the regulation of collagenase 
gene expression. Being able to specifically reduce the protein level of each PKD 
isoform was therefore crucial in this understanding. To achieve this, siRNA was 
first used. Initial optimisation experiments were performed to establish the 
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optimum concentration of siRNA and time point needed to achieve the maximal 
gene silencing. Concentrations of 25, 50, 75 and 100 nM were used at time 
points of 24, 48, 72 and 95 hours. Here, a final concentration of 100 nM of 
siRNA added for 48 hours was found to be the optimum concentration and time 
point for gene silencing.  
3.3.1.1 siRNA mediated gene silencing of PKD1 
To establish the specificity and capacity of each siRNA, in the silencing of each 
isoform of PKD, the effect of each siRNA on the mRNA and protein expression 
of each PKD isoform was assessed. To find specific and effective siRNAs a 
total of 9 siRNAs, with 3 targeting each isoform of PKD were used. To assess 
changes in mRNA and protein levels, RT-PCR and western blotting were used. 
Figure 3.1.A shows that the PKD1 siRNAs #1, #2 and #3 all reduce the mRNA 
expression of PKD1 by 55%, 68% and 53% respectively (Figure 3.1. A). These 
data suggest that each siRNA is significantly reducing the mRNA levels of 
PKD1 within HAC. To establish the specificity of each PKD1 siRNA, the effect of 
each siRNA on the gene expression of PKD2 and PKD3 was examined. No 
effects on the gene expression of PKD2 or PKD3 were seen when cells were 
treated with these siRNAs (Figure 3.1. B and C).  
When examining the effects of each siRNA targeting PKD1 on the protein 
expression of PKD1, no changes to the protein expression of PKD1 was 
observed (Figure 3.1. D). These data suggest all 3 of the siRNAs were capable 
of silencing PKD1 at the mRNA level, but not at the protein level. To establish 
protein silencing of PKD1 further siRNAs were used (ON-TARGETplus siRNA 
were purchased and targeted PKD1: siRNA codes L-005028-00-0005, l-
004197-00-0005, L-005029-00-005). These, similar to the data shown here 
were either unspecific or had no effect on the protein expression of PKD1 (data 
not shown).  
3.3.1.2 siRNA mediated gene silencing of PKD2 
Figure 3.1. B shows that the PKD2 siRNAs #1, #2 and #3 all reduce the mRNA 
expression of PKD2 by 59%, 72% and 55% respectively (Figure 3.1. B). These 
data suggest that each siRNA significantly reduced the mRNA levels of PKD2 
within HAC. These data also confirm that each siRNA was specific, with no 
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effects on the gene expression of PKD1 or PKD3 being observed with these 
siRNAs (Figure 3.1. A and C). This shows specificity of the siRNA against each 
isoform, indicating these siRNAs to be effective tools for specifically silencing 
PKD2 at the mRNA level.  
When examining the effect of each PKD2 siRNA on the protein level of PKD2, 
marked reduced expression of PKD2 is observed (Figure 3.1. D). These data 
indicated that the PKD2 siRNA #3 had the greatest and most consistent 
silencing of PKD2 at the protein level. For this reason PKD2 siRNA #3 was 
used in all following experiments in this thesis.   
3.3.1.3 siRNA mediated gene silencing of PKD3 
Figure 3.1. C shows that the PKD3 siRNAs #1, #2 and #3 all reduce the mRNA 
expression of PKD3 by 50%, 48% and 48% respectively (Figure 3.1. C). When 
examining the specificity of each PKD3 siRNA (Figure 3.1. A and B), it was 
observed that PKD3 siRNA #3, also reduced the gene expression of PKD1. 
These data therefore indicate this siRNA to be non-specific and could therefore 
not be used in this study. The PKD3 siRNAs, #1 and #2, were seen to be 
specific and therefore effective tools for specifically silencing PKD3 at the 
mRNA level.  
When examining the effects of each PKD3 siRNA on the protein level of PKD3 
a clear reduction in the protein expression of PKD3 is seen (Figure 3.1. D). 
HACs treated with the PKD3 siRNAs #1, #2 and #3 all have reduced protein 
expression of PKD3. All 3 siRNAs reduce the level of PKD3 to a similar degree 
but due to the lack of specificity of #3, therefore it was decided that PKD3 
siRNA #2 would be used for all subsequent experiments.  
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Figure 3.1. siRNA mediated gene silencing of each isoform of PKD. P1 HAC in 96 well 
plates were treated with 9 individual siRNA specific to PKD1, PKD2 or PKD3 (3 siRNAs per 
isoform) or non-targeting siCON (100 nM) for 48 hours. Cells were lysed and lysates reversed 
transcribed to cDNA. Real-time PCR was performed for (A) PKD1, (B) PKD2 and (C) PKD3, as 
described in the Materials and Methods. Data plotted are the mean ± S.E.M. of at least three 
separate chondrocyte populations (each assayed in hextuplicate) presented as relative 
expression levels normalised to 18S rRNA housekeeping gene. Comparisons shown are 
specific transfected PKD isoform versus control, transfection, where PKD expression in control 
was normalised to 100% expression. ***, p≤0.001, **, p≤0.01 vs siCON. (D) P1 HAC in 6 well 
plates were treated as above. Cell lysates were then immunoblotted using antibodies against 
PKD1, PKD2 and PKD3, as described in the Materials and Methods. Data are representative of 
at least three separate chondrocyte populations. GAPDH was used as a loading control. 
 
A) 
B) 
C) 
D) 
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3.3.2 Lentiviral characterisation and optimisation 
As described in section 3.3.1.1, the silencing of PKD1 at the protein level was 
unsuccessful. To try and silence PKD1 at the protein level multiple, siRNAs and 
varied experimental conditions were used. These changes and the use of new 
reagent still failed to silence PKD1 at the protein level. To overcome this, it was 
decided a new approach to reduce the protein expression of PKD1 would be 
utilised. It was decided that lentiviral mediated shRNA gene delivery would be 
used. The production of lentiviral particles containing shRNA had not previously 
been performed within this laboratory. This technique therefore needed to be 
characterised, with the production of viral particles needing to be optimised as 
well as the transduction of HAC. The purpose of this was to establish lentiviral 
mediated delivery of shRNA, using virus produced in-house and capable of 
silencing PKD1 at the protein level.  
3.3.2.1 Initial production of GFP containing lentivirus 
The production of lentiviral particles was first established. Here, using a second 
generation packaging and envelope plasmid system, the production of lentiviral 
particles was optimised. Initial lentiviral particles were produced using a plasmid 
which expressed a GFP protein. Transduced SW1353 cells or HAC could 
therefore by identified by GFP expression using live cell imaging. This ensured 
that living, transduced, cells could be identified. As Figure 3.2 shows, when 
lentiviral particles were generated using the method described in section 2.2.4, 
viral particles were produced capable of transducing both SW1353 cells and 
HAC, although HAC did not transduce as readily as SW1353 cells.. 
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Figure 3.2. Characterisation of lentiviral transduction of SW1353 cells and HAC using 
confocal microscopy. SW1353 cells or P0 HAC were plated into 96 well plates, allowed to 
adhere overnight and then medium was removed and replaced with 100 μl of viral supernatant 
total. Supernatant was replaced after 24 hours and cells were visualised after a further 48 
hours. Levels of transduction were equated to expression of GFP protein. The bright field image 
indicates the cells present, the GFP image indicates the levels of GFP .  
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3.3.2.2  Polybrene (hexadimethrine bromide) increases viral transduction 
Polybrene is a cationic polymer which increases the efficiency of viral 
transduction by neutralising the negative charge of the virion and cell 
membrane. Polybrene has therefore been shown to increase viral transduction 
at varying concentrations (Davis et al., 2004). Initial experiments were 
performed to find the optimum concentration of Polybrene to yield the greatest 
transduction of HAC cells. To achieve this, Polybrene was added to cells at the 
same time point as transduction at a range of 2-10 μg/ml. After observing the 
number of GFP-expressing cells between each condition and further insight 
from the literature, a concentration of 8 μg/ml was decided on as the optimum 
concentration of Polybrene (Figure 3.3).   
 
 
 
 
Figure 3.3. Characterisation of the optimum Polybrene concentration in HAC. P0 HAC 
were trypsinised and plated into 96 well plates, allowed to adhere overnight and then medium 
was removed and replaced with 100 μl of viral supernatant total. To this supernatant varying 
concentrations of Polybrene were added (ranging from 2-10 μg/ml). Supernatant was replaced 
after 24 hours and cells were visualised after a further 48 hours. Levels of transduction were 
equated to expression of GFP protein. The brightfield image indicates the cells present and the 
GFP image indicates the levels of GFP. 
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3.3.2.3 Lentiviral concentration 
Initial viral preparations showed poor transduction of both HAC and SW1353 
cells, indicated by the low GFP expression. To increase viral transduction, 
increased volumes of the viral preparations were used, and moderate increases 
in the amount of GFP expression were observed (data not shown). Therefore, 
to increase lentiviral transduction further, lentiviral viral preparations were 
concentrated following production. This was performed using the Clontech 
Lenti-x concentrator kit as described in section 2.2.3. Viral preparations were 
concentrated 50-fold, allowing for an increase in the number of viral particles 
added per well. Once concentrated, viral supernatant was added at varying 
volumes to both HAC and SW1353 cells (data not shown). Figure 3.4 
represents the increase in viral transduction observed with the concentrated 
viral particles.  
 
 
 
Figure 3.4. The effect of lentiviral concentration on lentiviral transduction in HAC. P0 HAC 
were trypsinised and plated into 96 well plates, allowed to adhere overnight and then medium 
was removed and replaced with either 100 μl of viral supernatant total or 10 μl of concentrated 
lentiviral supernatant in a total volume of 100 μl SFM. Polybrene at a concentration of 8 μg/ml 
was also added. Supernatant was replaced after 24 hours and cells were visualised after a 
further 48 hours. Levels of transduction were equated to expression of GFP protein. The bright 
field image indicates the cells present and the GFP image indicates the levels of GFP . 
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3.3.2.4 Centrifugation of cells transduced with lentiviral particles 
To further optimise the transduction of HAC the technique of spinoculation was 
used. This technique utilises centrifugation to increase transduction efficiency, 
this technique has been shown to dramatically increase the transduction of 
difficult to transfect cells (O'Doherty et al., 2000). However, this effect is not 
always replicated (Strang et al., 2005). As Figure 3.5 shows, centrifugation of 
HAC post addition of viral supernatant had no positive effect on the number of 
cells transduced.  
 
 
 
 
 
Figure 3.5. The effect of centrifugation on lentiviral mediated transduction of HAC. P0 
HAC were trypsinised and plated into 96 well plates, allowed to adhere overnight and then 
medium was removed and replaced with 10 μl of concentrated lentiviral supernatant in a total of 
volume of 100 μl of SFM. Polybrene at a concentration of 8 μg/ml was then added. Cells were 
then left or centrifuged at 1200 g for 60 minutes at room temperature. Supernatant was 
replaced after 24 hours and cells were visualised after a further 48 hours. Levels of transduction 
were equated to expression of GFP protein. The bright field image indicates the cells present 
and the GFP image indicates the levels of GFP.  
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3.3.2.5 Time course of transduction 
Once it was established that lentiviral preparations were capable of transducing 
both HACs and SW1353 cells, achieving this using lentiviral preparations 
containing a shRNA which targeted PKD1 was optimised. shRNA expression 
plasmids were therefore purchased from Open Biosystems; these were TRIPZ- 
based PKD1 shRNA plasmids. These plasmids use a tet-on operator, in which 
doxycycline must be present for the promoter of the shRNA to become active 
and expression of the shRNA to occur. This operator contains a tetracycline 
response element (TRE) and a transactivator (rtTA3). The transactivator binds 
to the TRE promoters in the presence of doxycycline leading to expression of 
the shRNA. These plasmids facilitated the expression of RFP instead of GFP, 
but only when the shRNA was being expressed. Viral preparations containing 
these shRNAs were produced. To optimise the experimental conditions needed 
to achieve maximal expression of the shRNA the cell line SW1353 were first 
used. These cells were readily available in large quantities, unlike HAC. As the 
presence of doxycycline was needed to induce the expression of the shRNA, 
the optimum time point needed for maximal transduction and shRNA expression 
was established. A time course study was therefore performed. Here, using the 
expression of RFP as an indicator of shRNA expression, the number of RFP 
positive cells was observed. The same well of a 96 plate was examined for up 
to 72 hours, and from this it was established that cells left for 72 hours achieved 
a maximal transduction (Figure 3.6), with no increase in viral transduction 
observed in cells left beyond this time (data not shown).  
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Figure 3.6. Optimum time point for maximal viral transduction in SW1353 cells. SW1353 
cells were plated into 96 well plates, allowed to adhere overnight and then medium was 
removed and replaced with 5 μl of concentrated lentiviral supernatant in a total volume of 100 μl 
SFM. Polybrene at a concentration of 8 μg/ml was also added. Supernatant was replaced after 
8 hours with serum containing medium which also contained 2 μg/ml of doxycycline. Cells were 
then repeatedly visualised every 24 hours for a further 72 hours. Levels of shRNA expression 
were equated to expression of RFP protein. The bright field image indicates the cells present 
and the RFP image indicates the levels of RFP .  
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3.3.2.6  Doxycycline concentrations 
To further optimise the expression of the shRNA, the optimum concentration of 
doxycycline was assessed. To achieve this, a concentration response 
experiment for doxycycline was set up. Here cells were treated for 72 hours 
post viral treatment with 0-3 μg/ml of doxycycline. No doxycycline was used as 
a control, to confirm that the promoter was not leaky and doxycycline was 
needed to express the shRNA. As Figure 3.7 shows, a concentration of 3 μg/ml 
of doxycycline induced the greatest expression of the RFP, indicating the 
greatest expression of the shRNA. Higher concentrations of doxycycline were 
used but no further increase in RFP expression was observed (data not shown) 
 
 
 
 
Figure 3.7 The effect of different concentrations of Doxycycline on RFP expression in 
SW1353 cells. SW1353 cells were plated into 96 well plates, allowed to adhere overnight and 
then medium was removed and replaced with 5 μl of concentrated lentiviral supernatant in a 
total volume of 100 μl SFM. Polybrene at a concentration of 8 μg/ml was also added. 
Supernatant was replaced after 8 hours with serum containing medium which also contained 
either no, 1, 2 or 3 μg/ml of doxycycline. Cells were then visualised after 72 hours. Levels of 
shRNA expression were equated to expression of RFP protein. The bright field image indicates 
the cells present and the RFP image indicates the levels of RFP.  
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3.3.2.7 Lentiviral mediated TRIPZ shRNA gene silencing in SW1353 cells  
Once it was established that SW1353 cells could be transduced to around 80-
90%, with tet-on shRNAs, the effect of these shRNA on the gene expression of 
PKD1 were assessed. Using three different viral preparations, each containing 
1 of the 3 shRNAs, gene silencing of each isoform of PKD was examined. As 
Figure 3.8. A shows, when doxycycline is not present there is no effect on the 
gene expression of PKD1. The effect of each shRNA in the presence of 
doxycycline was then assessed. As Figure 3.8. B shows, PKD1 shRNA #1, #2 
and #3 reduced PKD1 mRNA expression by 65%, 54% and 52%, respectively, 
when compared to cells transduced with a scrambled shRNA. To confirm the 
specificity of each shRNA, the effect on PKD2 and PKD3 gene expression was 
examined; the shRNAs had no effect on the other two isoforms (Figure 3.8. C 
and D). These data indicated that all 3 of the shRNAs were specific and 
effective at silencing PKD1 only.  
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Figure 3.8. The effect of lentiviral mediated delivery of TRIPZ shRNA on PKD gene 
expression in SW1353 cells. SW1353 cells were plated into 96 well plates, allowed to adhere 
overnight and then medium was removed and replaced with 5 μl of concentrated lentiviral 
supernatant of either control, shRNA PKD1 #1, #2 or #3 in a total volume of 100 μl SFM. 
Polybrene at a concentration of 8 μg/ml was also added. Supernatant was replaced after 8 
hours with serum containing medium which also contained either (A) no doxycycline or (B), (C) 
and (D) 3 μg/ml of doxycycline. Cells were then visualised after 72 hours to confirm shRNA 
expression. Cells were then lysed and lysates reversed transcribed to cDNA. Real-time PCR 
was performed for (A) PKD1, (B) PKD1 (C) PKD2 and (D) PKD3 as described in the Materials 
and Methods. Data plotted are the mean ± S.E.M. of at least three separate chondrocyte 
populations (each assayed in hextuplicate) presented as relative expression levels normalised 
to 18S rRNA housekeeping gene. Comparisons shown are specific transfected PKD isoform 
versus control, transfection, where PKD expression in control was normalised to 100% 
expression.**, p≤0.01, *, p≤0.05 vs shCON. 
 
A) B) 
C) D) 
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3.3.2.8 Lentiviral mediated TRIPZ shRNA delivery in HAC 
Once the optimum conditions needed to maximally transduce SW1353 cells 
were established, these conditions were used as a starting point for HAC 
transduction. Varying time points and concentrations of doxycycline were also 
used. When the levels of RFP expression in HACs transduced with the tet-on 
shRNAs were examined, low levels of RFP expression were observed (Figure 
3.9. A). This indicated one of two possibilities; poor shRNA expression due to 
the doxycycline not inducing expression, and/or poor transduction of HAC. As 
these viral particles had been shown to transduce SW1353 cells and HACs had 
previously been shown to be transduced well with GFP expressing lentiviruses, 
transduction was not thought to be the problem. These data therefore implied 
that the doxycycline was not capable of inducing expression in HAC. To try and 
overcome this, a new batch of doxycycline was purchased. Transduced HAC 
were therefore treated with either batch of doxycycline. As Figure 3.9. B shows, 
no increases in the levels of RFP were observed in the cells treated with the 
new doxycycline. Changes in viral concentration, doxycycline concentrations 
and duration of incubation with doxycycline also had no effect on viral 
transduction (data not shown). 
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Figure 3.9. Lentiviral mediated shRNA expression in HAC. P0 HAC were plated into 96 well 
plates, allowed to adhere overnight and then medium was removed and replaced with 10 μl of 
concentrated shCON lentiviral supernatant in a total volume of 100 μl SFM. Polybrene at a 
concentration of 8 μg/ml was also added. (A) Supernatant was replaced after 8 hours with 
serum containing medium which also contained 3 μg/ml of original doxycycline. (B) Supernatant 
was replaced after 8 hours with serum containing medium which also contained 3 μg/ml of 
original doxycycline or a new batch of doxycycline. Cells were then visualised after 72 hours. 
Levels of shRNA expression were equated to expression of RFP protein. The brightfield image 
indicates the cells present and the RFP image indicates the levels of RFP.  
 
 
A) 
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3.3.2.9 Lentiviral mediated delivery of GIPZ shRNA into HAC 
Due to time restraints and lack of improvement of the shRNA expression in 
HAC using the TRIPZ based tet-on shRNAs, new shRNA expression plasmids 
were purchased. These constructs did not require doxycycline to induce shRNA 
expression. Initial experiments set out to confirm whether HAC could be 
transduced with these new viral preparations and whether they expressed the 
shRNA. Experiments showed that viral particles containing these shRNAs were 
capable of transducing HAC to levels similar to that of the TRIPZ shRNAs in 
SW1353 cells, albeit when a larger volume of viral supernatant was used. 
Therefore, to reduce the variability between viral preparations and increase the 
reproducibility of this work, the multiplicity of infection (MOI) of HAC and 
SW1353 cells was calculated. To achieve this, the Clontech Lenti-X qRT-PCR 
Titration kit was used (see section 2.2.3 for details). As Figure 3.10 shows, an 
MOI of 30 led to the maximal transduction of HAC, with no increase in the 
number of transduced cells observed when cells were treated with virus 
equating to a MOI of 45. An MOI of 15 was found to be optimal for SW1353 
cells (data not shown). With every new batch of lentivirus made, the number of 
viral particles per ml was calculated and from this the volume of viral 
supernatant needed to transduce both HAC and SW1353 cells was calculated. 
This increased the reproducibility of viral transduction between different viral 
preparations.  
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Figure 3.10. Calculation of the MOI of HAC. P0 HAC were trypsinised and plated into 96 well 
plates, allowed to adhere overnight and then medium was removed and replaced with shCON 
viral supernatant equating to a MOI of 5, 15, 30 or 45 in a total volume of 100 μl SFM. 
Polybrene at a concentration of 8 μg/ml was also added. Supernatant was replenished with 
fresh serum containing medium after 24 hours. Cells were then visualised after 48 hours. Levels 
of shRNA expression were equated to expression of GFP protein. The bright field image 
indicates the cells present and the RFP image indicates the levels of GFP.  
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3.3.2.10 The effect of lentiviral mediated shRNA delivery of a PKD1 shRNA 
on PKD1 gene and protein expression in HAC 
 
Once it was established that transduction of HACs using the GIPZ-based 
shRNA plasmids could be achieved, the effects of these two PKD1 shRNAs on 
PKD gene and protein expression were assessed.  
Here cells were treated with two viral populations; these expressed either the 
GIPZ based PKD1 #1 shRNA or the GIPZ based PKD1 #2 shRNA. 
Transduction of HAC with GIPZ PKD1 #1 shRNA and GIPZ PKD1 #2 shRNA 
led to a 54% and 64% reduction in PKD1 gene expression, respectively (Figure 
3.11. A). Although there were no effects on PKD2 gene expression with either 
shRNA for PKD1 (Figure 3.11. B), GIPZ PKD1 #1 shRNA did reduce the 
expression of PKD3 (Figure 3.11. C). A clear reduction in the protein level of 
PKD1 was observed when cells were transduced with PKD1 #2 shRNA. This 
shRNA was therefore capable of specifically reducing PKD1 at both the mRNA 
and protein level in HAC and was therefore used in subsequent experiments. 
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Figure 3.11 The effect of lentiviral mediated GIPZ based PKD1 shRNA on PKD1 mRNA 
and protein expression in HAC. P0 HAC were trypsinised and plated into 96 well plates, 
allowed to adhere overnight and then medium was removed and replaced with viral supernatant 
containing either shCON, PKD1 #1 or PKD1 #2 shRNA at a MOI of 30, in a total volume of 100 
μl SFM. Polybrene at a concentration of 8 μg/ml was also added. Supernatant was replenished 
with fresh serum containing medium after 24 hours. Cells were then visualised 72 hours post 
transduction to confirm shRNA expression. Cells were then lysed and lysates reversed 
transcribed to cDNA. Real-time PCR was performed for (A) PKD1, (B) PKD2 (C) PKD3 as 
described in the Materials and Methods. Data (mean ± S.E.M.) are accumulative data of at least 
three separate chondrocyte populations (each assayed in hextuplicate) presented as relative 
expression levels normalised to 18S rRNA housekeeping gene. Comparisons shown are 
specific transfected PKD isoform versus control, transfection, where PKD expression in control 
was normalised to 100% expression. ***, p≤0.001, **, p≤0.01, *, p≤0.05. (D) HACs were treated 
as above (using only PKD1 #2 shRNA), except plated into 6 well plates in a total of 1 ml SFM. 
Cell lysates were then immunoblotted using antibodies against PKD1, PKD2 and PKD3, as 
described in the Materials and Methods. Data are representative of at least three separate 
chondrocyte populations. GAPDH was used as a loading control. 
 
A) 
D) 
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3.3.3 PKD1 over-expression optimisation 
Whilst optimising the conditions needed to silence PKD1 at the mRNA and 
protein level, the technique of protein over-expression of PKD1 was optimised 
to complement my research and understand the role of PKD1 in the regulation 
of collagenase gene expression. To achieve this, the optimum experimental 
conditions and transfection reagent for the over-expression of PKD1 were 
established. A PKD1 expression plasmid was purchased (Addgene). The PKD1 
plasmid was used in all experiments and included the backbone of pcDNA3.1, 
whilst transfection of the empty vector was used as a control. The plasmid 
contained a HA tag which aided in the identification of over-expression. The HA 
tag, unfortunately, could not be detected in HACs. 
Optimisation began by identifying the best transfection reagent to over-express 
the PKD1 plasmid; several commercially available transfection reagents were 
used. The magnetic bead based transfection reagent Magnet Assisted 
Transfection (MATra) transfection reagent (IBA, Goettingen, Germany), a 
cationic polymer based transfection reagent Exgene 500 (Thermo Scientific), a 
non-liposomal based transfection reagent Fugene HD (Promega) and the 
cationic polymer based transfection reagent JetPEI were all used.  
Experiments were first optimised in SW1353 cells. As Figure 3.12. A shows, the 
greatest expression of PKD1 when compared to control plasmid was achieved 
using Exgene 500 (both the magnetic transfection reagent and Fugene HD 
were cytotoxic at 4 μg of DNA). The optimum quantity of plasmid DNA and 
volume of Exgene 500 to use in transfection experiments was then sought. As 
Figure 3.12. B shows, little differences in the amount of over-expressed PKD1 
was observed when different amounts of DNA were used, a concentration of 3 
μg of DNA was chosen, to ensure over-expression of PKD1 was achieved. 
From the data observed in Figure 3.12. C it was decided that 9.87 μl of Exgene 
500 should be used to transfect in the PKD1 plasmid.  
Unfortunately, after this optimisation process, Exgene 500 became unavailable. 
A new cationic polymer based transfection reagent was therefore sought, as 
this reagent type had been shown to achieve the greatest transfection in both 
cell types. A new cationic polymer based transfection reagent, JetPEI, was 
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purchased. When comparing the expression of PKD1 in cells transfected with 
JetPEI to that of Exgene 500 no differences in over-expression were observed 
(Figure 3.12. D). JetPEI transfection reagent was therefore used in all further 
experiments performed in this thesis. Over-expression of PKD1 was achieved 
using 1 μg of DNA to 2 μl of JetPEI in SW1353 cells, without cytotoxicity. JetPEI 
was also used to over-express PKD1 in HAC, where 3 μg of plasmid DNA at 1:2 
ratio of transfection reagent successfully over-expressed PKD1 in HAC (Figure 
3.12. E) 
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D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Optimisation of the over-expression of PKD1 in SW1353 cells and HAC. 
SW1353 cells were plated into 6 well plates, and left over-night. (A) The following day cells were 
transfected using MATra based magnetic transfection, Exgen 500, Fugene HD as described in 
the manufactures instructions. Cells were transfected with either 4 μg of control backbone 
plasmid or 3 or 4 μg of PKD1 plasmid DNA. (B) Cells were transfected using Exgen 500 at 1:3 
ratio using either 4μg of control plasmid or PKD1 plasmid DNA as indicated. (C) Cells were 
transfected using Exgen 500 using volumes of as indicated and 3 μg of control and PKD1 
plasmid DNA. (D) Cells were transfected using either 9.87 μl of Exgen 500 and 3 μg of control 
plasmid or 1 or 3 μg of PKD1 plasmid DNA or JetPEI at 1:2 ratio of DNA to transfection reagent. 
1μg of control plasmid or PKD1 plasmid DNA were used. (E) P0 HAC were trypsinised and 
plated into 6 well plates and left over-night. Cells were transfected using JetPEI at 1:2 ratio of 
DNA to transfection reagent. 5 μg of control plasmid DNA was transfected along with PKD1 
plasmid DNA as indicated. Cells were lysed and separated by electrophoresis and then 
immunoblotted using antibodies indicated, as described in the Materials and Methods. Data are 
representative of at least three separate chondrocyte populations. GAPDH was used as a 
loading control. 
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3.4  Discussion 
Understanding the isoform specific roles of PKD was one of the major aims of 
this thesis. Therefore, ensuring that the biological techniques used to modulate 
the expression levels of each PKD isoforms were both robust and specific was 
the major initial aim. Much time was therefore spent on the optimisation and 
characterisation of RNAi and over-expression. These methods have long been 
established as important molecular biological techniques, enabling the 
understanding of the downstream effects of protein signalling molecules, within 
a particular system.  
It was first established that PKD2 and PKD3 could be silenced at the mRNA 
and protein level using siRNA specific for each isoform. PKD1 could be silenced 
at the mRNA level but not at the protein using siRNA. Off target effects were 
also seen when using some of these siRNAs.  
The siRNAs or shRNAs purchased were validated against each isoform. Even 
though these were validated reagents, off target effects were observed. 
Birmingham et al., using bioinformatics, observed off-target effects were often 
caused between match of the seed region of a siRNA (position 2-7) and the 
3’UTR of the non-specific gene. As this sequence is often not checked for when 
designing a siRNA or shRNA this could explain the off target effects observed, 
especially as all isoforms of PKD are closely related and may have similar 
3’UTRs (Birmingham et al., 2006). 
As well as bioinformatical studies, the final concentration of siRNA used can 
have a profound effect on siRNA efficiency. Increased concentration of siRNA is 
seen to increase the likelihood of off-target effects (Semizarov et al., 2003). To 
try and overcome this optimisation experiments performed. When the siRNA 
was used at lower concentrations than the 100 nM used, these reagents were 
seen to be less efficient and reductions in their off target effects were not 
observed. SMARTpool siRNAs from ThermoScientific were also used. These 
use a pool of 4 siRNAs and therefore when using 100 nM of siRNA each of the 
4 siRNAs are at a concentration of 25 nM, potentially reducing any off target 
effects. Off target effects were still observed when using these siRNAs (data not 
Chapter 3. The characterisation of lentiviral-mediated gene silencing and optimisation of over-
expression and siRNA-mediated gene silencing of PKD in human articular chondrocytes 
 
117 
 
shown). Therefore it was concluded that all siRNAs must be screened to 
confirm specificity at both the mRNA and protein level.  
Also of note is the increased expression of the other isoforms of PKD when an 
alternative isoform was silenced. This can be seen when cells are treated with 
both PKD2 and PKD3 siRNAs. An increase in the expression of PKD1 and 
PKD3 is observed when PKD2 was silenced; PKD1 and PKD2 protein 
expression also increased when PKD3 was silenced (Figure 3.1). This suggests 
a compensatory mechanism in which the reduction in the expression of one 
isoform is compensated for by increased expression of another. The effects of 
the PKD1 siRNA also appear to have this affect, as these reagents weren’t 
used in further experiments and the shRNA used appears to have no effect 
(Figure 3.11. D), these data were not of concern.  
One of the major problems to overcome in this study was to find a molecular 
biological tool capable of silencing PKD1 at the protein level. Research shows 
the importance of studying both the mRNA and protein expression of a target 
gene when using siRNA (Aleman et al., 2007). The levels of mRNA and protein 
expression are often thought of as very linear in relation to one another, with 
increased mRNA expression leading to increased protein expression. This, 
however, is not always the case, with the translational machinery dictating 
protein levels (Schwanhausser et al., 2011). As well as this, it is also observed 
that decreases in mRNA expression, as observed in these data, do not always 
correlate with decreased protein expression (Morgan et al., 2006) and are 
shown to have temporal differences in expression (Fournier et al., 2010). 
Therefore one explanation for the decrease in mRNA levels but not protein 
could be that the protein half-life of PKD1 exceeded the half-life of the mRNA. 
This means that any mRNA silencing by the siRNA was not sufficient in duration 
to cause a decrease in total protein. This effect has been noted in previous 
studies, with mRNA loss but no effect on protein expression (Dani et al., 1984, 
Franch et al., 2001).  
As PKD1 protein stability may exceed its own mRNA half-life, to try and 
increase the possibility of protein silencing the incubation time of SW1353 cells 
and HAC with the siRNA was increased. When siRNA incubation time was 
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increased no effect on the protein levels were observed (data not shown). This 
is unsurprising as the half-life of an siRNA is thought to be around 48 hours with 
the complete removal of the siRNA being observed after 96 hours (Pushparaj 
and Melendez, 2006). Therefore to try and overcome this problem, lentiviral 
mediated delivery of shRNA was used. This incorporated shRNA into the host 
genome allowing constitutive expression of the shRNA, increasing the duration 
of siRNA expression. 
The use of lentiviral mediated gene expression has many advantages over 
transient transfection of siRNA and shRNA, as well as the delivery of shRNA by 
other retroviral and adenoviral methods of transduction. Adenoviruses have 
been shown to transduce HAC and express the lacZ gene (Doherty et al., 
1998). However, adenoviruses only transiently transduce their target cell, with 
no incorporation of the shRNA in to the host genome. Retroviruses, unlike 
lentiviruses, require cells to be dividing in order to transduce. HACs are known 
to divide and grow slowly, suggesting lentiviral mediated transduction to be a 
better method to incorporate a shRNA into HAC than other retroviral methods. 
This has been shown, with Li et al., showing that lentivirus vectors gave up to 
three fold higher transduction efficiency in chondrocytes than retrovirus vectors 
(Li et al., 2004). For these reasons it was decided that lentiviral mediated gene 
silencing was the most appropriate technique to use.  
To optimise the lentiviral mediated transduction of SW1353 cells and HAC 
numerous steps were used. To ensure transduction and expression of the 
shRNA of interest could be quantified, all used virions were capable of inducing 
RFP or GFP expression. This enabled the identification of the cells which had 
been transduced.  
To increase the likelihood of transduction, viral preparations produced were 
concentrated. The use of the VSV-G viral coat protein gives the virus the 
capability to be concentrated (Burns et al., 1993). This stable and strong viral 
coat allows the integrity of the virus to be maintained when concentrated. The 
concentration of the virus allows more viral particles to come into contact with a 
cell increasing the likelihood of transduction, as shown in Figure 3.4. One 
problem with using VSV-G as the coat for the viral particles is the effect that 
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serum complement can have on these particles. VSV-G pseudotypes have 
been shown to be inactivated by serum complement (DePolo et al., 2000), and 
for this reason heat-inactivated FBS was used in the production of the lentiviral 
particles. All transduction of HAC or SW1353 cells were performed in native 
medium to also prevent inactivation in the initial steps of transduction.  
Much work has demonstrated poor transduction efficiency of retroviruses to be 
due to the slow diffusion and rapid inactivation. Viral particles are thought to be 
able to diffuse only a few microns before losing their bioactivity, for these 
reasons a large proportion of the viral particles are inactive before they come 
into contact with the cells (Davis et al., 2004). To therefore reduce these effects 
and increase viral transduction Polybrene was used. Polybrene masks the net 
negative charge, reducing charge repulsion (Coelen et al., 1983). The addition 
of Polybrene was seen to increase viral transduction (Figure 3.3). The 
technique of spinoculation was also used. Spinoculation works by concentrating 
virions onto the surface of target cells reducing diffusion; this technique should 
therefore increase the binding of viruses to target cell, enhancing the efficacy of 
virus-based incorporation of shRNA (O'Doherty et al., 2000). However, a 
decrease in the levels of transduction was seen when centrifuged; this may 
have been due to increases in cell death due to centrifugation of the cells  
Once it was established that a protocol to transduce both SW1353 cells and 
HAC had been achieved, I next sought to optimise the delivery of shRNA into 
the host genome. To achieve this, shRNA which were under the control of tet-
on operator, in which doxycycline was needed, were first used. As Figure 3.7 
and Figure 3.8 show, the conditions needed to successfully transduce SW1353 
cells with these shRNAs and also silence PKD1 specifically at the mRNA level 
were achieved. However when this technique was extrapolated into HAC, even 
when two different batches of doxycycline were used, little to no expression of 
the shRNA is observed. As previously high levels of viral transduction had been 
seen, it was believed that the doxycycline was not initiating promoter activity. 
One explanation for this could be due to the doxycycline not being able to enter 
primary cells, but doxycycline at a concentration 10 μg/ml has been shown to 
enter and have an effect on HAC (Shlopov et al., 2001). As high levels of 
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transduction were seen in SW1353 cells with the same viral populations and 
doxycycline, the reason for this limitation remains unclear. 
It is also of note that doxycycline can inhibit MMP activity and expression (Liu et 
al., 2003, Curci et al., 2000, Shlopov et al., 2001). As both control and PKD1 
shRNA expressing cells were treated with doxycycline, the effects of the 
doxycycline would likely have been normalised. But because of the problems 
with the optimisation of this system and the potential alterations in the results 
from the doxycycline I decided not to continue with the Tet-on based shRNAs.  
To continue this work, a set of GFP expressing, non-inducible shRNAs were 
used. The GFP expression was therefore used to calculate the MOI of SW1353 
cells and HAC (Figure 3.10). The calculation of the MOI was important to 
ensure confidence in the reproducibility of results between different viral 
preparations. Calculating the number of viral particles per ml for every viral 
preparation made enabled the same number of viral particles to be added in 
each experiment, increasing reproducibility and protein silencing. Once this was 
calculated the effect of the GIPZ based shRNA was assessed. As Figure 3.11 
shows, the shRNA GIPZ PKD1 #2 was capable of both silencing PKD1 at the 
mRNA and protein level.  
Whilst optimising lentiviral mediated gene silencing of PKD1, the technique of 
over-expression was utilised. Data show that the use of cationic polymers 
based transfection reagents were the best transfection reagents to use for over-
expressing PKD1 in SW1353 cells and HAC. The change of transfection 
reagent from Exgen 500 to JetPEI had no effect on experiments performed; 
JetPEI was then used in all further experiments.  
The tools needed to silence each isoform of PKD specifically were eventually 
found and optimised, as well as the over-expression of PKD1. The work 
achieved in this chapter laid the foundation for the rest of the work in this thesis, 
increasing confidence that any results obtained were specific to the isoform 
stated.  
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3.4.1 Summary 
Studies in this chapter have shown: 
 Isoforms PKD2 and PKD3 can be silenced at the mRNA and protein 
level using siRNA.  
 Using GIPZ expression plasmids containing a shRNA against PKD1 
was capable of silencing PKD1 at both the mRNA and protein level.  
 Optimum PKD1 over-expression was observed using cationic 
polymer based transfection reagents.  
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4 Chapter 4. The role of PKD isoforms in the regulation of 
MMP gene expression 
4.1 Introduction 
As mentioned previously, the irreversible degradation of the cartilage matrix 
which lines articular joints leads to the loss of normal joint function and 
homeostasis. This process is characterised by the proteolytic degradation of 
collagen and proteoglycan found within the ECM of this cartilage. The 
degradation of proteoglycan is rapid yet reversible (Dingle et al., 1987) and for 
this reason the irreversible degradation of cartilage collagen, albeit slower, is 
thought of as a key step in cartilage breakdown (Jubb and Fell, 1980). The 
major family of enzymes involved in this process are a sub group of the MMPs 
known as the collagenases. The collagenases consist of MMP-1, -8, -13 and -
14. Of these, MMP-1 and MMP-13 are thought to be of greatest importance in 
the cleavage of type II collagen during arthritis progression.  
To understand the regulation of these proteolytic enzymes within chondrocytes 
in inflammatory context, the inflammatory cytokines IL-1 and OSM were used as 
a model stimulus. These two pro-inflammatory cytokines have been shown to 
synergise, leading to the induction of collagenase gene expression. Various 
studies from within our laboratory have shown the induction of collagenase 
gene expression by these pro-inflammatory cytokines to correlate with cartilage 
degradation in human, murine and bovine models (Barksby et al., 2006, 
Cawston et al., 1995b, Rowan et al., 2001, Rowan et al., 2003, Koshy et al., 
2002b).  
The precise mechanism by which these pro-inflammatory cytokines regulate 
collagenase gene expression within chondrocytes remains unclear. Only a few 
studies have explored the signalling cascades that are activated by this 
combined stimulus (Catterall et al., 2001, Litherland et al., 2010, Litherland et 
al., 2008). Work within this chapter therefore sets out to assess the role of the 
PKD family in the induction of collagenase gene expression under the 
stimulation of IL-1 in combination with OSM. From these data and our own 
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previous work indicating the PKC family as collagenase regulators (Litherland et 
al., 2010), I wanted to establish the role of this PKC substrate in the regulation 
of collagenase gene expression. 
I therefore set out in this chapter to discover the role of each individual isoform 
of PKD in the regulation of collagenase gene expression in HACs. To perform 
this work the PKD inhibitor kb NB 142-70 was first used to elucidate the role of 
PKD as an entity within chondrocytes. Then using RNAi and over-expression 
techniques the role of each isoform of PKD on collagenase expression (as well 
as other matrix degrading enzymes) was assessed.   
4.2 Aims 
The aim of this chapter was to elucidate the role of each isoform of PKD in the 
regulation of collagenase gene expression under the synergistic stimulus of IL-1 
in combination with OSM.  
The specific aims were:- 
 Identify whether PKD regulates collagenase gene expression within HAC 
 Identify the isoform-specific roles of PKD on collagenase gene 
expression 
 Identify other MMPs potentially regulated by each isoform 
4.3 Results 
4.3.1  Identifying PKD as a regulator of collagenase gene expression  
Litherland et al., have tentatively implicated PKD in the regulation of 
collagenase gene expression within HAC (Litherland et al., 2010). PKD 
inhibition using the PKC/PKD inhibitor Gӧ6976 showed a reduction in 
collagenase gene expression within HACs stimulated with IL-1 in combination 
with OSM. Collagen release and collagenase activity was inhibited in bovine 
nasal cartilage by (Litherland et al., 2010). Gӧ6976 inhibits PKD (Gschwendt et 
al., 1996) as well as PKCα and PKCβ (Martiny-Baron et al., 1993). Since 
Litherland et al., concluded that aPKC isoforms were most important in 
collagenase gene regulation; I wanted to confirm or otherwise a specific role for 
PKD in the regulation of collagenase expression. To achieve this, the PKD 
inhibitor kb NB 142-70 was used. This inhibitor has been shown to be PKD 
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specific, with similar IC50s for each isoform of PKD (Bravo-Altamirano et al., 
2011) 
4.3.1.1 PKD inhibition modulates collagenase expression 
The cytotoxic effect of kb NB 142-70 in HAC was first assessed. Using the 
ToxiLight assay the levels of cell death were equated in HAC treated with the 
inhibitor vs inhibitor vehicle. No increased cytotoxicity was observed when using 
the inhibitor at concentrations up to 5 μM (Figure 7.1 supplementary data). To 
reduce the possibility of cytotoxicity and off target effects a concentration of 1 
μM was used. As Figure 4.1. A and B shows, a significant decrease in MMP-1 
and MMP-13 gene expression was observed in HAC in basal conditions and 
when stimulated with IL-1 alone or in combination with OSM when treated with 
the inhibitor.  
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Figure 4.1. The effect of PKD inhibition on collagenase expression in human articular 
chondrocytes. P0 HAC plated into 96 well plates were grown to ~70% confluency and then 
serum starved overnight. HAC were pre-incubated with 1 μM kb-NB 142-70 or the same volume 
of DMSO vehicle for 1 hour prior to stimulation with IL-1 (0.05 ng/ml) ± OSM (10 ng/ml) for 24 h. 
Cells were lysed and lysates reversed transcribed to cDNA. Real-time PCR was performed for 
(A) MMP-1 and (B) MMP-13, as described in the Materials and Methods. Data (mean ± S.E.M.) 
are representative of at least three combined chondrocyte populations (each assayed in 
hextuplicate) presented as relative expression levels normalised to 18S rRNA housekeeping 
gene. Comparisons shown are specific for PKD inhibitor versus control DMSO treated, where 
***, p≤0.001, *, p≤0.05 vs DMSO. 
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4.3.2  The isoform specific roles of PKD on collagenase gene expression 
Once a role for PKD in the regulation of collagenase gene expression was 
established, I next sought to elucidate the effect of each isoform of PKD on 
collagenase gene expression. Using over-expression and RNAi of PKD, I set 
out to understand how each isoform of PKD regulated collagenase gene 
expression within chondrocytes stimulated with IL-1 alone or in combination 
with OSM. The effect of PKD1 over-expression and PKD1, PKD2 and PKD3 
gene silencing were assessed using western blotting to confirm over-expression 
or gene silencing (as seen in chapter 3)  
4.3.2.1  The effect of PKD1 on collagenase gene expression  
PKD1 over-expression in HAC stimulated with IL-1 alone and in combination 
with OSM led to a significant reduction in the gene expression of MMP-1 and 
MMP-13 (Figure 4.2 A and B). To validate the overexpression data, PKD1 was 
specifically silenced using lentiviral-mediated delivery of shRNA. PKD1 
silencing led to a significant increase in expression of MMP-1 and MMP-13 
when stimulated with the synergistic stimuli IL-1 in combination OSM; no 
increase was seen with IL-1 stimulation alone (Figure 4.3 A and B). These two 
complementary techniques therefore confirmed PKD1 to down-regulate 
collagenase gene expression in HAC stimulated with IL-1 in combination with 
OSM. The over-expression and shRNA-mediated gene silencing of PKD1 had 
the same effects in the chondrocytic cell line SW1353 (Figure 7.2 and Figure 
7.3 supplementary data).  
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Figure 4.2. The effect of PKD1 over-expression on collagenase expression in human 
articular chondrocytes. P0 HAC were trypsinised and plated into 96 well plates, and left over-
night. The following day cells were transfected with pcDNA3-PKD1 or pcDNA3.1, and then 
serum starved overnight. The following day cells were stimulated with IL-1 (0.05 ng/ml) ± OSM 
(10 ng/ml) for 24 h. Cells were lysed and lysates reversed transcribed to cDNA. Real-time PCR 
was performed for (A) MMP-1 and (B) MMP-13, 48 h after start of transfection as described in 
the Materials and Methods. Data (mean ± S.E.M.) are accumulative of at least three separate 
chondrocyte populations (each assayed in hextuplicate) presented as relative expression levels 
normalised to 18S rRNA housekeeping gene. Comparisons shown are specific transfected PKD 
isoform versus control over-expression, where **, p≤0.01, *, p≤0.05 vs transfected vector 
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Figure 4.3. The effect of PKD1 gene silencing on collagenase expression in human 
articular chondrocytes. P0 HAC were trypsinised and plated into 96 well plates, allowed to 
adhere overnight and then mediumwas removed and replaced with viral supernatant containing 
either PKD1 shRNA #2 or shCON at a MOI of 30, in a total volume of 100 μl SFM. Polybrene at 
a concentration of 8 μg/ml was also added. Supernatant was replenished with fresh serum 
containing medium after 24 hours. Cells were then visualised 72 hours post transduction to 
confirm shRNA expression. Cells were then serum starved over-night. The following day cells 
were stimulated with IL-1 (0.05 ng/ml) ± OSM (10 ng/ml) for 24 hours. Cells were lysed and 
lysates reversed transcribed to cDNA. Real-time PCR was performed for (A) MMP-1 and (B) 
MMP-13, 96 h after start of transduction as described in the Materials and Methods. Data (mean 
± S.E.M.) are accumulative data of at least three separate chondrocyte populations (each 
assayed in hextuplicate) presented as relative expression levels normalised to 18S rRNA 
housekeeping gene. Comparisons shown are specific transduced PKD isoform versus control 
transduced, where **, p≤0.01 vs shCON. 
A) 
B) 
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4.3.2.2  The effect of PKD2 silencing on collagenase gene expression  
Specific PKD2 gene and protein silencing was achieved using siRNA against 
PKD2. When PKD2 was silenced no effects on MMP-1 or MMP-13 gene 
expression were observed in HACs under either stimulus (Figure 4.4 A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. The effect of PKD2 gene silencing on collagenase expression in human 
articular chondrocytes. P0 HAC were trypsinised and plated into 96 well plates, and left over-
night. The following day cells were transfected with siRNA specific to PKD2 #3 or siCON (100 
nM). 48 hours later cells were serum starved over-night. The following day cells were stimulated 
with IL-1 (0.05 ng/ml) ± OSM (10 ng/ml) for 24 h. Cells were lysed and lysates reversed 
transcribed to cDNA. Real-time PCR was performed for (A) MMP-1 and (B) MMP-13, 72 h after 
start of transfection as described in the Materials and Methods. Data (mean ± S.E.M.) are 
accumulative data of at least three separate chondrocyte populations (each assayed in 
hextuplicate) presented as relative expression levels normalised to 18S rRNA housekeeping 
gene.  
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4.3.2.3 The effect of PKD3 silencing on collagenase gene expression  
Specific PKD3 gene and protein silencing was achieved using siRNA specific 
against PKD3. Gene silencing of PKD3 led to a significant decrease in the gene 
expression of MMP-1 and MMP-13 when stimulated with IL-1 alone and in 
combination with OSM (Figure 4.5 A and B). A more profound effect of PKD3 
silencing was seen on MMP-13 than MMP-1 gene expression. PKD3 silencing 
led to a 43% reduction in MMP-1 gene expression compared to a 72% 
reduction in MMP-13, when stimulated with IL-1 in combination with OSM. The 
same is observed for the simple stimulus of IL-1 alone, a 37% reduction in 
MMP-1 gene expression is seen compared to a 62% reduction for in MMP-13. 
PKD3 activity therefore leads to the induction of both MMP-1 and MMP-13 in 
chondrocytes stimulated with IL-1 in combination with OSM. The MMP-13 data 
suggests that synergy is nearly completely abrogated when PKD3 is silenced. 
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Figure 4.5. The effect of PKD3 gene silencing on collagenase expression in human 
chondrocytes. P0 HAC were trypsinised and plated into 96 well plates, and left over-night. The 
following day cells were transfected with siRNA specific to PKD3 #2 or siCON (100 nM). 48 
hours later cells were serum starved over-night. The following day cells were stimulated with IL-
1 (0.05 ng/ml) ± OSM (10 ng/ml) for 24 h. Cells were lysed and lysates reversed transcribed to 
cDNA. Real-time PCR was performed for (A) MMP-1 and (B) MMP-13, 72 h after start of 
transfection as described in the Materials and Methods. Data (mean ± S.E.M.) are accumulative 
data of at least three separate chondrocyte populations (each assayed in hextuplicate) 
presented as relative expression levels normalised to 18S rRNA housekeeping gene. 
Comparisons shown are specific transfected PKD isoform versus control transfection, where ***, 
p≤0.001, **, p≤0.01, *, p≤0.05 vs siCON. 
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4.3.3  Isoform specific roles of PKD on wider MMP gene expression 
As both PKD1 and PKD3 silencing had profound effects on the expression of 
the classical collagenases MMP-1 and MMP-13, I wanted to further assess their 
role in regulating other collagen degrading MMPs. This was to elucidate 
whether these findings were specific to the classical collagenases or the 
regulation of collagen degrading MMPs in general. Understanding the global 
effects of PKD1 and PKD3 in the regulation of MMP gene expression would 
provide further information about the consequences of PKD1 and PKD3 
inhibition, if either were taken further as possible therapeutic targets.  
To understand the regulation of further MMPs in HAC by PKD1 and PKD3, a 
range of MMPs were examined, many of which had previously been seen to be 
induced by IL-1 in combination with OSM in chondrocytes (Koshy et al., 2002b). 
These specific MMPs were chosen as they belonged to the three major 
subclasses of MMPs believed to be involved in native fibrillar collagen 
degradation (the collagenases, gelatinases and membrane bound MMPs) 
(Gioia et al., 2007). The role of PKD1 and PKD3 in the regulation of MMP-8 and 
MMP-14 was assessed as they are known to have similar substrate specificity 
as the classic collagenases. MMP-14 is also a member of the membrane bound 
MMP family which has high affinity for cleavage of type I and III collagen, as 
well as being able to cleave type II collagen (Gioia et al., 2007, Ohuchi et al., 
1997). MMP-2 was also studied as it belongs to the gelatinase subgroup of the 
MMPs. This enzyme is capable of cleaving both native and denatured collagen 
(Creemers et al., 1998, Aimes and Quigley, 1995). This member was again 
chosen to give further insight into the regulation of collagen degrading MMPs as 
a whole. Understanding whether PKD1 and PKD3 can regulate these collagen 
degrading MMPs will give greater insight into the specificity of the MMPs 
regulated by each isoform of PKD within HACs.  
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4.3.3.1  The effect of PKD1 silencing on the gene expression of other collagen 
degrading MMPs 
To determine whether the observed effects of PKD1 silencing were specific to 
MMP-1 and MMP-13 a range of collagen degrading MMPs were assessed 
(Figure 4.6). PKD1 silencing led to decreased gene expression of MMP-2 and 
MMP-14 in cells stimulated with both IL-1 alone and in combination with OSM. 
No effect on MMP-8 gene expression was observed. These findings indicate a 
level of selectivity with respect to PKD1 following cytokine stimulation of human 
chondrocytes, showing differences in the regulation of MMPs gene expression 
by this isoform of PKD.  
4.3.3.2 The effect of PKD3 on the gene expression of other collagen degrading 
MMPs 
PKD3 silencing led to decreased gene expression of MMP-2 and MMP-8 in 
HAC stimulated with both IL-1 alone and in combination with OSM, whilst no 
effect on MMP-14 gene expression was observed (Figure 4.7). These findings 
indicate some specificity with respect to PKD3 following cytokine stimulation of 
human chondrocytes. These data also imply differences in MMP gene 
regulation via each isoform of PKD under the stimulus of IL-1 in combination 
with OSM. 
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Figure 4.6. The effect of PKD1 gene silencing on MMP expression in human articular 
chondrocytes. P0 HAC were trypsinised and plated into 96 well plates, allowed to adhere 
overnight and then mediumwas removed and replaced with viral supernatant containing either a 
PKD1 shRNA #2 or shCON at a MOI of 30, in a total volume of 100 μl SFM. Polybrene at a 
concentration of 8 μg/ml was also added. Supernatant was replenished with fresh serum 
containing medium after 24 hours. Cells were then visualised 72 hours post transduction to 
confirm shRNA expression. Cells were then serum starved over-night. The following day cells 
were stimulated with IL-1 (0.05 ng/ml) ± OSM (10 ng/ml) for 24 hours. Cells were lysed and 
lysates reversed transcribed to cDNA. Real-time PCR was performed for (A) MMP-2, (B) MMP-
8, (C) MMP-14, 96 h after start of transduction as described in the Materials and Methods. Data 
(mean ± S.E.M.) are accumulative data of at least three separate chondrocyte populations 
(each assayed in hextuplicate) presented as relative expression levels normalised to 18S rRNA 
housekeeping gene. Comparisons shown are specific transduced PKD isoform versus control 
transduced, where **, p≤0.01, *, p≤0.05 vs shCON. 
A) 
B) 
C) 
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Figure 4.7. The effect of PKD3 gene silencing on MMP expression in human articular 
chondrocytes. P0 HAC were trypsinised and plated into 96 well plates, and left over-night. The 
following day cells were transfected with siRNA specific to PKD3 #3 or siCON (100 nM). 48 
hours later cells were serum starved over-night. The following day cells were stimulated with IL-
1 (0.05 ng/ml) ± OSM (10 ng/ml) for 24 h. Cells were lysed and lysates reversed transcribed to 
cDNA. Real-time PCR was performed for (A) MMP-2, (B) MMP-8, (C) MMP-14, 72h after start of 
transduction as described in the Materials and Methods. Data (mean ± S.E.M.) are 
accumulative data of at least three separate chondrocyte populations (each assayed in 
hextuplicate) presented as relative expression levels normalised to 18S rRNA housekeeping 
gene. Comparisons shown are specific transfected PKD isoform versus control transfection, 
where ***, p≤0.001, **, p≤0.01, *, p≤0.05 vs siCON. 
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4.4  Discussion 
IL-1 in combination with OSM has been shown to be a potent cytokine stimulus 
of cartilage ECM degradation (Cawston et al., 1998b). This degradation has 
been shown to be catalysed by the MMPs (Cawston and Wilson, 2006). These 
enzymes have high affinity for type II collagen, with this cleavage initiating the 
irreversible degradation of the ECM of cartilage. The signalling events involved 
in the induction of MMP gene expression induced by this pro-inflammatory 
stimulus have not been well studied, with only a few studies examining the 
signalling events involved (Litherland et al., 2008, Litherland et al., 2010, 
Catterall et al., 2001).  
In this chapter I examined the role of a protein kinase family; PKD, in the 
induction of these matrix degrading enzymes. The role of PKD in the expression 
of MMPs has previously been shown to be important in metastasis in cancer 
(Biswas et al., 2010, Eiseler et al., 2009), this process has not previously been 
studied in relation to cartilage destruction. In this chapter I therefore assessed 
the role of each isoform of PKD on collagenase gene expression, establishing 
whether the effects observed are specific against the major collagenases 
involved in initiating cartilage degradation. 
4.4.1 The effect of PKD inhibition on collagenase gene expression 
 
To establish whether PKD regulated the expression of MMP-1 and MMP-13 
within chondrocytes stimulated with IL-1 alone or in combination with OSM, the 
PKD inhibitor, kb NB142-70 was used. Kb NB 142-70 is a more potent analogue 
of the non-competitive ATP inhibitor CID 755673, the first specific pan-PKD 
inhibitor to be classified. This inhibitor was identified by high throughput 
screening of the National Institutes of Health small molecule repository library 
(Sharlow et al., 2008). Further study of the structure-activity relationships (SAR) 
of this compound structure led to the development of the more potent inhibitor 
kb NB 142-70 (Bravo-Altamirano et al., 2011). PKD inhibition using kb NB 142-
70 showed for the first time that pan PKD inhibition within chondrocytes leads to 
decreased collagenase gene expression. These data implicate PKD activity in 
the regulation of collagenase gene expression within chondrocytes in basal 
conditions and when stimulated with the pro-inflammatory cytokines IL-1 alone 
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or in combination with OSM.  However, the use of this inhibitor does not yield 
useful information in regards to which isoforms of PKD are regulating these 
effects. Understanding the role of each isoform of PKD within chondrocytes was 
next sought. 
4.4.2 The effect of PKD1 over-expression and gene silencing of PKD1 on 
MMP gene expression 
 
Using the over-expression of PKD1 and shRNA mediated gene silencing of 
PKD1, this isoform was found to inhibit the expression of the collagenases 
MMP-1 and MMP-13 (no effect on MMP-8) in HACs stimulated with the pro-
inflammatory cytokines IL-1 in combination with OSM. The same results were 
observed for MMP-1 and MMP-13 (no other MMPs assessed) in the human 
chondrosarcoma cell line SW1353 (Figure 7.2 and Figure 7.3 supplementary 
data). These data imply that the pro-inflammatory cytokine stimulus of IL-1 in 
combination with OSM can lead to a down-regulation of these catabolic 
enzymes. The role of PKD1 in the regulation of collagenase gene expression 
under the simple stimulus of IL-1 is not as clear. The over-expression of PKD1 
appears to lead to a decrease in gene expression MMP-1 and MMP-13 when 
stimulated with IL-1 alone, whilst PKD1 silencing had no effect in cells 
stimulated with IL-1 alone. These results do not show a clear role for PKD1 in 
IL-1 dependent collagenase gene expression.  
The reason for this observation is not clear, but could be due to limitations 
within both techniques. One reason for these opposing results could be due to 
artificial results being observed in the over-expression data. Increasing the 
levels of PKD1 may lead to regulatory interactions occurring between signalling 
molecules which would not normally occur within HAC. This has been 
previously reported as a problem with transient over-expression (Gibson et al., 
2013). A simpler explanation could be that PKD1 silencing may not be sufficient 
to cause signalling inhibition through PKD1 in IL-1 stimulated chondrocytes. 
This could however be simply explained by differences in the regulation of 
collagenase gene expression within the different cell types. However, as the 
gain of function and loss of function results do not give reciprocal effects in the 
context of IL-1, the role of PKD1 in classical collagenase gene expression under 
this stimulus is still unclear. 
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As well as the inhibition of MMP-1 and MMP-13, PKD1 is seen to induce the 
expression of both MMP-2 and -14. No effects on MMP-8 gene expression were 
observed. MMP-8 is not well expressed in primary chondrocytes [14] and for 
this reason is not thought to play a major role in the cartilage destruction via the 
stimulation of chondrocytes with IL-1 in combination with OSM. These 
experiments were performed to gain a further understanding of the MMPs that 
PKD1 signalling may regulate. 
MMP-2 belongs to the gelatinase family of the MMPs, with the role of this MMP 
in the progression of arthritis being an area of much debate. This enzyme can 
cleave type IV collagen, the major structural component of basement 
membranes, as well as other denatured collagens and gelatines (Aimes and 
Quigley, 1995). In MMP-2 knockout mice increased joint erosion, bone defects, 
altered osteoblast and osteoclast regulation is observed (Mosig et al., 2007), 
implying that MMP-2 may inhibit the progression of arthritis, within murine 
models of arthritis. As well as this, mutations within MMP-2 are shown to lead to 
arthritis syndrome (Martignetti et al., 2001). However, there are contradictory 
results, with MMP-2 being implicated with disease progression through bone 
erosion (Hill et al., 1995) and increased severity of septic arthritis (Puliti et al., 
2012). The pathological role of MMP-2 induced by PKD1 in chondrocytes is 
therefore open to debate, with previous data implying MMP-2 could both 
decrease and increase cartilage destruction. The effects of the induction of 
MMP-2 by PKD1 in a disease context are therefore unclear.  
MMP-14 (also known as MT-MMP1) belongs to the membrane bound MMP 
subfamily. This enzyme has the capability to cleave type II collagen at the same 
efficiency as MMP-8 (Konttinen et al., 1998) as well as the cleavage of other 
collagen molecules (Ohuchi et al., 1997, d'Ortho et al., 1997). MMP-14 also has 
the capability to increase cartilage degradation by activating both proMMP-13 
and proMMP-2, increasing collagen degradation (Knauper et al., 1996a, Murphy 
et al., 1999). The role in the up-regulation of MMP-14 in chondrocytes implies 
PKD1 signalling could induce cartilage damage though increased expression of 
this cartilage-degrading enzyme. These results therefore show contrasting 
findings to the inhibitory effects seen in PKD1 regulation of MMP-1 and MMP-
13, which are thought of as the major initiators of cartilage degradation.  
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Also of note is the finding that PKD1 has the opposite effect on collagenase 
gene expression compared to pan PKD inhibition using kb NB 142-70. The 
reason for this remains unclear as the potency of the inhibitor against each 
isoform of PKD is similar (with the IC50 values are 28.3, 58.7 and 53.2 nM for 
PKD1, 2 and 3 respectively (Bravo-Altamirano et al., 2011)). The expression of 
each isoform of PKD was also assessed to understand whether there was a 
dominant isoform of PKD expressed in HAC. RNA sequencing data showed the 
expression of PKD1 within both healthy and OA chondrocytes to be higher 
compared to that of PKD2 and relative in comparison to PKD3 (DA Young, 
personal communication). These data therefore imply that differences between 
the expression of each isoform could not alone account for these results. 
Alternatively, the kinase activity of PKD3 towards MMP-regulating effects in 
chondrocytes may be greater than that of PKD1, despite slightly lower 
transcription. The reason for these results remains unclear but does suggest 
that pan PKD inhibition within chondrocytes has the potential to reduce the 
expression of MMPs stimulated with pro-inflammatory cytokines. The design of 
isoform specific inhibitors may lead to a greater inhibition of collagenase 
expression within chondrocytes. 
4.4.3 The effect of PKD2 gene silencing on collagenase gene expression 
Next, the role of PKD2 in the regulation of MMP-1 and MMP-13 gene 
expression was examined. PKD2 has been implicated in the induction of MMP 
gene expression through the regulation of ERK and JNK signalling pathways 
(Bernhart et al., 2013). Regulation of MMPs -1, -9 and -14 has been previously 
observed via PKD2 (Bernhart et al., 2013, Zou et al., 2012). PKD2 gene 
silencing in HACs had no effect on MMP-1 and MMP-13 gene expression under 
any stimuli. These data imply PKD2 does not regulate collagenase gene 
expression within primary chondrocytes when stimulated with IL-1 in 
combination with OSM. This data is further implied by the fact that PKD2 gene 
silencing also appears to increase the expression of PKD1 and PKD3; these 
isoforms have opposing roles in the regulation of collagenase gene expression. 
Therefore, as no increase or decrease in MMP gene expression is seen, these 
data further suggest PKD2 to have no effect on collagenase gene expression.  
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During the optimisation of these experiments the well-established chondrocyte 
like cell line SW1353 was used. This cell line was used to optimise many of the 
siRNAs used against each PKD isoform. This was due to HAC being technically 
difficult, due to their difficulty to obtain and variable responses. Previous work 
from our group has demonstrated variation in the responses of chondrocytes to 
the stimulation of IL-1 in combination with OSM (Barksby et al., 2006). These 
difficulties were overcome by the use of multiple HAC populations and the 
removal of any populations that did not respond well to cytokine stimulation. 
The SW1353 cell line has been shown to be a useful model to study 
collagenase response to IL-1 stimulation, with MMP-1 and MMP-13 responding 
in a similar manner under this stimulus to HAC (Gebauer et al., 2005). These 
cells were therefore used as a model for collagenase expression within primary 
chondrocytes when HACs were unavailable. When examining the effects of 
PKD2 gene silencing in SW1353 cells, a reduction in collagenase expression of 
both MMP-1 and MMP-13, under both stimuli is seen (Figure 7.4 supplementary 
figures). This again shows cell specificity in the actions of each isoform of PKD, 
indicating that PKD2 regulation of collagenase gene expression is dependent 
on cell type. This may explain some of the conflicting roles of PKD within the 
literature. These data also show the value of using primary cells in studying a 
disease, as cell lines may not exhibit the same behaviour.  
An explanation for these differences could be due to the expression profile of 
each isoform of PKD varying between different cell types. As previously 
mentioned, PKD1 is epigenetically suppressed in many tumour cells. This 
implies that cellular regulation of PKD expression can lead to the modulation of 
downstream effectors such as the expression of the MMPs. When comparing 
the expression profile of PKD1, PKD2 and PKD3 within normal and 
osteoarthritic cartilage, the expression pattern of each does not change (D A 
Young, personal communication). However, there is around 70% less PKD2 
gene expression in both OA and normal cartilage compared to PKD1 and 
PKD3. RNA sequencing from the Young group, compared 6 samples of normal 
cartilage from neck of femur (NOF) fractures to 10 samples of osteoarthritic 
cartilage from patients undergoing total hip replacement (for methods see (Bui 
et al., 2012)). These data could explain why PKD2 silencing had no effect on 
Chapter 4. The role of PKD isoforms in the regulation of MMP gene expression 
 
141 
 
collagenase gene expression compared to the other two isoforms of PKD within 
primary chondrocytes. This may also explain why PKD2 has an effect in 
SW1353 cells, as the expression pattern of PKD2 may be different in these cells 
compared to primary chondrocytes, although such data are not available.   
4.4.4 The effect of PKD3 gene silencing on MMP gene expression 
The role of the PKD3 in the regulation of collagenase gene expression was then 
examined. siRNA mediated gene silencing of PKD3 led to decreased 
expression of MMP-1, MMP-2, MMP-8 and MMP-13, but had no effect on MMP-
14. The same results were observed for MMP-1 and MMP-13 (no other MMPs 
assessed) in SW1353 (data not shown). The up-regulation of MMP-8, but lack 
of regulation of the gene expression of MMP-14, implies isoform specific 
regulation of MMP gene expression between PKD1 and PKD3, with each 
kinase regulating the expression of individual MMPs rather than the MMP family 
as a whole. As well as the expression of the MMPs studied, MMP-9 gene 
expression was examined. Unfortunately, when examining the effects of PKD1 
silencing on the expression of MMP-9 the data were inconclusive, with the 
expression of MMP-9 being undetectable in many of the populations of HAC 
studied. PKD3 silencing was, however, shown not to regulate the expression of 
MMP-9 in HAC (Figure 7.6 supplementary figures).  
These data imply that PKD1 and PKD3 have opposing roles in regulating 
collagenase gene expression in HACs stimulated with IL-1 in combination with 
OSM. However, silencing of both PKD1 and PKD3 led to a decrease in the 
expression of MMP-2, implying that the mechanisms by which the expression of 
each MMP family member is regulated by is different; each isoform of PKD may 
therefore be regulating different MMPs via the same or distinct signalling 
pathways. Clues into the differential regulation may lie in the study of the 
transcription factors binding elements in different MMP promoters. These data 
shows the necessity to study not only each isoform of PKD and their regulation 
of MMP-1 and -13 gene expressions but to study the effects on other MMPs to 
fully elucidate their role in cartilage degradation.  
The role of each individual isoform of PKD, in one study, within the same cell 
type has not previously been reported. However, two individual studies have 
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looked at the individual isoforms of PKD in the same prostate cancer cell lines. 
Biswas et al., used PC3 cells and DU145 cells to elucidate the role of PKD1 in 
MMP gene expression, whereas Zou et al., used both cell lines to study the 
roles of PKD2 and PKD3 in MMP regulation (Biswas et al., 2010, Zou et al., 
2012). These two papers show that within these prostate cancers cell lines, all 
isoforms of PKD up-regulate the expression of MMP-9. These two papers 
suggest opposing roles for the expression of MMP-9 in these cancer cells, 
implying MMP-9 to either induce or suppress cancer progression. Other data 
within the literature in which different cell types have been used show conflicting 
effects of PKD1 (Wille et al., 2013). PKD1 is seen to both induce and suppress 
MMP-2 (Biswas et al., 2010, Onishi et al., 2012, Eiseler et al., 2009), with data 
presented in this chapter showing isoform specific regulation of this MMP. 
PKD1 has also been shown to down-regulate the expression of MMP-13 
(Eiseler et al., 2009), as observed in the data presented here. However, the 
data presented within that paper showed PKD1 to also down regulate MMP-2 
(Eiseler et al., 2009), opposing the data presented in this chapter. These data 
therefore imply that PKD1 dependent MMP regulation is dependent on cell type 
as well as the MMP studied. This is consistent with the data in this chapter, in 
which different MMPs are regulated in opposing manners through the same 
isoform under the same stimulus. The literature and the work performed in this 
chapter imply the need to study each isoform of PKD as well as the role of 
these on individual MMPs. Also of importance is the use of primary cells when 
studying a disease. If the cell line SW1353 had been primarily used, PKD2 
would have thought to play a major role in collagenase gene induction in 
chondrocytes, and in HAC this is not the case.  
The aims of this chapter were to elucidate the role of each PKD isoform in the 
regulation of collagenase gene expression. Here, I show for the first time 
opposing roles of PKD1 and PKD3 in regulating MMP-1 and MMP-13 gene 
expression within HAC. PKD2 appears to be poorly expressed within 
chondrocytes compared to the other isoforms; this may be an explanation for 
PKD2 not regulating collagenase gene expression in HAC stimulated with IL-1 
in combination with OSM. Data imply that the use of a pan-PKD inhibitor leads 
to reduced collagenase gene expression, indicating this inhibitor as a potential 
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therapeutic lead against the induction of these matrix degrading enzymes. 
However, this inhibitor is known to inhibit PKD1, which from the data shown in 
this study appear to suggest PKD1 to have the potential to be an anabolic 
kinase. Design of a PKD3 specific inhibitor may therefore be a better 
therapeutic. In the following chapter, I set out to further understand the 
signalling pathways which are regulated by each isoform of PKD under the 
stimulation of IL-1 in combination with OSM, in order to elucidate how PKD 
regulates collagenase expression under this pro-inflammatory stimulus.  
4.4.5 Summary 
Studies in this chapter have shown: 
 PKD inhibition via the pan-PKD inhibitor kb NB 142-70 leads to the loss 
of MMP-1 and MMP-13 gene expression in chondrocytes stimulated with 
IL-1 alone or IL-1 in combination with OSM. 
 PKD1 overexpression leads to a decrease in the expression of MMP-1 
and MMP-13 in chondrocytes stimulated with IL-1 alone or IL-1 in 
combination with OSM. 
 PKD1 down regulates the expression of the classical collagenases MMP-
1 and MMP-13. PKD1 can also increase the expression of MMP-2 and 
MMP-14, no effect on MMP-8 is observed. This data suggests PKD1 can 
up and down regulate cartilage degrading enzymes. 
 PKD2 does not regulate MMP-1 and MMP-13 gene expression within 
chondrocytes stimulated with IL-1 or IL-1 in combination with OSM. 
 PKD3 signalling leads to the induction of MMP-1, -2, -8 and -13. No 
effect on MMP-14 gene expression is observed. PKD3 signalling induces 
the expression of cartilage degrading enzymes under a pro-inflammatory 
stimulus.  
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5 Chapter 5: The role of PKD in regulating signalling pathways 
and transcription factors involved in MMP gene induction 
5.1 Introduction 
Data presented in Chapter 4 demonstrated that collagenase gene expression is 
regulated in a PKD isoform specific manner. To understand the specific roles of 
each PKD isoform in the regulation of MMP gene expression, the modulation of 
signalling pathways known to promote collagenase gene expression were 
studied. Using gene silencing and over-expression of the individual isoforms of 
PKD, the regulation of these signalling pathways was studied in HAC and 
SW1353 cells. These cells were stimulated with IL-1, OSM or both in 
combination. These combined stimuli were used to represent the complex 
inflammatory milieu of cytokines elevated within an arthritic joint during disease.   
MAPKs, STATs, PKC and the PI3K pathways have all been implicated in the 
regulation of collagenase gene expression under the complex stimulus of IL-1 in 
combination with OSM (Catterall et al., 2001, Litherland et al., 2008, Litherland 
et al., 2010, Richards et al., 2001). These signalling pathways have been shown 
to regulate the activity and expression of the AP-1 transcription factor, leading 
to MMP gene induction, under the stimulation of IL-1 in combination with OSM 
(Catterall et al., 2001, Litherland et al., 2010). Work performed in this chapter 
therefore was performed to understand how each isoform of PKD lies within 
these signalling cascades. The consequences of PKD signalling on the 
expression of the AP-1 transcription factor components and further latent 
transcription factors recently implicated in MMP gene induction were also 
examined. 
IL-1 in combination with OSM has been shown to induce the gene expression of 
multiple MMPs in HAC (Koshy et al., 2002b). The first paper to try to elucidate 
the signalling consequences which regulate their induction within a chondrocyte 
setting was by Catteral et al., 2001. Here, the effects of IL-1 in combination with 
OSM were studied on MMP-1 gene expression; data implicated that the STAT 
signalling pathway and AP-1 family transcription factors were important in this 
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regulation. To understand the induction of MMP-1 gene expression induced by 
IL-1 in combination with OSM, the binding of transcription factors to the 
proximal promoter of MMP-1 was studied. The proximal MMP-1 promoter has 
two AP-1 binding elements located at -181 and -72bp upstream from the 
transcriptional start site. A STAT binding element (SBE) is also found adjacent 
to the -72 AP-1 site (Yan and Boyd, 2007). When AP-1 and STAT binding to the 
proximal region (-517/+63) of the MMP-1 promoter was assessed using EMSA, 
it was found that AP-1 proteins were constitutively associated with this 
promoter, under basal conditions. No STAT proteins could be detected bound to 
the SBE element (Catterall et al., 2001). However, data did imply a role for the 
STATs in the induction of MMP-1. The over-expression of protein inhibitor of 
activated STAT-3 (PIAS-3) completely abolished OSM dependent MMP-1 
promoter activity. These data implied that STAT-3 regulated MMP-1 gene 
expression, albeit not through direct binding to the MMP-1 promoter. 
Unpublished EMSA data from our laboratory suggest that STAT-1, -3 and -5 are 
all capable of binding to the c-fos promoter under synergistic conditions 
(Rowan, personal communication). This work implies that the STAT pathway 
regulates MMP-1 gene expression via the induction of c-fos. 
The regulation and induction of AP-1 transcription factors is not only dependent 
on OSM-dependent STAT induction; IL-1 and OSM can also induce AP-1 
component expression via the regulation of the MAPK pathways. 
The ERK pathways can be activated by both IL-1 and OSM (Vincenti and 
Brinckerhoff, 2002, Heinrich et al., 2003). This pathway can induce the 
expression of Fos as well as inducing post-translational modifications, 
increasing the transcriptional capabilities of this transcription factor. ERK, upon 
activation, translocates to the nucleus, inducing the phosphorylation of Elk-I 
(Gille et al., 1995), leading to increased Fos transcription. ERK is also seen to 
directly phosphorylate Fos at Ser374, leading to increased stability and 
transactivation activity (Chen et al., 1993). ERK inhibition was shown to 
significantly reduce Fos protein expression in cells stimulated with IL-1 in 
combination with OSM; this was suggested to abrogate collagenase gene 
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expression (Litherland et al., 2010). All of these data implicate ERK signalling in 
the regulation of collagenase gene expression. 
The JNK signalling pathway is the major regulator of the Jun family of 
transcription factors. Phosphorylation and activation of JNK leads to its 
translocation to the nucleus. Within the nucleus JNK phosphorylates Jun at 
Ser63 and Ser73, enhancing the transactivation potential of Jun (Hess et al., 
2004). This implicates the regulation of Jun via JNK as an important signalling 
cascade in the induction of collagenase gene expression. This is important due 
to Jun/Fos dimers being seen as the most potent AP-1 complex to drive MMP-1 
gene expression (Bakiri et al., 2002). JNK can also regulate the expression of c-
fos through Elk-1 phosphorylation (Cavigelli et al., 1995), further illustrating the 
importance of this signalling molecule in AP-1 component expression and 
activity.  
p38, the final member of the MAPK family can also induce c-fos gene 
expression. p38, like ERK, is known to phosphorylate Elk-1 enhancing its 
transcriptional activity, leading to the induction of c-fos (Whitmarsh et al., 1997). 
This induction has been shown to modulate MMP gene expression (Reunanen 
et al., 2002, Lim and Kim, 2011). Unpublished data from this laboratory has 
shown p38 gene silencing to reduce the expression of both MMP-1 and MMP-
13 when stimulated with IL-1 in combination with OSM (Litherland and Rowan, 
personal communication), indicating the importance of this signalling pathway.  
The PI3K signalling pathway has also been implicated in the regulation of 
collagenase gene expression in chondrocytes stimulate with IL-1 in combination 
with OSM. These data implicated PI3K class IA of PI3Ks as the regulators of 
collagenase expression; this activation was shown to be via Akt activation 
(Litherland et al., 2008). PKC, a further downstream target of both PI3K 
signalling and IL-1 has been implicated in the regulation of collagenase gene 
expression. PKC, the upstream activator of PKD has been shown to regulate 
collagenase expression through the induction of the STAT and ERK pathways, 
leading to changes in AP-1 component gene expression (Litherland et al., 
2010).  
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All of these signalling pathways have been implicated in the regulation of 
collagenase gene expression, with stimulation leading to changes in the 
expression and stability of the components of the AP-1 transcription factor. 
Understanding the role of each PKD isoform in the regulation of these signalling 
cascades will provide mechanistic data into the induction of collagenase gene 
expression modulated by PKD. Using our model of the inflammatory milieu of 
cytokines involved in arthritis, I will examine the role of each PKD isoform in the 
regulation of signalling pathways implicated in the modulation of collagenase 
gene expression.  
5.2 Aims 
 Understand whether PKD is phosphorylated in HAC stimulated with 
either IL-1 or OSM. 
 Establish whether PKC regulates PKD phosphorylation in HAC and the 
isoforms which are involved. 
 Establish the consequences of PKD1 over-expression and silencing, as 
well as PKD2 and PKD3 silencing on the signalling pathways known to 
regulate collagenase gene expression under the pro-inflammatory 
stimulation of IL-1 and OSM alone or when in combination. 
 Establish the role of each isoform of PKD on the expression of the AP-1 
family members; c-jun and c-fos and other newly identified post-AP-1 
factors. 
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5.3 Results 
5.3.1  Phosphorylation and activation of PKD by IL-1 and OSM 
To assess the phosphorylation of PKD by IL-1 or OSM, two PKD 
phosphorylation sites were studied; Ser744/748 and Ser916. The Ser744/748 
site is phosphorylated directly by PKC whilst the Ser916 is an 
autophosphorylation site which indicates PKD activation. Although these are the 
sites of PKD1 phosphorylation, both antibodies cross-react with each PKD 
isoform (except Ser916 in PKD3, as this site is not present within this isoform). 
As Figure 5.1. A shows, IL-1 stimulation of HACs led to a transient activation of 
PKD. Phosphorylation is identified with both antibodies at the 20 minute time 
point. This is nearly completely abrogated by 45 minutes, with levels of 
phosphorylation at both sites being diminished to levels only slightly higher than 
the basal conditions. For OSM, phosphorylation at Ser744/748 occurred from 
20 minutes, and persisted until 120 minutes. The peak phosphorylation was at 
20-45 minutes, with 45 minutes also being the time point for maximal 
phosphorylation at Ser916 which was much more transient (Figure 5.1. B).  
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Figure 5.1. The phosphorylation of PKD in chondrocytes stimulated with IL-1 or OSM. P0 
HAC plated in 6 well plates were grown to ~70% confluency, and then serum starved over-night. 
The following day cells were stimulated for various time points with either (A) IL-1 (0.2 ng/ml) or 
(B) OSM (10 ng/ml) for the times shown. Cell lysates were then  immunoblotted using the 
antibodies shown, as described in the Materials and Methods. Data are representative of at 
least three separate chondrocyte populations. GAPDH was used as a loading control. 
 
 
 
 
A) 
B) 
 0       20      45      90      120    180      (Mins) 
  0        20      45     90     120    180      (Mins) 
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5.3.2 The subcellular distribution of each isoform of PKD 
The subcellular distribution of each isoform of PKD in SW1353 cells, when 
stimulated with IL-1 in combination with OSM, was examined. As Figure 5.2 
shows, all isoforms of PKD were detected in the cytoplasmic, membrane and 
nuclear fractions (PKD isoforms could not be detected in the chromatin bound 
or cytoskeletal fractions (data not shown)). Stimulation with IL-1 in combination 
with OSM led to a small increase in the protein levels of each isoform in the 
cytoplasmic fraction, but appeared to have little effect on the subcellular 
distribution of each PKD isoform.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. The subcellular distribution of each PKD isoform when stimulated with IL-1 in 
combination with OSM in SW1353 cells. SW1353 cells were plated into 10 cm dishes and 
grown to ~70% confluency, and then serum starved over-night. The following day cells were 
stimulated for various time points with IL-1 (0.5 ng/ml) in combination with OSM (10 ng/ml) for 
the time points shown. Cells were scraped into PBS and separated into subcellular fraction 
using the Pierce subcellular fractionation kit as described by the manufacturer’s instructions. 
Fractions were then separated by electrophoresis. Protein was then transferred to PVDF 
membrane and immunoblotted using the antibodies shown, as described in the Materials and 
Methods. Data are representative of at least two separate chondrocyte populations. MEK2 was 
used as a cytoplasmic loading control, Caveolin-1 was used as a membrane loading control and 
Lamin A/C was used as a nuclear loading control.  
 
 
(Mins) 
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5.3.3 The regulation of PKD via PKC 
Previous data within our group have demonstrated a role for the PKCι and 
PKCζ in the regulation of collagenase gene expression in HAC stimulated with 
IL-1 in combination with OSM (Litherland et al., 2010). As PKD is well 
established as a downstream signalling target of PKC (Waldron et al., 2004, 
Iglesias et al., 1998, Zugaza et al., 1996), it was hypothesised that PKD may be 
regulated by one/both of these proteins.  
5.3.3.1 Broad spectrum PKC inhibition 
To first establish whether PKC phosphorylates PKD in chondrocytes stimulated 
with IL-1 or OSM, HACs were treated with the PKC inhibitor Gӧ6983. This 
inhibitor is a potent and reversible ATP-competitive inhibitor that does not 
effectively inhibit PKD at low concentrations. The addition of Gӧ6983 completely 
abolished PKD phosphorylation at both phosphorylation sites. This implicated 
PKC in the direct phosphorylation of PKD at the Ser744/748 site as well as PKD 
activation, as indicated by loss of phosphorylation at the Ser916 site (Figure 
5.3. A).  
5.3.3.2 Isoform specific roles of PKC in the regulation of PKD 
Following effective PKCι and PKCζ silencing (Figure 5.3. B), loss of PKD 
phosphorylation at the PKC dependent phosphorylation site, Ser744/748, was 
only observed with PKCι depletion (Figure 5.3. C) 
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Figure 5.3. The role of PKC in the regulation of PKD activity. (A) P0 HAC were plated into 6 
well plates and grown till ~70% confluency, and then serum starved over-night. The following 
day cells were pre-treated with Gӧ6983 (20 μM) for 1 hour prior to being stimulated with either 
IL-1 (0.2 ng/ml) or OSM (10 ng/ml) for 20 minutes and then lysed. (B) P0 HAC were trypsinised 
and plated into 6 well plates and then left over-night. The following day cells were transfected 
with siRNA against PKCζ, PKCι or siCON (100 nM) for 48 hours. Cells were then serum starved 
over-night. Cells were then either lysed or (C) stimulated with IL-1 (0.2 ng/ml) in combination 
with OSM (10 ng/ml) for 20 minutes and then lysed. Lysates were then separated by 
electrophoresis. Protein was then transferred to PVDF membrane and immunoblotted using the 
antibodies shown, as described in the Materials and Methods Data are representative of at least 
three separate chondrocyte populations. GAPDH was used as a loading control. 
 
A) 
B) 
C) 
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5.3.4 PKD regulates multiple signalling pathways involved in MMP gene 
expression  
Once the individual role of each isoform of PKD in the regulation of collagenase 
gene expression was established (see chapter 4), I next sought to understand 
how each isoform of PKD could be regulating these changes. To achieve this 
each isoform of PKD was either silenced or over-expressed and the effects of 
this on known signalling pathways involved in MMP gene expression were 
studied.  
5.3.4.1  The effect of PKD1 overexpression on IL-1- ± OSM stimulated 
signalling pathways in SW1353 
Over-expression of PKD1 was confirmed by the identification of the HA tag, 
which was covalently linked to the over-expressed PKD1. PKD1 expression was 
also used to confirm expression. PKD1 was not identified in control cells due to 
the high expression of PKD1 in the over-expressed cells, preventing the 
identification of the native PKD1 be western blotting.  
As can be seen in Figure 5.4, when PKD1 was over-expressed in SW1353 cells 
stimulated with IL-1 alone, the phosphorylation of p38 and JNK was abrogated. 
No changes in the phosphorylation of ERK were observed. 
As Figure 5.5 shows, when PKD1 was over-expressed in SW1353 cells 
stimulated with OSM alone, a reduction in Akt phosphorylation occurred, 
suggesting reduced Akt signalling. PKD1 over-expression had no effect on the 
phosphorylation of ERK, STAT-1 or STAT-3 at their tyrosine phosphorylation 
site.  
When PKD1 was over-expressed in SW1353 cells stimulated with IL-1 in 
combination with OSM, a reduction in the levels of phosphorylation of both p38 
and JNK was seen (Figure 5.6). Interesting to note is the change in kinetics for 
the time points at which JNK and p38 are phosphorylated when comparing IL-1 
alone to IL-1 in combination with OSM. No effects on the phosphorylation of 
Akt, ERK, STAT-1 or STAT-3 at their tyrosine phosphorylation site were 
observed. 
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Figure 5.4. The effect of PKD1 over-expression on the signalling pathways activated by 
IL-1. (A) SW1353 cells were plated into 6 well plates and left over-night. The following day cells 
were transfected using 1 μg of PKD1 plasmid DNA with JetPEI, at 1:2. 1μg of vector was used 
as a control. Cells were left for 24 hours and then serum starved over-night. The following day 
cells were stimulated with IL-1 (0.5 ng/ml) for 20 or 60 minutes. Cell lysates were then  
immunoblotted using the antibodies shown. All procedures were followed as described in the 
Materials and Methods. Data are representative of at least three separate chondrocyte 
populations. GAPDH was used as a loading control. (B) Histograms show quantification of 
bands normalized to GAPDH levels presented as a percentage of the cytokine-induced 
expression. Histograms are cumulative data of at least 3 individual cell populations (Mean ± 
S.D) **, p≤0.01, vs transfected vector. 
(Mins) 
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Figure 5.5. The effect of PKD1 over-expression on the signalling pathways activated by 
OSM. (A) SW1353 cells were plated into 6 well plates and left over-night. The following day 
cells were transfected using 1 μg of PKD1 plasmid DNA with JetPEI, at 1:2. 1μg of vector was 
used as a control. Cells were left for 24 hours and then serum starved over-night. The following 
day cells were stimulated with OSM (10 ng/ml) for 20 or 60 minutes. Cells were lysed and 
separated by electrophoresis. Proteins were then transferred to PVDF membrane and 
immunoblotted using the antibodies shown. All procedures were followed as described in the 
Materials and Methods. Data are representative of at least three separate chondrocyte 
populations. GAPDH was used as a loading control. (B) Histograms show quantification of 
bands normalized to GAPDH levels presented as a percentage of the cytokine-induced 
expression. Histograms are cumulative data of at least 3 individual cell populations (Mean ± 
S.D) **, p≤0.01, vs transfected vector. 
(Mins) 
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Figure 5.6. The effect of PKD1 over-expression on the signalling pathways activated by Il-
1 in combination with OSM. (A) SW1353 cells were plated into 6 well plates and left over-
night. The following day cells were transfected using 1 μg of PKD1 plasmid DNA with JetPEI, at 
1:2. 1μg of vector was used as a control. Cells were left for 24 hours and then serum starved 
over-night. The following day cells were stimulated with IL-1 (0.5 ng/ml) in combination with 
OSM (10 ng/ml) for 20 or 60 minutes. Cell lysates were then  immunoblotted using the 
antibodies shown. All procedures were followed as described in the Materials and Methods. 
Data are representative of at least three separate chondrocyte populations. GAPDH was used 
as a loading control. (B) Histograms show quantification of bands normalized to GAPDH, levels 
presented as a percentage of the cytokine-induced expression. Histograms are cumulative data 
of at least 3 individual cell populations (Mean ± S.D) **, p≤0.01 vs transfected vector. 
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5.3.4.2 The effect of PKD1 gene silencing on IL-1- ± OSM stimulated signalling 
pathways in HAC 
After the optimisation of the gene silencing of PKD1 using lentiviral-mediated 
delivery of shRNA, I used this technique to establish the role of PKD1 in HAC. 
This work only studied the effects of PKD silencing on signalling pathways 
induced by IL-1 in combination with OSM. Unlike the work using PKD1 over-
expression, these experiments were performed in HAC. As Figure 5.7 shows, 
PKD1 gene silencing led to a decrease in the phosphorylation of ERK, JNK and 
p38. However, PKD1 gene silencing also increased the levels of Akt, STAT-1 
phosphorylation at the Tyr701 and Ser727 sites. No effect on the 
phosphorylation of STAT-3 at Ser727 or Tyr705 was observed.  
NFκB signalling was then assessed. Unfortunately, due to poor detection of 
NFκB protein by the antibody, these results were only replicated in two HAC 
populations. As Figure 5.8 shows, when PKD1 was silenced in two HAC 
populations an increase in the levels of phosphorylated p65 were detected.  
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Figure 5.7. The effect of PKD1 gene silencing on the signalling pathways activated by IL-
1 in combination with OSM in HAC. (A) P0 HAC were trypsinised and plated into 6 well plates 
and left over-night. The following day the medium was removed and replaced with viral 
supernatant containing either PKD1 shRNA #2 or shCON at a MOI of 30, in a total volume of 1 
ml SFM. Polybrene at a concentration of 8 μg/ml was also added. Supernatant was replenished 
with fresh serum containing medium after 24 hours. Cells were then visualised 72 hours post 
transduction to confirm shRNA expression. Cells were then serum starved over-night. The 
following day cells were stimulated with IL-1 (0.2 ng/ml) in combination with OSM (10 ng/ml) for 
20 or 60 minutes. Cell lysates were then immunoblotted using the antibodies shown. All 
procedures were followed as described in the Materials and Methods. Data are representative 
of at least three separate chondrocyte populations. GAPDH was used as a loading control. (B) 
Histograms show quantification of bands normalized to GAPDH levels, presented as a 
percentage of the cytokine-induced expression (shCON-transfected).Histograms are cumulative 
data of at least 3 individual cell populations (Mean ± S.D) ***, p≤0.001, **, p≤0.01, *, p≤0.05. vs 
shCON. 
B) 
A) 
0      20     60       0      20      60 
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Figure 5.8. The effect of PKD1 gene silencing on p65 phosphorylation when stimulated 
with IL-1 in combination with OSM in two individual HAC populations. (A) P0 HAC were 
trypsinised and plated into 6 well plates and left over-night. The following day the medium was 
removed and replaced with viral supernatant containing either PKD1 shRNA #2 or shCON at a 
MOI of 30, in a total volume of 1 ml SFM. Polybrene at a concentration of 8 μg/ml was also 
added. Supernatant was replenished with fresh serum containing medium after 24 hours. Cells 
were then visualised 72 hours post transduction to confirm shRNA expression. Cells were then 
serum starved over-night. The following day cells were stimulated with IL-1 (0.2 ng/ml) in 
combination with OSM (10 ng/ml) for 20 or 60 minutes. Cell lysates were then immunoblotted 
using the antibodies shown. All procedures were followed as described in the Materials and 
Methods. Data are representative of two separate chondrocyte populations. GAPDH was used 
as a loading control.  
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5.3.4.3 The effect of PKD2 gene silencing on IL-1- ± OSM stimulated signalling 
pathways in HAC 
As can be seen in Figure 5.9, when PKD2 is silenced in HAC stimulated with IL-
1 alone, a reduction in the phosphorylation of ERK, p38 and JNK, STAT-1 and 
STAT-3 (Ser727) is observed. PKD2 appears to regulate all signalling pathways 
implicated in collagenase gene expression that are stimulated by IL-1.  
When PKD2 is silenced in HAC stimulated with OSM alone, the phosphorylation 
of Akt is abrogated (Figure 5.10). No effect on the phosphorylation of ERK or 
the tyrosine phosphorylation of STAT-1 and STAT-3 is seen.  
Figure 5.11 shows that when PKD2 is silenced in HAC stimulated with IL-1 in 
combination with OSM, the phosphorylation of STAT-1 and STAT-3 at Ser727 is 
reduced. Signalling through PKD2 appears to increase the phosphorylation of 
p38, suggesting this pathway is usually inhibited by PKD2 under this stimulus. 
PKD2 does not appear to regulate the phosphorylation of Akt, ERK, JNK or the 
tyrosine phosphorylation of STAT-1 (Tyr701) and STAT-3 (Tyr705). 
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Figure 5.9. The effect of PKD2 gene silencing on IL-1 stimulated signalling pathways 
known to regulated collagenase gene expression. (A) P0 HAC were trypsinised and plated 
into 6 well plates and left over-night. The following day cells were treated with either siPKD2 #3 
or siCON (100 nM) for 48 hours. Cells were serum starved over-night. The following days cells 
were stimulated with IL-1 (0.2 ng/ml) for 20 or 60 minutes. Cell lysates were then immunoblotted 
using the antibodies shown. All procedures were followed as described in the Materials and 
Methods. Data are representative of at least three separate chondrocyte populations. GAPDH 
was used as a loading control. (B) Histograms show quantification of bands normalized to 
GAPDH, levels presented as a percentage of the cytokine-induced expression (siCON-
transfected). Histograms are cumulative data of at least 3 individual cell populations (Mean ± 
S.D) ***, p≤0.001, **, p≤0.01, vs siCON. 
B) 
A) 
(Mins) 
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Figure 5.10. The effect of PKD2 gene silencing on OSM stimulated signalling pathways 
known to regulated collagenase gene expression. (A) P0 HAC were trypsinised and plated 
into 6 well plates and left over-night. The following day cells were treated with either siPKD2 #3 
or siCON (100 nM) for 48 hours. Cells were serum starved over-night. The following days cells 
were stimulated with OSM (10 ng/ml) for 20 or 60 minutes. Cell lysates were then  
immunoblotted using the antibodies shown. All procedures were followed as described in the 
Materials and Methods. Data are representative of at least three separate chondrocyte 
populations. GAPDH was used as a loading control. (B) Histograms show quantification of 
bands normalized to GAPDH, levels presented as a percentage of the cytokine-induced 
expression (siCON-transfected). Histograms are cumulative data of at least 3 individual cell 
populations (Mean ± S.D) **, p≤0.01, vs siCON. 
B) 
A) 
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Figure 5.11. The effect of PKD2 gene silencing on IL-1 in combination with OSM 
stimulated signalling pathways known to regulated collagenase gene expression. (A) P0 
HAC were trypsinised and plated into 6 well plates and left over-night. The following day cells 
were treated with either siPKD2 #3 or siCON (100 nM) for 48 hours. Cells were serum starved 
over-night. The following days cells were stimulated with IL-1 (0.2 ng/ml) in combination with 
OSM (10 ng/ml) for 20 or 60 minutes. Cell lysates were then immunoblotted using the 
antibodies shown. All procedures were followed as described in the Materials and Methods. 
Data are representative of at least three separate chondrocyte populations. GAPDH was used 
as a loading control. (B) Histograms show quantification of bands normalized to GAPDH levels, 
presented as a percentage of the cytokine-induced expression (siCON-transfected). Histograms 
are cumulative data of at least 3 individual cell populations (Mean ± S.D) **, p≤0.01, *, p≤0.05 vs 
siCON.  
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5.3.4.4  The consequences of PKD3 gene silencing on IL-1- ± OSM stimulated 
signalling pathways in HAC 
PKD3 gene silencing in HAC stimulated with IL-1 alone, led to the reduction of 
ERK, p38, JNK, STAT-1 and STAT-3 (Ser727) phosphorylation (Figure 5.12). 
PKD3 appears to regulate all signalling pathways implicated in collagenase 
gene expression which are stimulated by IL-1.  
As Figure 5.13 indicates, PKD3 gene silencing in HAC stimulated with OSM 
alone had no effect on any of the signalling pathways studied. 
As shown in Figure 5.14, PKD3 gene silencing in HAC stimulated with IL-1 in 
combination with OSM led to the abrogation of ERK, p38, JNK, STAT-1 and 
STAT-3 (Ser727) phosphorylation. PKD3 silencing has no effect on the 
phosphorylation of Akt, STAT-1 (Tyr701) or STAT-3 (Tyr 705). 
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Figure 5.12. The effect of PKD3 gene silencing on IL-1 stimulated signalling pathways 
known to regulated collagenase gene expression. (A) P0 HAC were trypsinised and plated 
into 6 well plates and left over-night. The following day cells were treated with either siPKD3 #2 
or siCON (100 nM) for 48 hours. Cells were serum starved over-night. The following days cells 
were stimulated with IL-1 (0.2 ng/ml) for 20 or 60 minutes. Cell lysates were then immunoblotted 
using the antibodies shown. All procedures were followed as described in the Materials and 
Methods. Data are representative of at least three separate chondrocyte populations. GAPDH 
was used as a loading control. (B) Histograms show quantification of bands normalized to 
GAPDH levels presented as a percentage of the cytokine-induced expression (siCON-
transfected). Histograms are cumulative data of at least 3 individual cell populations (Mean ± 
S.D) ***, p≤0.001, **, p≤0.01, *, p≤0.05 vs siCON. 
B) 
A) 
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Figure 5.13. The effect of PKD3 gene silencing on OSM stimulated signalling pathways 
known to regulated collagenase gene expression. (A) P0 HAC were trypsinised and plated 
into 6 well plates and left over-night. The following day cells were treated with either siPKD3 #2 
or siCON (100 nM) for 48 hours. Cells were serum starved over-night. The following days cells 
were stimulated with OSM (10 ng/ml) for 20 or 60 minutes. Cells were then immunoblotted using 
the antibodies shown. All procedures were followed as described in the Materials and Methods. 
Data are representative of at least three separate chondrocyte populations. GAPDH was used 
as a loading control. (B)Histograms show quantification of bands normalized to GAPDH levels 
presented as a percentage of the cytokine-induced expression (siCON-transfected). Histograms 
are cumulative data of at least 3 individual cell populations (Mean ± S.D)  
B) 
A) 
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Figure 5.14. The effect of PKD3 gene silencing on IL-1 in combination with OSM 
stimulated signalling pathways known to regulated collagenase gene expression. (A) P0 
HAC were trypsinised and plated into 6 well plates and left over-night. The following day cells 
were treated with either siPKD3 #2 or siCON (100 nM) for 48 hours. Cells were serum starved 
over-night. The following days cells were stimulated with IL-1 (0.2 ng/ml) in combination with 
OSM (10 ng/ml) for 20 or 60 minutes. Cell lysates were then immunoblotted using the 
antibodies shown. All procedures were followed as described in the Materials and Methods. 
Data are representative of at least three separate chondrocyte populations. GAPDH was used 
as a loading control. (B)Histograms show quantification of bands normalized to GAPDH levels 
presented as a percentage of the cytokine-induced expression (siCON-transfected). Histograms 
are cumulative data of at least 3 individual cell populations (Mean ± S.D), **, p≤0.01, vs siCON. 
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5.3.5 The regulation of STATs in human articular chondrocytes 
Once it was established that PKD regulated the phosphorylation of STAT-1 and 
STAT-3 at their serine phosphorylation site, further work was performed to try 
and understand the regulation of the STAT pathway by PKD. Litherland et al., 
(2010) had previously shown STAT-3 to be important in the induction of 
collagenase gene expression under the stimulus of IL-1 in combination with 
OSM (Litherland et al., 2010). The role of STAT-3 in the regulation of 
collagenase gene expression was therefore further examined using the STAT-3 
inhibitor, S3I-201. As well as this, understanding the mechanism by which PKD 
may regulate the serine phosphorylation of STAT-1 and STAT-3 was examined.  
 
5.3.5.1 The effect of STAT-3 inhibition on classical collagenase gene 
expression 
The cytotoxicity of the STAT-3 inhibitor S3I-201 in HAC was first assessed. As 
seen in Figure 7.5, no increased cytotoxic effects were seen in chondrocytes 
treated with the inhibitor at varying concentrations. STAT-3 inhibition in HAC 
using 100 μM of S3I-201 led to a significant reduction in MMP-1 and MMP-13 
gene expression (Figure 5.15). These data further confirmed the role of STAT-3 
in the regulation of collagenase gene expression under the pro-inflammatory 
cytokine stimulus of IL-1 in combination with OSM.  
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Figure 5.15. The effect of STAT-3 inhibition on collagenase expression in human articular 
chondrocytes. P0 HAC plated into 96 well plates were grown to 70% confluency and then 
serum starved overnight. HAC were pre-incubated with 100 μM S3I-201 or DMSO vehicle for 1 
hour prior to stimulation with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml) for 24 h. 
Cells were lysed and lysates reversed transcribed to cDNA. Real-time PCR was performed for 
(A) MMP-1 and (B) MMP-13, as described in the Materials and Methods. Data (mean ± S.E.M.) 
are representative of at least three combined chondrocyte populations (each assayed in 
hextuplicate) presented as relative expression levels normalised to 18S rRNA housekeeping 
gene. Comparisons shown are specific for PKD inhibitor versus control DMSO treated, where 
***, p≤0.001, **, p≤0.01 vs DMSO control. 
 
A) 
B) 
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5.3.5.2 The effect of JNK gene silencing on STAT-1 and STAT-3 serine 
phosphorylation 
PKD has not previously been implicated in the phosphorylation of the STAT-1 or 
STAT-3 at either phosphorylation site; therefore no mechanistic data were 
available into how PKD may regulate this phosphorylation. It was therefore 
unclear whether PKD directly or indirectly phosphorylated STAT-1 and STAT-3 
at their serine phosphorylation sites. The MAPKs have previously been 
implicated in the phosphorylation of this site (Decker and Kovarik, 2000); 
however, ERK was previously shown not to phosphorylate this site in HAC 
(Litherland et al., 2010). As PKD regulated the activation of JNK, I assessed the 
role of this MAPK in the serine phosphorylation of STAT-1 and STAT-3. 
Following effective silencing of JNK using siRNA against the JNK isoforms 
JNK1 and JNK2 (Figure 5.16. A), a reduction in phosphorylation of STAT-1 and 
STAT-3 in chondrocytes stimulated with IL-1 in combination with OSM is 
observed when JNK2 was silenced (Figure 5.16. B). No effects on the serine 
phosphorylation of STAT-1 and STAT-3 were observed when the JNK1 isoform 
was silenced. 
 
 
 
 
 
 
 
 
 
Figure 5.16 The effect of JNK gene silencing on STAT-1 and STAT-3 serine 
phosphorylation. (A) P0 HAC were trypsinised and plated into 6 well plates and left over-night. 
The following day cells were treated with siJNK1, siJNK2 or siCON (100 nM) for 48 hours. Cells 
were serum starved over-night. The following days cells were either lysed or (B) stimulated with 
IL-1 (0.02 ng/ml) in combination with OSM (10 ng/ml) for 20 or 60 minutes. Cell lysates were 
then immunoblotted using the antibodies shown. All procedures were followed as described in 
the Materials and Methods. Data are representative of at least three separate chondrocyte 
populations. GAPDH was used as a loading control.  
A) 
B) 
(Mins) 
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5.3.5.3 The effect of PKD3 gene silencing on STAT-1 and STAT-3 nuclear 
translocation 
PKD3 silencing had no effect on the tyrosine phosphorylation of STAT-1 or 
STAT-3 in whole cell lysates (see Figure 5.14); however I set out to establish 
whether PKD regulated the levels of tyrosine phosphorylated STATs within the 
nucleus. To assess these effects, lysates in which PKD3 had been silenced 
were subjected to cytoplasmic and nuclear fractionation. As Figure 5.17 shows, 
when PKD3 is silenced the levels of tyrosine phosphorylated STAT-3 within the 
nucleus are depleted, this is in contrast to STAT-1 in which no changes are 
observed.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17. The effects of PKD3 gene silencing on the translocation of tyrosine 
phosphorylated STATs. P0 HAC were trypsinised and plated into 6 cm dishes and left over-
night. The following day cells were treated with either siPKD3 #2 or siCON (100 nM) for 48 
hours. Cells were serum starved over-night. The following days cells were stimulated with IL-1 
(0.2 ng/ml) in combination with OSM (10 ng/ml) for 20 or 60 minutes. Cells were scraped in PBS 
and subjected to cytoplasmic and nuclear separation. Cytoplasmic and nuclear lysates were 
then immunoblotted using the antibodies shown. All procedures were followed as described in 
the Materials and Methods. Data are representative of at least three separate chondrocyte 
populations. MEK2 was used as a cytoplasmic loading control, whereas Lamin A/C was used as 
a nuclear loading control.  
(Mins) 
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5.3.6 The regulation of AP-1 transcription factor components by each 
individual PKD isoform in HAC 
The role of the AP-1 transcription factor is well established in the expression of 
MMPs (Benbow and Brinckerhoff, 1997). The main AP-1 binding site found 
within the promoters of MMP-1 and MMP-13 bind dimers of Fos and Jun 
proteins (Vincenti et al., 1998). Of these family members c-fos and c-jun were 
shown to be the major components of the AP-1 transcription factor involved in 
regulating collagenase gene expression (Chamberlain et al., 1993). PKD 
signalling has been shown to regulate both of these proteins (Sinnett-Smith et 
al., 2007b, Sinnett-Smith et al., 2004, Bernhart et al., 2013, Yamashita et al., 
2010). As data within this chapter showed PKD to regulate many signalling 
pathways known to induce both the expression and activity of members of AP-
1, I sought to understand the isoform specific roles of PKD on the expression of 
Fos and Jun.  
 
5.3.6.1  The effects of PKD isoform specific gene silencing on c-fos and c-jun 
mRNA expression in HAC 
Silencing of PKD1 using lentiviral mediated shRNA delivery in HAC stimulated 
with either IL-1 alone or in combination with OSM had no effects on the mRNA 
expression of c-fos or c-jun (Figure 5.18. A).  
Similarly, PKD2 gene silencing using siRNA in HAC stimulated with either IL-1 
alone or in combination with OSM had no effect on the mRNA expression of c-
fos or c-jun (Figure 5.18. B).  
siRNA mediated silencing of PKD3 in HAC led to a significant decrease in the 
expression of both c-fos and c-jun when stimulated with IL-1 alone and in 
combination with OSM (Figure 5.18. C). To further validate these data and 
identify whether PKD3 also regulated Jun activity and the protein levels of Jun 
and Fos, PKD3 was silenced and the effects on the phosphorylation of Jun and 
the protein expression of Fos and Jun examined. As Figure 5.18. D shows, a 
clear reduction in the protein levels of Jun and Fos in the nucleus is observed 
when PKD3 is silenced in HAC stimulated with IL-1 in combination with OSM. 
As well as this, a clear reduction in the levels of phosphorylated Jun is seen.  
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Figure 5.18. The effect of PKD silencing on the key AP-1 transcription factor members c-
fos and c-jun. P0 HAC were trypsinised plated into 96 well plates and left over-night. (A) The 
following day cells were transduced using lentiviral particles contain either shRNA (MOI = 30) 
specific to PKD1 or shCON for 72 hours, or transfected with siRNA against (B) PKD2, (C) PKD3 
or siCON for 48 hours. Cells were stimulated with IL-1 (0.05 ng/ml) ± OSM (10 ng/ml) for 1h. 
Cells were lysed and lysates reversed transcribed to cDNA. Real-time PCR was performed for 
c-fos and c-jun, as described in the Materials and Methods. Data plotted are the mean ± S.E.M. 
data of at least three separate chondrocyte populations (each assayed in hextuplicate) 
presented as relative expression levels normalised to 18S rRNA housekeeping gene. 
Comparisons shown are specific transduced PKD isoform versus control transduced, where **, 
p≤0.01, *, p≤0.05 vs siCON. (D) P0 HAC were trypsinised and plated into 6 cm dishes and left 
over-night. The following day cells were treated with either siPKD3 or siCON (100 nM) for 48 
hours. Cells were serum starved over-night. The following days cells were stimulated with IL-1 
(0.2 ng/ml) in combination with OSM (10 ng/ml) for 20 or 60 minutes. Cells were scraped in PBS 
and subjected to cytoplasmic and nuclear separation. Nuclear lysates were then immunoblotted 
using the antibodies shown. Data are representative of at least three separate chondrocyte 
populations. Lamin A/C was used as a nuclear loading control.  
(Mins) 
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5.3.7 The effect of PKD3 gene silencing on post-AP-1 transcription 
factors and cytokine 
The maximal expression of c-fos, as well as maximal phosphorylation of Jun in 
HAC stimulated with IL-1 in combination with OSM, is at 1 hour post stimulation 
(Rowan, personal communication). However, the maximal transcriptional 
expression of MMP-1 and MMP-13 is observed after 24 hours. It was therefore 
hypothesised that other post-AP-1 transcription factors must be involved in 
collagenase gene expression. A DNA microarray on unstimulated and IL-1 in 
combination with OSM stimulated HAC (performed by C. Macdonald, Newcastle 
University) identified a number of significantly up-regulated novel transcription 
factors at a 1 hour 15 mins time point, compared to a 1 hour time point. Once 
identified, these transcription factors were validated by siRNA and the effects of 
their silencing on MMP-1 and MMP-13 gene expression studied. This work 
identified activating transcription factor 3 (ATF3), early growth response 2 
(EGR2), nuclear factor of activate T-cells cytoplasmic 1 (NFATc1) and Axin-1 
induced gene (AXUD1) as modulators of collagenase gene expression (Rowan, 
unpublished data). Bone morphogenic protein (BMP-2), although not a 
transcription factor, was also up-regulated and shown to regulate MMP gene 
expression. I therefore wanted to assess whether PKD3, as a regulator of Fos 
and Jun expression, also regulated the expression of these proteins.  
5.3.7.1  The role of PKD3 in the expression of post AP-1 transcription factors 
To establish the role of PKD3 in the regulation of these post-AP-1 transcription 
factors and cytokine, the effects of PKD3 gene silencing on the gene expression 
of these factors was assessed. As Figure 5.19 shows, a significant reduction in 
the levels of ATF3, EGR2 and NFATc1 gene expression is observed in cells 
stimulated with IL-1 and when in combination with OSM. BMP-2 expression is 
also reduced, but only in HAC stimulated with IL-1 in combination with OSM. No 
effects on the expression of AXUD1 were observed under any stimulus.  
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Figure 5.19. The effect of PKD3 gene silencing on post AP-1 transcription factors. P0 
HAC were trypsinised and plated into 96 well plates and left over-night. The following day cells 
were transfected with siRNA specific to PKD3 or siCON (100 nM). 48 hours later cells were 
serum starved over-night. The following day cells were stimulated with IL-1 (0.05 ng/ml) ± OSM 
(10 ng/ml) for 1.15 h. Cells were lysed and lysates reversed transcribed to cDNA. Real-time 
PCR was performed for (A) ATF3, (B) AXUD1, (C) EGR2, (D) NFATc1 and (E) BMP-2 72 h after 
start of transfection as described in the Materials and Methods. Data plotted are the mean ± 
S.E.M. data of at least three separate chondrocyte populations (each assayed in hextuplicate) 
presented as relative expression levels normalised to 18S rRNA housekeeping gene. 
Comparisons shown are specific transfected PKD isoform versus control transfection, where ***, 
p≤0.001, **, p≤0.01, *, p≤0.05 vs siCON. 
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5.4 Discussion 
Results from Chapter 4 demonstrated that in HAC stimulated with IL-1 in 
combination with OSM, PKD1 gene silencing up-regulated MMP-1 and MMP-13 
gene expression. Whilst results indicated PKD2 to play no role in this regulation, 
PKD3 silencing was shown to down-regulate MMP-1 and MMP-13 gene 
expression. Therefore, to try and elucidate how these structurally similar 
proteins can have opposing effects on the same genes under the same pro-
inflammatory stimulus, each isoform was over-expressed or silenced and the 
consequences of this on signalling pathways known to regulate collagenase 
gene expression studied. As well as understanding the signalling cascades 
which were being regulated, AP-1, one of the key transcription factors involved 
in MMP gene expression was examined. This was achieved by studying the 
isoform specific effects of PKD on c-jun and c-fos gene expression. All of these 
data would provide further insight into the regulation of collagenase gene 
expression under this pro-inflammatory stimulus.  
5.4.1 The regulation of PKD in chondrocytes 
The effect of IL-1 and OSM on the phosphorylation of PKD was assessed. The 
phosphorylation of PKD by IL-1 was shown to be transient, whereas OSM 
dependent phosphorylation was shown to be longer in duration. PKD has 
previously been shown to be phosphorylated and activated under the stimulus 
of IL-1, implicating PKD downstream of the IL-1 receptor (Fleenor et al., 2003). 
OSM has not previously been shown to be an activator of PKD. However, OSM 
is known to activate the PI3K signalling cascade within chondrocytes (Litherland 
et al., 2008), and this pathway has been directly linked with the activation of 
PKC and PKD (Lynch et al., 2013), showing a potential mechanism by which 
OSM stimulation led to PKD phosphorylation.  
The subcellular distribution of each isoform of PKD was assessed when cells 
were stimulated with IL-1 in combination with OSM. Data suggest that 
stimulation increased the levels of each PKD isoform within the cytoplasm, but 
had no effects on the shuttling of each isoform to the cell membrane or nucleus. 
The increase in cytoplasmic PKD was probably due to increased stability of 
each isoform, due to the stimulation. These data suggest that within SW1353 
cells each isoform of PKD shuttles between these compartments in basal 
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conditions, this is not surprising as translocation has been shown to be 
independent of activation (Matthews et al., 1999). PKD has been shown to 
translocate to the cell membrane, here PKD is further activated, this leads to the 
translocation of PKD to the nucleus where PKD mediated signalling events alter 
MMP gene expression (Ha et al., 2008). These data show the importance of 
PKD translocation in altering MMP gene expression. Unfortunately, due to the 
large quantities of HAC required and reproducibility between patient samples 
the subcellular distribution of PKD isoforms in HAC was not found.  
PKC is a known activator of PKD and has previously been implicated in the 
regulation of collagenase gene expression in HAC under the stimulus of IL-1 in 
combination with OSM (Litherland et al., 2010). The effect of PKC inhibition on 
the phosphorylation of PKD was therefore assessed. PKC was first inhibited by 
the PKC inhibitor Gӧ6983. This is a PKC specific inhibitor, that only inhibits PKD 
when used at high concentrations, allowing any effect observed to be 
accredited to PKC inhibition and not PKD inhibition (Gschwendt et al., 1996). 
PKC inhibition led to a loss of PKD phosphorylation at the PKC dependent 
phosphorylation (Ser744/48) and autophosphorylation (Ser916) sites. These 
data show PKC to be involved in the direct phosphorylation of PKD in HAC 
stimulated with IL-1 in combination with OSM and suggest that PKC activates 
PKD under this stimulus.  
Isoform specific roles of PKC were then examined. Gene silencing of PKCι 
implicated this isoform in the regulation of PKD phosphorylation. Previously to 
these data, only the nPKCs have been implicated in the regulation of PKD 
phosphorylation (Zugaza et al., 1996, Bhavanasi et al., 2011, Yuan et al., 2002). 
When examining the literature, it can be seen that PKCι has not been 
specifically studied as a regulator of PKD phosphorylation. The aPKC have only 
been previously discounted in the regulation of PKD phosphorylation as PKCζ 
was shown not to regulate this phosphorylation (Yuan et al., 2002), in 
agreement with data presented here. Other Isoforms of PKC may also be 
involved in the phosphorylation and activation of PKD within HAC. PKCδ has 
been previously shown to regulate collagenase gene expression in HAC when 
stimulated with basic fibroblast growth factor (bFGF) (Im et al., 2007). This 
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isoform has also been shown to phosphorylate and activate PKD (Storz and 
Toker, 2003). PKCδ may therefore also play a role in the phosphorylation of 
PKD in HAC, along with other members of the nPKCs. It would have therefore 
been of interest to examine these isoforms also. However the data presented 
here, for the first time, implicates PKCι in the regulation of PKD phosphorylation 
in HAC, suggesting a novel role for PKCι in the phosphorylation of PKD.  
5.4.2 PKD modulation of signalling cascades involved in regulating 
collagenase gene expression 
Once it was established that PKD was being activated by both IL-1 and OSM in 
a PKCι dependent manner, the role of each isoform of PKD in the 
phosphorylation of downstream signalling pathways known to be involved in 
collagenase gene expression were examined. To assess PKD1 signalling, 
whilst the optimisation of PKD1 lentiviral-mediated shRNA gene silencing was 
being undertaken, the complementary technique of over-expression was used. 
This work was performed in SW1353 cells because of their increased 
availability compared to HAC and also their increased reproducibility.  
Isoform specific gene silencing of each MAPK in HAC under the stimulation of 
IL-1 in combination with OSM has shown the importance of each MAPK isoform 
in the regulation of collagenase gene expression (Litherland and Rowan, 
unpublished data). These data along with previously published data from within 
our group (Litherland et al., 2008, Litherland et al., 2010, Catterall et al., 2001) 
have shown the importance of various signalling pathways in regulating 
collagenase gene expression.  
5.4.2.1 PKD1 modulates signalling cascades involved in collagenase gene 
expression 
5.4.2.1.1 Over-expression of PKD1 in SW1353 cells 
To understand how the over-expression of PKD1 down-regulated the 
expression of MMP-1 and MMP-13, and how PKD1 gene silencing led to 
increased MMP-1 and MMP-13 gene expression in SW1353 cells (Figure 7.2, 
supplementary data), the role of PKD1 in the regulation of signalling pathways 
which regulate collagenase gene expression were examined. In this work the 
effects of PKD1 on signalling pathways stimulated with IL-1 and OSM alone or 
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in combination were studied. The work in SW1353 cells aimed to give insights 
into the potential signalling pathways PKD1 regulated in HAC.  
PKD1 over-expression had no effects on the phosphorylation of ERK or STAT-1 
and STAT-3 at their tyrosine phosphorylation site (phosphorylation at the serine 
phosphorylation site could not be detected in these cells), under any stimulus. 
These data suggest PKD1 does not regulate collagenase gene expression via 
modulation of these pathways.  
However, the over-expression of PKD1 in SW1353 cells stimulated with IL-1 
alone or in combination with OSM abrogated the phosphorylation of JNK and 
p38. Both of these signalling proteins have been implicated in the modulation of 
collagenase gene expression (Mengshol et al., 2001, Mengshol et al., 2000, 
Reunanen et al., 2002), through changes in AP-1 family member transcription 
and post translational modifications (Hess et al., 2004, Cavigelli et al., 1995, 
Whitmarsh et al., 1997); this could be a possible mechanism by which PKD1 
modulates collagenase gene expression in SW1353 cells. Inhibition of these 
key signalling pathways by PKD1 may reduce the expression and transcription 
potential of AP-1 family members in SW1353 cells.  
PKD1 over-expression also led to a decrease in Akt phosphorylation; however, 
this was only observed in SW1353 cells stimulated with OSM. In this work 
phosphorylation at the Ser473 only site was studied, due to poor identification of 
phosphorylation and reproducibility of results when studying the Thr308 site. 
These data suggest that the complex stimulus masks the effects of OSM 
signalling when used alone. The phosphorylation of Akt by IL-1 in combination 
with OSM is known to be less potent than when stimulated with OSM alone 
(Litherland et al., 2008), these data could explain the loss of PKD1 effects on 
this pathway, with PKD1 no longer being able to regulate Akt phosphorylation 
under this less potent stimulus of Akt. 
Taken together these results imply that PKD1 regulates collagenase gene 
expression in SW1353 cells through the modulation of the JNK and p38 
signalling pathways. The consequences of this, may be changes in the 
transcription of AP-1 transcription factor. These data provide insight into the 
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mechanism by which PKD1 regulates collagenase gene expression within HAC 
under the cytokine stimuli used.  
5.4.2.1.2 Gene silencing of PKD1 in HAC 
To understand how the gene silencing of PKD1 led to an increase in the 
expression of MMP-1 and MMP-13 (Chapter 4, Figure 4.3) and also a down-
regulation in collagenase gene expression when over-expressed (Chapter 4, 
Figure 4.2) in HAC, the effect of PKD1 gene silencing on signalling pathways 
which regulate collagenase gene expression were examined. In this work the 
effects of PKD1 silencing on signalling pathways stimulate by IL-1 in 
combination with OSM were only studied, this was due to time constraints due 
to the time taken to optimise this technique.  
PKD1 gene silencing in HAC stimulated with IL-1 in combination with OSM 
abrogated the phosphorylation of JNK, ERK and p38. These data are contrary 
to findings in SW1353 cells, in which the phosphorylation of JNK and p38 were 
reduced when PKD1 was over-expressed. This was an unexpected result, as 
these pathways are thought to be crucial for the induction of collagenase gene 
expression. However, PKD1 has previously been implicated in both the 
activation (Yamamoto et al., 2010, Zhang et al., 2005) and inhibition (Wang et 
al., 2004) of the JNK pathway, implying this process to be stimulus and cell 
specific. PKD1 has only been shown previously to activate ERK signalling, with 
this being through the regulation of upstream MAP2K and MAP3Ks (Sinnett-
Smith et al., 2004, Ziegler et al., 2011), as seen in HAC. The role of PKD in the 
regulation of p38 has been shown to be complex, with PKD being shown to 
phosphorylate p38 leading to p38 signal transduction (Bernhart et al., 2013, 
Hao et al., 2012). However, PKD has also been shown to be regulated by p38, 
with a novel p38 phosphorylation site being identified within the PKD structure. 
Phosphorylation at this site was shown to inhibit PKD (Sumara et al., 2009). 
The literature may therefore be suggesting that PKD acts in a feedback loop, 
with PKD activating p38 leading to its own inhibition by p38, preventing further 
signal transduction.  
The role for increased p38 signalling via PKD1 in the modulation of collagenase 
gene expression is not clear. As well as being a positive regulator of MMP gene 
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expression, p38 signalling has been shown to inhibit MMP gene expression. 
p38 signalling is shown to inhibit the expression of MMP-1 via the down 
regulation of ERK signalling (Westermarck et al., 2001), with the inhibitory 
effects of p38 being dependent on the upstream MAP2K which phosphorylates 
p38. Westermarck et al. showed that MKK3/MKK3 activation of p38 lead to 
decreased MMP gene expression (Westermarck et al., 2001). This work 
showed p38α to be the important isoform in this regulation, this data may 
suggest that isoform specific roles of p38 in the regulation of MMP gene 
expression. As PKD1 has been shown to regulate the phosphorylation of MKK3 
(Song et al., 2009), this suggests a potential mechanism by which PKD1 can 
inhibit MMP gene expression via p38 signalling. 
These data suggest that PKD1 signalling in HAC activates all three MAPK 
pathways, but this does not induce collagenase gene expression. These data 
therefore suggests that the activation of the MAPK signalling pathways via 
PKD1 may not induce collagenase gene expression in HAC under the stimulus 
of IL-1 in combination with OSM. However, if p38 signalling is a negative 
regulator of collagenase gene expression as proposed, this could explain the 
effects of PKD1 silencing on this protein.  
PKD1 silencing in HAC led to an increase in the phosphorylation of Akt. These 
data suggest that PKD1 in chondrocytes inhibits Akt signalling under these 
conditions, implying a potential mechanism by which PKD1 can regulate 
collagenase gene expression.  
The effects of PKD1 silencing on Akt phosphorylation observed in HAC have 
been supported in the literature. Here two mechanisms have been proposed as 
to how PKD may inhibit Akt phosphorylation; these mechanisms have the 
potential to work in tandem to regulate Akt phosphorylation. Ni et al. suggested 
that PKD1 can regulate the phosphorylation of the regulatory subunit of PI3K, 
p85α. Phosphorylation of p85 led to the binding and activation of Phosphatase 
and tensin homolog (PTEN) (Ni et al., 2013). PTEN can then dephosphorylate 
PIP3, the main upstream signalling molecule of PDK-1. PDK-1 can then no 
longer phosphorylate and activate Akt. Although PDK-1 is thought to primarily 
phosphorylate Akt at the Thr308 site, it has been implicated in the 
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phosphorylation of Ser473; the Rictor-mTOR Complex is also thought to 
phosphorylate at this site (Sarbassov et al., 2005). As well as this, Hinchliffe et 
al. proposed a mechanism by which PKD phosphorylates a type II PIP kinase, 
leading to its inactivation. This therefore leads to a reduction in the levels of the 
PI3K substrate PIP2 (Hinchliffe and Irvine, 2006). Reduced levels of PIP2 means 
PI3K no longer generates PIP3 and thus reduces Akt phosphorylation. These 
two mechanisms could therefore be working in tandem, allowing PKD1 control 
over Akt activation.  
NFκB is well established in the regulation of collagenase gene expression in 
HAC stimulated with IL-1 (Fan et al., 2006). Data presented in this chapter show 
PKD1 gene silencing to induce the phosphorylation of p65, suggesting PKD1 to 
usually inhibit the activation of NFκB signalling (Figure 5.8). PKD and 
specifically PKD1 have been shown to regulate the activation and 
transcriptional activity of this signalling molecule and transcription factor (Storz 
and Toker, 2003, Chen et al., 2011). These data suggest the opposite to what is 
seen in this present study. This may therefore further suggest cell specificity in 
the regulation of signalling pathways modulate by PKD1 in different cells types. 
As PKD1 is seen to increase the phosphorylation (suggesting increased activity) 
of NFκB, these data could suggest a signalling and transcriptional mechanism 
by which PKD1 can inhibit collagenase gene expression when stimulated with 
IL-1 in combination with OSM. PKD2 and PKD3 were seen to have no effect on 
phosphorylation of p65 or degradation of IκBα in HAC (data not shown).   
Increased levels of STAT-1 phosphorylated at Tyr701 were observed in PKD1 
gene silencing studies. These data therefore suggest that PKD1 signalling could 
potentially inhibit STAT-1 dimerisation and translocation to the nucleus, 
reducing the transcription potential of STAT-1. The loss of activation of this 
transcription factor, may explain one of the mechanisms by which PKD1 inhibits 
collagenase gene expression in HAC stimulated with IL-1 in combination with 
OSM. Although Litherland et al. (2010) did not show a significant effect of 
STAT1 silencing on collagenase gene expression; this along with the loss of Akt 
may work in tandem to inhibit collagenase gene expression.  
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No data within the literature has previously demonstrated any isoform of PKD in 
the regulation of STAT phosphorylation; therefore no mechanistic data are 
available to suggest how this may occur. Inhibition of the tyrosine 
phosphorylation of STATs has been shown to be indirect, with the inhibition of 
JAKs being shown to be important (Starr and Hilton, 1999). Two protein families 
are known to be involved in the inhibition of JAK signalling leading to decreased 
STAT tyrosine phosphorylation; these are SHP-1 and suppressors of cytokine 
signalling (SOCS) family members (Starr and Hilton, 1999). PKD1 may 
therefore increase the activity or expression of these proteins leading to 
decreased tyrosine phosphorylation of STAT-1 by JAKs.  
PKD1 silencing in HAC also led to an increase in the levels of STAT-1 serine 
phosphorylation. This again implies a potential mechanism by which PKD1 
could inhibit collagenase gene expression in HAC, with decreased 
phosphorylation at this site leading to a reduction in the transcriptional activity of 
STAT-1. How the modulation of STAT-1 via PKD1 regulates collagenase gene 
expression remains unclear, as PKD1 silencing had no effect on the mRNA 
expression of c-fos. However, this could be due to c-fos gene expression 
already being at maximal capacity, with no increase in expression being 
induced with the silencing of PKD1. Examining the protein level of Fos may give 
further insight into the regulation of the STAT pathway by PKD1. 
To confirm that the increased tyrosine and serine phosphorylation of STAT-1 
were due to PKD1 silencing, the effects of PKD1 silencing on interferon-α and 
interferon-γ gene expression were examined. This was assessed as viral 
transduction is known to induce to an interferon response (Kenworthy et al., 
2009). Interferons have been shown to directly phosphorylated and activate 
STAT proteins (Decker and Kovarik, 2000). As Figure 7.7 (supplementary data) 
shows, no increase in either interferon was observed, suggesting the increase 
in phosphorylation to be caused by PKD1 gene silencing. 
The conflicting data found between SW1353 cells and HAC shows the 
importance of studying a disease within the primary cell type of interest. This 
data shows that the same signalling protein can have opposing effects on the 
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same signalling pathway but still lead to the same downstream consequence in 
different cell types.  
5.4.2.2 PKD2 modulates signalling cascades involved in collagenase gene 
expression when stimulated with IL-1 alone or when used in 
combination with OSM 
The signalling consequences of PKD2 silencing in HAC were studied to try and 
understand why this isoform does not regulate collagenase gene expression. 
The effect of PKD2 silencing was assessed on signalling pathways stimulated 
with all three stimuli in HAC.  
The effect of PKD2 silencing on the phosphorylation of the MAPK pathways 
appeared to be stimulus dependent. When PKD2 was silenced and cells were 
stimulated with IL-1 alone, a reduction in the phosphorylation of all 3 MAPK was 
seen. However, when cells were stimulated with IL-1 in combination with OSM 
the reduction in the phosphorylation of ERK or JNK was no longer seen, 
interestingly p38 phosphorylation increased.  
These data suggest that the addition of OSM led to the loss of PKD2 mediated 
regulation of the MAPKs. One explanation for the loss of PKD2 mediated 
regulation of the MAPKs could be due to further OSM mediated phosphorylation 
of these proteins. It would appear that IL-1 stimulation does not maximally 
phosphorylate JNK, p38 and ERK with the addition of OSM leading to further 
phosphorylation. The addition of OSM to IL-1 stimulated human gingival 
fibroblasts has been shown to increase the phosphorylation of JNK (Hosokawa 
et al., 2010). The addition of OSM may therefore further phosphorylate JNK via 
a mechanism that is distinct to IL-1 and PKD2 regulation. The loss of JNK 
phosphorylation via PKD2 in IL-1 only stimulated cells may be counteracted by 
this increased phosphorylation by a PKD2 independent OSM-mediated 
pathway. ERK and p38, like JNK, may be further activated by the addition of 
OSM in a PKD2 independent, OSM driven manner. These data could help 
explain how PKD2 silencing had no effect on collagenase gene expression, as 
the JNK, ERK and p38 pathways all are known to be important in inducing gene 
expression.  
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The increase in the levels of p38 phosphorylation under the stimulus of IL-1 in 
combination with OSM could be explained by the dysregulation of a negative 
feedback loop that PKD and p38 are potentially involved within.  
PKD2 silencing in HAC led to a significant reduction in the level of Akt 
phosphorylation, but only when stimulated with OSM alone. This data suggest 
that like the MAPK data when the complex stimulus is used the effects of PKD2 
on Akt phosphorylation were masked. A further explanation could be down to 
the fact that stimulation of Akt with IL-1 in combination with OSM does not 
phosphorylate Akt to the same levels as seen with OSM alone (Litherland et al., 
2008), the effects of PKD2 on Akt signalling could therefore be lost.  
PKD2 silencing had no significant effect on tyrosine phosphorylation of either 
STAT-1 or STAT-3, when stimulate with OSM alone or in combination with 
OSM. However, PKD2 silencing led to a reduction in the phosphorylation of 
STAT-1 and STAT-3 at their serine phosphorylation site under the stimulus of 
IL-1 alone or in combination with OSM. The loss of STAT-1 and STAT-3 serine 
phosphorylation does not appear to lead to changes in the transcription of 
collagenase gene expression suggesting the loss of this regulatory 
phosphorylation is not itself sufficient to drive collagenase gene expression.  
5.4.2.3 PKD3 regulates signalling cascades involved in collagenase gene 
expression when stimulated with IL-1 alone or when used in 
combination  
To understand how the gene silencing of PKD3 led to a decrease in the 
expression of MMP-1 and MMP-13 (Chapter 4, Figure 4.5), the effect of PKD3 
gene silencing on signalling pathways which regulate collagenase gene 
expression in HAC were examined. In this work the effects of PKD3 silencing on 
signalling pathways activated by all three stimuli were studied.  
PKD3 silencing abrogated the phosphorylation of all three MAPK signalling 
proteins in HAC stimulated with IL-1 alone or in combination with OSM. These 
data suggest a potential mechanism by which PKD3 up-regulates collagenase 
gene expression in HAC stimulated with IL-1 in combination with OSM. PKD3 
signalling has been poorly studied with no real mechanistic data being available 
into how PKD3 regulates the phosphorylation of these MAPKs. PKD3 may 
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regulate JNK in a similar manner to PKD1, with data suggesting PKD1 to 
interact directly with JNK (Hurd et al., 2002) as well as phosphorylating the 
upstream MAP3K, ASK1, with this phosphorylation leading to increased JNK 
activity (Zhang et al., 2005). The mechanism by which PKD3 phosphorylates 
ERK still remains unclear, but like PKD1 may occur via MAP3K and MAP2K 
activation. It has been shown that PKD1 phosphorylates Ras and Rab 
interactor-1 (RIN1), releasing RAF from its inhibitory binding to RAS, leading to 
the activation of the RAF-MEK-ERK pathway (Wang et al., 2002). PKD3 may 
activate p38 leading to the phosphorylation of its downstream target Elk-1, 
leading to increased stability and enhanced transcriptional activity. The 
increased transcriptional activity may lead to an increase in the expression of 
the AP-1 component Fos. (Whitmarsh et al., 1997). MMP gene expression 
could then be induced by the increased expression of the AP-1 components.  
PKD3 silencing in HAC has no effect on Akt phosphorylation under stimulation 
with OSM alone or when in combination with IL-1. These data suggest that 
PKD3 does not regulate collagenase gene expression through the modulation 
of the Akt pathway.  
PKD3 silencing did not lead to any significant changes in the tyrosine 
phosphorylation of either STAT-1 or STAT-3, under any stimuli. Like when 
PKD1 was over-expressed and PKD2 silenced, small but insignificant increases 
in levels of phosphorylation were observed. However, decreases in STAT-1 and 
STAT-3 serine phosphorylation were observed with PKD2 and PKD3 gene 
silencing. Serine phosphorylation of both STAT-1 and STAT-3 has been shown 
to decrease tyrosine phosphorylation of both STATs (Chung et al., 1997). 
Therefore the reduced levels of serine phosphorylation observed with PKD2 
and PKD3 gene silencing, could potentially increase in the levels of tyrosine 
phosphorylation due to the loss of this regulatory mechanism.  
PKD3 silencing led to a reduction in the phosphorylation of STAT-1 and STAT-3 
at this serine phosphorylation site, priming them for transcription. The increased 
phosphorylation at this STAT priming event along with the regulation of the 
MAPKs imply a potential mechanism by which PKD3 could induce the gene 
expression of MMP-1 and MMP-13,. 
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5.4.3 PKD and the regulation of STAT-1 and STAT-3 
Once it was established that each isoform of PKD regulated the phosphorylation 
of STAT-1 and/or STAT-3, their role in MMP gene expression was assessed. 
Furthermore, the potential mechanism by which PKD regulated the 
phosphorylation of STAT-1 and STAT-3 at their serine phosphorylation site was 
examined. 
Frist, to confirm that STAT-3 regulated the expression of MMP-1 and MMP-13, 
STAT-3 was inhibited using S3I-201 in HAC stimulated with IL-1 in combination 
with OSM. STAT-3 inhibition led to a significant decrease in MMP-1 and MMP-
13 gene expression, confirming STAT-3 regulated collagenase gene expression 
in HAC.  
Gene silencing of all PKD isoforms led to changes in the phosphorylation of 
either/both STAT-1 and STAT-3 at their serine phosphorylation site. The 
mechanism by which this may occur in HAC is unclear. The MAPKs are well 
established as regulators of STAT serine phosphorylation (Decker and Kovarik, 
2000). However, the MAPK(s) involved in this phosphorylation has been shown 
to be both cell and stimulus specific (Kovarik et al., 1999). Much data has 
focused on ERK as the major regulator of both STAT-1 and STAT-3 serine 
phosphorylation, however in chondrocytes stimulated with IL-1 in combination 
with OSM ERK has been shown not to be necessary (Litherland et al., 2010). 
PKD has not been previously shown to regulate the phosphorylation of STAT-1 
or STAT-3 at either site, therefore no data are available to whether PKD directly 
or indirectly phosphorylates this site. However, each isoform of PKD has been 
shown to regulate the activation of JNK, a known serine STAT regulator. JNK 
silencing data showed JNK2 to decrease the levels of STAT-1 and STAT-3 
serine phosphorylation. These data suggest that PKD may inhibit JNK signalling 
leading to the loss of STAT-1 and STAT-3 serine phosphorylation.  
Another mechanism by which PKD3 may regulate collagenase gene expression 
is through increased nuclear translocation of STAT-3. PKD3 silencing is seen to 
inhibit the translocation of tyrosine phosphorylated STAT-3 into the nucleus. 
The mechanism by which this occurs is unclear, as no changes in the levels of 
tyrosine phosphorylated STAT-3 is observed in whole cell lysates. The effects 
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of PKD3 activity to increase the levels of transcriptionally active STAT-3 within 
the nucleus may increase the transcription of both MMP-1 and MMP-13. 
5.4.4 PKD isoforms and AP-1 gene expression regulation 
The induction of the signalling pathways studied is known to modulate the 
expression and activity of the key collagenase transcription factor, AP-1. The 
expression of the two major components of AP-1, Fos and Jun, were therefore 
assessed when each isoform of PKD was silenced in HAC stimulated with IL-1 
alone or in combination with OSM.  
PKD1 silencing had no effect on the expression of c-fos or c-jun. Previous data 
has suggested that through IL-1 stimulation, PKD1 can activate the AP-1 
transcription factor and MMP gene expression (Fleenor et al., 2003). If c-fos 
and c-jun expression, as described earlier, were at a maximal level no increase 
in mRNA level of either would be observed. Therefore examining further time 
points and also the protein expression and phosphorylation of these proteins 
may have provided further information into whether PKD1 could regulate the 
AP-1 transcription factor.   
PKD2 silencing had no effect on the transcription of either c-fos or c-jun in HAC 
under either stimulus. These data implicate a potential mechanistic reason why 
PKD2 is unable to regulate collagenase gene expression, as these transcription 
factors are known to induce the MMP-1 and MMP-13 gene expression. As 
PKD2 was unable to regulate JNK and ERK under the stimulus of IL-1 in 
combination with OSM, this may explain why unlike previous data PKD2 cannot 
regulate Jun and Fos in HAC (Sinnett-Smith et al., 2007b, Bernhart et al., 
2013).  
When examining the effects of PKD3 on the gene expression and protein level 
of Fos and Jun, it can be seen that PKD3 stimulation via IL-1 in combination 
with OSM increases the transcription and synthesis of these two transcription 
factors. As well as increasing the transcription of c-Jun, PKD3 also increases 
the phosphorylation of Jun, suggesting increased transcriptional activity. The 
signalling pathway by which PKD3 phosphorylates Jun under this stimulus is 
not clear. But PKD3, like PKD2 in other cell types, may phosphorylate Jun via 
JNK (Bernhart et al., 2013), as data presented here shows PKD3 to regulate the 
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phosphorylation of JNK. The increased expression of both Jun and Fos could 
also be explained by the regulation of all 3 MAPK pathways, as well as the 
induction of STAT signalling, as all these pathways have been implicated in the 
induction of both these transcription factors. 
5.4.5 PKD3 and the regulation of post-AP-1 transcription factors and 
cytokine 
To further understand the transcriptional regulation of collagenase gene 
expression, the effects of PKD3 silencing on the gene expression of ATF3, 
EGR2, NFATc1 and AXUD1 and BMP-2 was studied. These are newly 
identified novel collagenase gene modulators. The regulation of MMP-1 and 
MMP-13 gene expression differ between these factors. ATF3 and EGR2 
regulated the expression of MMP-13, whilst AXUD1 and NFATc1 were specific 
for MMP1 only. BMP-2 was shown to regulate MMP-1 and MMP-13 
(Macdonald, 2013). PKD3 silencing of these factors led to a decrease in the 
expression of ATF3, EGR2, NFATc1 and BMP-2, no effects on AXUD1 
expression was observed.  
The role of ATF3 in the regulation of MMP gene expression is an area of 
dispute. ATF3 has been shown to be a negative regulator of MMP gene 
expression (Stearns et al., 2004, Chen and Wang, 2004, Yan et al., 2002) in 
work focusing on MMP-2 gene regulation. This report showed that ATF3 
inhibited the trans-activation of MMP-2 by interacting and inhibiting cellular 
tumour antigen p53, a known MMP transcription factor. However, when looking 
specifically at the collagenases MMP-1 and MMP-13, ATF-3 has been shown to 
be a positive regulator of both MMPs, with over-expression leading to increased 
gene expression (Lv et al., 2011, Okamoto et al., 2006). Work showed that 
under basal conditions ATF3 could bind to the proximal AP-1 site, but with the 
addition of TGF-β, ATF-3 bound to Runt Domain/ Runt-related transcription 
factor (RD/RUNX) sites of the human MMP-13 promoter (Kwok et al., 2009). As 
well as this, ATF3 is known to induce the expression of RUNX2, a known MMP-
13 transcription factor (Mengshol et al., 2001) and principal regulator of skeletal 
formation (Stein et al., 2004). PKD has already been implicated in RUNX2 gene 
expression, suggesting a mechanism for the induction of this transcription factor 
(Jensen et al., 2009). PKD3 therefore may induce ATF3 expression through 
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induced AP-1 mediated transcription or potentially through the modulation of the 
MAPK pathways (Lu et al., 2007, Hai et al., 1999, Park et al., 2012). The 
increased expression of ATF3 may induce RUNX2 expression, leading to 
increased MMP-13 gene expression.  
EGR1 expression has previously been shown to be induced by IL-1 in 
chondrocytes (Goldring et al., 1994) and also shown to induce collagenase 
expression in RA synoviocytes (Trabandt et al., 1992). EGR2 may therefore 
regulate MMP gene expression in a similar manner under the stimulation of IL-1 
in combination with OSM. EGR2 over-expression is also known to induce 
collagen I expression, suggesting a further role in joint homeostasis (Fang et al., 
2011). PKD3 silencing decreased the expression of EGR2, suggesting a further 
mechanism by which PKD3 modulates collagenase gene expression. PKD has 
not been previously implicated in the regulation of EGR2 expression, so no 
mechanistic data are available as to how PKD3 regulates the changes in 
expression. However, data does suggest that the expression of EGR2 is 
regulated by MAPK stimulation, suggesting a potential mechanism by which 
PKD3 could regulate the expression of EGR2 in HAC (Fang et al., 2011).  
Previous work has implicated NFATc1 in arthritis progression and cartilage 
degradation. NFATc1 is shown to be expressed in the synovium of RA patients 
(Pessler et al., 2006) and NFAT inhibition has also been shown to decrease IL-
1-mediated collagenase gene expression (Yoo et al., 2007). PKD3 has been 
linked with the nuclear accumulation and gene induction of NFATc4 (Li et al., 
2011). This work also showed NFATc1 to induce the expression of PKD3. 
These data, along with my own, suggest PKD3 may lie in a regulatory loop, in 
which PKD3 could potentially induce the expression of NFATc1 as well as being 
stimulated itself by NFATc1. PKD3 may therefore regulate the levels and 
transcriptional activity of this protein leading to the induction of MMP gene 
expression. 
PKD has been shown to be phosphorylated and activated by BMP-2. BMP-2 is 
known to be important in the differentiation of osteoblast into bone and has 
been shown to induce the expression of both MMP-13 and RUNX2 (Caron et 
al., 2013). BMP-2 is shown to activate PKD, leading to JNK and p38 signalling 
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inducing RUNX2 (Jensen et al., 2009). Stimulation of HAC with IL-1 in 
combination with OSM therefore has the potential to stimulate PKD3, leading to 
the induction of BMP-2, which induces further activation of PKD3 driving 
RUNX2 expression, which in turn induce collagenase gene expression. 
Data presented in this chapter have shown the potential signalling 
consequences of each isoform of PKD in HAC stimulation with pro-inflammatory 
cytokines seen to be elevated in arthritic diseases. These data suggest potential 
mechanisms by which each isoform may regulate collagenase gene expression 
in HAC under these stimuli. 
5.4.6 Summary 
Studies in this chapter have shown: 
 PKD1 regulates signalling pathways known to induce collagenase gene 
expression in a cell dependent manner. 
 PKD1 activates the MAPK signalling pathways but inhibits the 
phosphorylation of Akt, STAT-1 at both phosphorylation sites and STAT-
3 at its serine phosphorylation site in HAC 
 PKD2 no longer regulates MAPK pathway regulation when OSM is in 
combination with IL-1; serine phosphorylation of STAT-1 and STAT-3 still 
occurs. 
 PKD3 phosphorylates all three MAPKs and also phosphorylates STAT-1 
and STAT-3 at their serine phosphorylation site 
 STAT-3 is crucial in the induction of collagenase gene expression 
 JNK2 is responsible for the phosphorylation of STAT-1 and STAT-3 at 
their serine phosphorylation site 
 PKD3 gene silencing inhibits the levels of tyrosine phosphorylated 
STATs in the nucleus 
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Figure 5.20 Signalling diagram of the potential mechanisms by which PKD1 and PKD3 
regulate collagenase gene expression in HAC stimulated with IL-1 in combination with 
OSM. 1) Stimulation of the IL-1 and OSM receptors has previously been shown to 
phosphorylate and activate PKCι (Litherland et al., 2010); this is suggested to occur via PIP3 
and PDK1, as well as p62 activation. PKCι is known to phosphorylate PKD at serine 744/748, 
activating the protein kinase. (2) Activation of PKD1 leads to the loss of Akt phosphorylation at 
its serine 473 site. Currently, it is unclear whether this is by direct inhibition of Akt or indirectly 
via PKD1 inhibition of PI3K signalling via activation of PTEN and/or other PIP phosphatases (Ni 
et al., 2013, Ittner et al., 2012). Phosphorylation of the p65 subunit of NFκB, a known Akt 
downstream target, is also reduced. PKD1 has the potential to regulate this phosphorylation via 
Akt, however PKD1 is also reported to inhibit IKK, a known upstream activator of p65 (Storz and 
Toker, 2003). (3) The loss of p65 phosphorylation negates its nuclear translocation, thus 
preventing transcription of MMP-1 and MMP-13. (4) PKD1  also inhibits phosphorylation of 
STAT-1 at its serine and tyrosine phosphorylation sites. (5) The consequences of this are not 
fully clear; the STATs have been shown to regulate FOS expression leading to the regulation of 
MMP gene expression (Catterall et al., 2001). However, the data presented here show no 
change in FOS expression when PKD1 is silenced. STAT1 may therefore directly bind the 
MMP-1 and MMP-13 promoters (El Mabrouk et al., 2007, Korzus et al., 1997), with PKD1 
preventing this from occurring by inhibiting STAT phosphorylation and hence reducing 
collagenase gene expression. (6) PKD1 is seen to phosphorylate and activate JNK, ERK and 
p38. However, the activation of these pathways, although important in the regulation of 
collagenase gene expression, does not appear to alter collagenase gene expression under the 
regulation of PKD1. The effect of PKD1 on NFκB, Akt and STAT-1 appears to ‘over-ride’ the 
activation of these MAPKs. In chondrocytes, the regulation of MAPKs at the MAPKK and 
MAPKKK levels remains unclear. However data suggest PKD family members regulate the 
MAPKKK, ASK-1, a known upstream activator of JNK and p38 (Zhang et al., 2005). PKD1 is 
also seen to phosphorylate the MAPKKK, RIN-1, leading to the binding of 14-3-3 to the protein, 
inducing proteasomal degradation. This leads to the phosphorylation of RAF and activation of 
ERK signalling (Ziegler et al., 2011). (7) PKD3 also phosphorylates and activates JNK, ERK and 
p38. Again the mechanism by which this occurs is not fully characterised, but like PKD1, may 
occur through the phosphorylation of MAPKKKs and MAPKKs. (8) Activation of the MAPK 
pathways is known to lead to an induction in the expression of FOS and JUN; two key members 
of the AP-1 heterodimer. These proteins are known to be crucial in the induction of MMP-1 and 
MMP-13 expression in HAC stimulated with IL-1 in combination with OSM (Litherland et al., 
2010, Catterall et al., 2001). JNK is known to phosphorylate and induce the stability of JUN 
(Leppa et al., 1998), whilst ERK and p38 are known to activate elk-1 inducing FOS expression 
(Hodge et al., 1998, Whitmarsh et al., 1997). (9) PKD3 also phosphorylates STAT-1 and STAT-
3 at their serine phosphorylation site, priming both for transcription. (10) STAT-1 and STAT-3 
bind to the c-fos promoter, inducing its expression (Catterall et al., 2001). (11) Induction of c-fos 
and c-jun in chondrocytes stimulated with IL-1 in combination with OSM has recently been 
shown to induce the expression of multiple post-AP-1 transcription factors, which have been 
demonstrated to be important in the regulation of collagenase gene expression (Macdonald, 
2013). PKD3 signalling via the regulation of the key signalling pathways highlighted, and 
through the modulation of c-fos and c-jun, regulates the expression of these transcription factors 
leading to the induction of MMP-1 and MMP-13 expression under this pro-inflammatory cytokine 
stimulus. The other isoform of the PKD family, PKD2, was shown not to regulate the expression 
of MMP-1 or MMP-13 although it does appear to regulate the serine phosphorylation of the 
STATs and the phosphorylation of p38. Together, this regulation appears insufficient to lead to 
downstream transcriptional changes of the collagenases. This may be due to the lower 
expression of PRKD2 in chondrocytes compared to the other two isoforms (D A Young, 
personal communication). 
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Cartilage degradation due to the expression of proteolytic enzymes is a key 
pathological process in arthritic disease. This stage in disease is characterised 
by irreversible collagenolysis. Of the enzymes capable of cleaving native 
collagen fibrils, MMP-1 is described as the key collagenase in RA, whereas 
MMP-13 is thought to be the major collagenolytic enzyme in OA. In disease, an 
increase in the expression of pro-inflammatory cytokines is observed, with 
elevated levels of IL-1 and OSM being detected (Hui et al., 1997, Fontana et al., 
1982). These two pro-inflammatory cytokines have been shown to synergise, 
leading to a robust induction of collagenase gene expression, protein synthesis 
and subsequent collagenolysis of cartilage collagen, all being induced within the 
chondrocyte (Rowan et al., 2003, Rowan et al., 2001, Koshy et al., 2002b, 
Cawston et al., 1995b, Barksby et al., 2006). Although used as a model of 
inflammatory arthritis, this stimulus has been shown to be an important model in 
understanding the complex signalling cascades and cross-talk that initiates 
MMP gene expression and cartilage degradation (Barksby et al., 2006, 
Litherland et al., 2008, Litherland et al., 2010). The induction of subsequent 
signalling events involved in collagenase gene expression have not been well 
examined, and only a few previous studies have examined the signalling events 
stimulated by IL-1 in combination with OSM which lead to collagenase gene 
expression in HAC (Litherland et al., 2008, Litherland et al., 2010, Catterall et 
al., 2001). The aim of this study was to further understand these signalling 
events, examining the signalling pathways regulated by the individual isoforms 
of PKD and known to modulate of collagenase gene expression.  
The in vitro model of arthritis used to investigate the signalling consequences 
which lead to the induction of collagenase gene expression in HAC within a pro-
inflammatory setting, is well-established and seen as a robust model for disease 
progression (Rowan et al., 2003). In vitro models have limitations, as do in vivo, 
and are only ever used as an indicator of the potential signalling events which 
occur within the chondrocytes of patients suffering from arthritis. In vitro data 
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does have relevance and can be used as an indicator of the roles of proteins 
within disease, further increasing our knowledge of disease progression. The 
use of primary HAC, over cell lines, further validates the data found within this 
thesis, as they are the cell type involved in disease.  
OSM is not the only pro-inflammatory cytokine which has been shown to 
synergise with IL-1, and the addition of the pro-inflammatory cytokine IL-6 with 
its receptor (IL-6 receptor) and IL-17, both synergise with IL-1 to induce 
collagenase gene expression in HAC (Rowan et al., 2001, Koshy et al., 2002a). 
The complex milieu of pro-inflammatory cytokines released during disease 
progression is seen to activate many of the signalling cascades studied within 
this thesis. These data show the model used, although simplified, is a relevant 
model for understanding the signalling events involved in the induction of 
collagenase gene expression that occurs in disease progression. Many have 
been shown, like IL-1 in combination with OSM to signal and activate MAPK 
signalling leading to the induction of AP-1 gene expression (Chakraborti et al., 
2003, Yan and Boyd, 2007). This in vitro model therefore demonstrates the 
activation of signalling events believed to occur within the chondrocytes during 
disease.  
During this thesis the cell line SW1353 was used to gain further insight into the 
regulation of collagenase gene expression within chondrocytes. This cell line 
was used to optimise many experiments and understand the regulation of 
collagenase gene expression. This cell line, although a good model for 
understanding the role of each isoform of PKD within chondrocytes, did have its 
limitations. Differences in the regulation of the MAPK signalling pathways under 
PKD1 regulation were observed in SW1353 cells and HAC. These differences 
did not alter the effect PKD1 had on collagenase gene expression, suggesting 
that different signalling events were involved in the modulation of collagenase 
gene expression within the two cell types. Also, PKD2 was shown to regulate 
collagenase gene expression in SW1353 cells, whereas this did not occur in 
HAC. These data show the importance of using primary cells, as although 
sometimes difficult to acquire and manipulate, they can give a greater 
understanding of the signalling events and gene induction that occur within 
disease.  
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6.1 The importance of developing and optimising tools capable of 
silencing each isoform of PKD specifically 
In this thesis, the role of each isoform of PKD was studied to understand their 
individual roles in modulating the expression of MMPs. Most current studies 
have examined PKD as an ‘entity’, with work focusing on the family as one 
kinase or examining the isoform PKD1 only. When I began this work, no data 
were published on the roles of each isoform of PKD within the same cell type; I 
therefore set out to understand the individual roles of each isoform of PKD in 
chondrocytes.  
To assess each PKD isoform, establishing robust and specific biological tools to 
silence and/or over-express these isoforms of PKD was crucial; siRNA-
mediated gene silencing was first used. siRNA was chosen over biological 
inhibitors due to the lack of specificity between isoforms, with similar IC50 values 
being found for each isoform of PKD for all PKD inhibitors available (Harikumar 
et al., 2010, George et al., 2011). As well as this, the specificities of most of 
these newly synthesised PKD inhibitors have not been fully elucidated, i.e., with 
kinome scans, and therefore off-target effects cannot be exluded. To study the 
effects of each PKD isoform on collagenase gene expression it was crucial to 
ensure that each PKD isoform was being specifically silenced.  
Lentiviral-mediated delivery of shRNA was also used in this work. This method 
of shRNA delivery has many advantages over transient transfection, with 
constant expression of the shRNA occurring. This increased the chances of 
gene and protein silencing, as increasing numbers of shRNA are present 
throughout the experiment. This is thought to be the explanation for the ability of 
shRNA to decrease the protein level of PKD1 compared to the transient delivery 
of siRNA, as siRNA half-life was no longer problematic. PKD1 over-expression 
was also optimised during the time taken to develop lentiviral-mediated delivery 
of shRNA, and work showed that the use of ionic polymers was best to achieve 
over-expression of PKD1. All of the time invested to develop specific and robust 
gene silencing or over-expression methods for the isoforms of PKD ensured 
that I could be confident that any effects observed on collagenase gene 
expression and signalling pathways could be accounted for by the individual 
isoforms of PKD.  
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6.2 Collagenase gene expression is regulated in an Isoform specific 
manner 
Once the tools enabling the silencing and over-expression of PKD isoforms 
were established, the effects of each individual isoform on MMP-1 and MMP-13 
gene expression were assessed. PKD has not been previously studied in 
chondrocytes or in the regulation of collagenase gene expression within the 
context of arthritis. However, PKD has been extensively studied in relation to 
MMP gene regulation and cancer progression. MMPs are known to be involved 
in cancer metastasis and cell mobility (Eiseler et al., 2009, Wille et al., 2013), 
with work focussing on the role of PKD1 in the expression of MMPs in both 
prostate and breast cancer cells. Data have suggested opposing roles for PKD1 
in the regulation of MMP gene expression, with this being dependent on cell 
type (Eiseler et al., 2009, Biswas et al., 2010). Data are now beginning to 
emerge on the roles of PKD2 and PKD3 in the regulation of MMP gene 
expression within these cell types (Zou et al., 2012, Bernhart et al., 2013). 
Interestingly opposing roles for PKD1 compared to PKD2 and PKD3 are being 
observed, even within the same cell type (Borges and Storz, 2013, Wille et al., 
2013).  
When examining the effects of PKD in relation to collagenase gene expression 
in HAC stimulated with IL-1 in combination with OSM, opposing roles between 
all three isoform of PKD are seen. These data show that three closely related 
isoforms can have distinct roles in the regulation of the expression of the same 
genes under the same stimulus. These data suggest a mechanism by which 
each isoform counteracts the other in chondrocytes under an inflammatory 
stimulus, demonstrating how within chondrocytes these closely related kinases 
attempt to counteract the effects of an influx of inflammatory cytokines into the 
synovial joint and prevent ECM remodelling.  
As well as the regulation of the gene expression of the classical collagenases 
(MMP-1 and MMP-13), other matrix degrading MMPs known to be crucial in the 
degradation of the ECM of cartilage were studied. Differences within the 
proximal promoters of each MMP have been seen (Rowan and Young, 2007, 
Vincenti et al., 1998); this could account for the differential effects PKD1 and 
PKD3 had on the expression of these MMPs. Results presented demonstrate 
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PKD3 silencing to reduce MMP-8 expression, whereas PKD1 silencing had no 
effect on the expression of this MMP. MMP-8 is seen to have an Erythroid-
specific transcription factor binding site (NF-E1); this transcription binding site is 
not found in the promoter any of the other MMPs studied. PKD3 may therefore 
have the capability of regulating this protein, inducing the expression of MMP-8 
in healthy chondrocytes. EGR1 is also only found within the promoter of MMP-
14 compared to the MMPs studied, PKD1 may therefore only regulate the 
expression of this transcription factor leading to modulation in MMP-14 
transcription, all of this is only speculation with no data to back up these 
theories. These data provide further understanding into the global 
consequences of individual PKD isoform inhibition on total MMP gene 
expression. If any isoform of PKD were to be examined as a potential 
therapeutic for arthritis, the consequence of their inhibition on MMP gene 
expression as whole would need to be fully understood. 
MMP-1 and MMP-13 are not solely expressed within chondrocytes, with each 
enzyme being expressed within other cell types found within the joint, as well as 
the invading immune cells. MMP-13 expression is mainly limited to 
chondrocytes and bone, but fibroblasts as well as the invading macrophages 
have been demonstrated to express MMP-13 (Cawston and Wilson, 2006). 
MMP-1 is ubiquitously expressed within many cell types within the joint 
including; macrophages, fibroblast, endothelial and epithelial cells (Cawston 
and Wilson, 2006, Vincenti and Brinckerhoff, 2002). Inhibition of the signalling 
events in chondrocytes cannot therefore reduce complete expression of these 
ECM degrading enzymes, but has the potential to significantly down regulate 
the levels of these cartilage degrading enzymes at the site of cartilage 
degradation. Understanding the regulation of collagenase gene expression 
modulated by PKD in other tissues of the joint would provide further information 
into the wider consequences of PKD inhibition within the joint, if ever taken 
further as a potential arthritis therapeutic. These data are of even more 
importance as cell specific regulation of MMP gene expression has been 
observed (Eiseler et al., 2009, Biswas et al., 2010). 
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6.3 PKD signalling regulation 
Once observations of differential regulation of MMPs by specific PKD isoforms 
had been demonstrated, I next sought to understand the signalling cascades 
each regulated. The MAPK signalling pathways have been shown to be 
important in the induction of collagenase gene expression within chondrocytes, 
but not fully understood (Rowan and Young, 2007). Signalling via JNK and ERK 
pathways activated by IL-1 leads to the phosphorylation and activation of the 
AP-1 family member Jun, inducing dimerization with Fos, which then drives the 
transcription of various MMP genes, including MMP-1 and -13 (Vincenti and 
Brinckerhoff, 2002). p38 is also seen to recruit the AP-1 complex to the 
promoter of MMP-13, leading to increased transcription (Mengshol et al., 2001). 
The consequences of PKD gene silencing on these signalling pathways is 
therefore crucial in understanding how each isoform of PKD regulates MMP-1 
and MMP-13 gene expression. 
PKD1 silencing data suggested that the MAPK signalling pathways were not 
sufficient in the regulation of collagenase gene expression in HAC when 
phosphorylated by this isoform. Data showed MAPK signalling to be inhibited by 
this isoform, but signalling events still led to an increase in collagenase gene 
expression. These data suggested that other signalling consequences may be 
necessary in addition to the MAPK pathway signalling events when regulated by 
PKD1. However, PKD3 silencing data clearly showed the importance of the 
MAPK pathway in regulating collagenase gene expression, implicating MAPK 
regulation as a key process in PKD3 driven induction of collagenase gene 
expression. This data suggests that other signalling pathways may be involved 
in the induction of collagenase gene expression than just MAPK regulation, with 
the total signal transduced by each isoform needed to be taken into account, 
rather than looking at one specific signalling cascade.  
PKD2 data showed this isoform only regulated the phosphorylation of the MAPK 
pathways when stimulated within IL-1 alone, whilst the addition of OSM 
appeared to mask these effects. When examining the consequences of PKD2 
silencing on collagenase gene expression under the stimulus of IL-1 alone, no 
effect on collagenase gene expression is observed, even with MAPK signalling 
being down-regulated. These data suggest that PKD2 has the potential to 
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regulate collagenase gene expression under this stimulus of IL-1 alone via 
MAPK regulation. One explanation for the modulation of the MAPK pathways 
but lack of downstream gene expression could be due to threshold levels of 
phosphorylation. The activation of signalling pathways is dependent on a 
threshold level of phosphorylation being met, with this level being exceeded for 
signal transduction to occur (Ferrell, 1996). The MAPKs pathways contain 
levels of complexity due to their three tiered system of activation. This system 
allows the action of this pathway to have numerous different cellular outcomes, 
dependent on stimuli. Here, it can be thought that the resting state of the MAPK 
could be well below the threshold level of phosphorylation needed to reach 
signal transduction. Therefore a small change in the levels of phosphorylation 
may lead to no signal transduction, with this being filtered out as noise (Ferrell, 
1996). This could be one explanation for how PKD2 can regulate the 
phosphorylation of JNK, ERK and p38 under the stimulation of IL-1, but have no 
downstream signalling effects, with the changes in phosphorylation observed 
being unable to exceed the threshold level needed for signal transduction.  
As well as the MAPKs, the PI3K signalling cascade has been implicated in the 
regulation of collagenase gene expression. The downstream substrate of the 
PI3K signalling pathway, Akt, has also been shown to modulate collagenase 
gene expression (Litherland et al., 2008). The downstream events of these 
pathways however remained unclear. Akt has been shown to regulate 
numerous downstream signalling cascades (Fresno Vara et al., 2004) and 
therefore understanding the downstream signalling consequences of PI3K and 
Akt may help to understand their role in the regulation collagenase gene 
expression  
PKD1 gene silencing in HAC showed a marked increase in the phosphorylation 
of Akt, the downstream signalling consequences of this however remained 
unclear, with Litherland et al, 2008 not showing any downstream signalling 
consequences. One known transcription factor, downstream of Akt, is NFκB.  
PKD1 modulation of Akt signalling may therefore decrease the activity of the 
NFκB signalling pathway, a known modulator of collagenase gene expression 
(Fan et al., 2006, Radwan et al., 2013, Mengshol et al., 2000). Data presented 
in this thesis show PKD1 silencing in HAC stimulated with IL-1 in combination 
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with OSM to increase p65 phosphorylation at its serine 536 phosphorylation site 
(Figure 5.8). This data opposes data presented by (Storz and Toker, 2003). 
PKD1 signalling in HAC stimulated with IL-1 in combination with OSM may 
therfore inhibit Akt, preventing its phosphorylation of IKK, inhibiting IκBα 
dissociation, leading to a reduction in the phosphorylation of p65, preventing its 
translocation to the nucleus and induction of MMP gene expression. These data 
suggest a potential negative feedback mechanism by which PKD1 can 
modulate transcriptional changes in collagenase gene expression. This 
mechanism does however have the potential to by Akt independent with IKK 
activation being seen to be directly modulated by IL-1, suggesting a further level 
of regulation of NFκB signalling by PKD1 under this stimulus.  
PKD2 and PKD3 silencing in HAC stimulated with IL-1 in combination with OSM 
had no effect on the phosphorylation of Akt, suggesting these isoforms do not 
signal through this pathway. No effect of NFκB signalling was seen either (data 
not shown).  
As well as activating the MAPK and PI3K signalling pathways, the pro-
inflammatory cytokine stimulus of IL-1 in combination with OSM can also 
regulate the activation of the STAT pathway. OSM mediated activation of the 
JAK/STAT pathway has been implicated in the induction of collagenase gene 
expression (Litherland et al., 2010, Catterall et al., 2001, Rowan et al., 2001) 
and may contribute to the pathogenic progression of OA and RA. The addition 
of IL-1 induces further activation of this pathway via serine phosphorylation, 
showing a point of cross talk between the IL-1 and OSM signalling pathways. 
The STAT pathway has been clearly implicated in the progression of RA, with 
the over-expression of the JAK inhibiting protein, SOCS-3, in antigen-induced or 
collagen-induced arthritis leading to a marked reduction in the phosphorylation 
of STAT-3 and reduced synovitis (Shouda et al., 2001) in mice. The importance 
of STAT signalling in arthritis is further confirmed by the development of JAK 
inhibitors, such as the drug Tofacitinib, a JAK3 inhibitor which is clinically 
available to treat RA (Rakieh and Conaghan, 2013). The data presented in this 
thesis suggest that PKD can regulate the activation of this pathway, leading to 
potential changes in collagenase gene expression. The opposing roles of PKD1 
and PKD3 in the serine phosphorylation of STAT-1 and STAT-3 suggest a 
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possible explanation for the opposing effects these two proteins have on 
collagenase gene expression.  
How each isoform of PKD regulates the phosphorylation of STAT-1 and STAT-3 
at their serine phosphorylation site remains unclear. This site is known to be 
phosphorylated by members of the MAPK family (Decker and Kovarik, 2000), 
but data presented in this thesis suggest that although JNK may play a role in 
the regulation of serine phosphorylation, PKD1 and PKD2 regulate this 
phosphorylation through an unknown, independent mechanism. When 
examining the literature, no data are evident linking PKD isoforms with STAT 
phosphorylation. However, stable isotope labelling of amino acids (SILAC) 
quantitative phosphoproteomic analysis was performed to detect 
phosphorylation events dependent on PKD1 activity in HEK293T cells; these 
data showed STAT-1 or STAT-3 were not detected as possible targets of PKD1 
(Franz-Wachtel et al., 2012). These data suggest that this regulation is not via 
direct phosphorylation. The mechanism by which each isoform of PKD 
regulates the phosphorylation of this site therefore still remains unclear. 
6.4 PKD and the transcriptional regulation of collagenase gene 
expression 
The AP-1 transcription factor is well established as a regulator of collagenase 
gene expression in HAC following pro-inflammatory cytokine stimulation 
(Vincenti and Brinckerhoff, 2002), including when stimulated with IL-1 in 
combination with OSM (Catterall et al., 2001). Fos and Jun are the two major 
components of this transcription factor in HAC (Catterall et al., 2001). Many of 
the signalling pathways studied have been shown to either induce the 
expression, or phosphorylate and stabilise the protein expression of both these 
transcription factors (Kok et al., 2009, Litherland et al., 2010, Catterall et al., 
2001, Gille et al., 1995, Wang et al., 2004, Cavigelli et al., 1995). The effects of 
isoform specific gene silencing on the mRNA expression of c-fos and c-jun were 
therefore examined. These data showed only PKD3 regulated their expression, 
suggesting a potential mechanism by which PKD3 signalling can lead to 
transcriptional changes in the mRNA expression of MMP-1 and MMP-13. The 
changes in expression of c-fos and c-jun as well as the phosphorylation of Jun 
may be regulated by PKD3 through the downstream activation of the MAPK and 
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STAT pathways, observed in this study. In hindsight it would have been 
interesting to have examined the effect of PKD1 silencing on the protein levels 
of Fos and Jun. As hypothesised, the expression of these may have already 
been maximally induced by IL-1 in combination with OSM, with gene silencing 
of PKD1 not further increasing mRNA expression. Increases in the duration of 
expression as well as the phosphorylation and stabilisation of these 
transcription factors may have occurred.  
A temporal lag between the maximal expression of Fos, the peak of Jun 
activation, and MMP gene expression occurs in HAC stimulated with IL-1 in 
combination with OSM. At 1 hour this maximal expression and activation of c-
fos and c-jun is seen, where as it takes 24 hours for peak MMP gene 
expression to occur. To understand this, the expression of factors which were 
induced as a direct consequence of AP-1 transcription were identified 
(Macdonald, 2013). The effect of PKD3 silencing on the expression of these 
factors was assessed. PKD3 was shown to regulate the expression of EGR2, 
BMP-2, NFATc1 and ATF3. This may be a direct result of AP-1-mediated 
transcription, but also a consequence of transcriptional changes modulated by 
the regulation of signalling pathways shown to be activated by PKD3 (Rockel et 
al., 2009, De Croos et al., 2007, Lu et al., 2007). As the expression of these 
factors occurred at an early time, further transcription factors may be expressed 
subsequently. One such example is RUNX2, which is known to regulate MMP-
13 gene expression (Mengshol et al., 2001) and has been shown to be 
regulated by PKD (Jensen et al., 2009). RUNX2 is known to be induced by 
ATF3 and BMP-2 suggesting this as a possible mechanism (James et al., 2006, 
Jensen et al., 2009). 
6.5 PKD as a potential therapeutic target 
The role of the MMP family in disease is contradictory, with opposing roles in 
the progression and inhibition of different diseases reported. As well as their 
importance in disease, MMPs are shown to be important in normal physiology. 
They are shown to be crucial in development, with remodelling of ECM needed 
for bone deposition (Johansson et al., 1997) and also in wound healing (Ravanti 
and Kahari, 2000). As a consequence, broad-spectrum MMP inhibition is not 
thought to be a viable therapeutic option for the treatment of arthritis. Such 
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inhibitors were shown to be ineffective, with many drugs causing 
musculoskeletal side-effects (Clark and Parker, 2003). Therefore, 
understanding the upstream signalling events which lead to the induction of 
these catabolic enzymes, under a pro-inflammatory context similar to that 
observed in disease, may lead to the discovery of potential novel therapeutic 
targets. Understanding the global signalling consequences activated during 
disease will give further insight into the possible outcomes of drug inhibitors, 
and will help provide specificity of the drug, leading to reduced side effects.  
There are currently no treatments that inhibit the cartilage destruction observed 
in OA, and treatments for RA can be expensive and seen to be ineffective in 
many patients. With an ageing population and increased disease burden, the 
development of new therapies to treat age related disease is crucial. The 
success of current biological therapies suggests that targeting key signalling 
mediators is a viable therapeutic strategy. Data presented in this thesis have 
demonstrated that PKD3 is able to specifically inhibit MMP-1 and MMP-13 
expression, suggesting this kinase to be a possible therapeutic target for both 
OA and RA. However, a better understanding of the mechanisms by which 
PKD3 mediates collagenase gene expression is needed. For PKD3 to become 
a viable therapeutic target the development of isoform-specific inhibitors are 
needed. Isoform specific inhibitors are thought as potential therapeutics for the 
treatment of cancer patients, with the need for PKD3 specific inhibitors also 
required, as results show that PKD1, like in chondrocytes, PKD1 down 
regulates MMP gene expression (Borges and Storz, 2013). Once such inhibitors 
are available they may be even more effective in combination with other 
currently used therapeutics. 
The current study further highlights the complexity that underpins MMP gene 
regulation following an inflammatory stimulus, with multiple points for cross-talk. 
A detailed understanding of these signalling events activated during disease 
progression will help to understand the processes involved in the induction of 
proteolytic enzymes that induce cartilage degradation. IL-1 and OSM, although 
not the only pro-inflammatory cytokines involved in disease progression, 
activate a multitude of signalling pathways known to be stimulated by other 
proinflammatory cytokines during disease. The understanding of signalling 
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kinases activated by many of the inflammatory mediators expressed during 
disease provides a more specific and targetable approach to treating disease, 
compared targeting one of the cytokines elevated during disease. 
6.6 Future work 
The work in this thesis highlights the importance of the individual isoforms of 
PKD in the regulation of collagenase gene expression. A number of points are 
raised into the possible mechanism by which each isoform is capable of 
achieving this regulation. Future work is therefore required to address these 
questions as well as confirming some of the conclusions made in this study. 
 To further implicate PKD in MMP regulation and cartilage degradation, 
the effects of pan PKD inhibition, using the PKD specific inhibitor kb NB 
142-70, on collagen release could be assessed. Using the bovine nasal 
hydroxy proline assay, bovine nasal cartilage treated with IL-1 in 
combination with OSM with or without the inhibitor could be used to 
assess the effects of PKD on collagen release. This assay could also be 
performed on bovine or human cartilage, although the latter is known to 
be difficult due to poor cartilage breakdown when stimulated with IL-1 in 
combination with OSM. This will provide information into the effect of pan 
PKD inhibition in cartilage degradation.  
 Further use of the PKD inhibitor in HAC may give further clues into the 
dominant isoform of PKD in HAC. Using this inhibitor to study the effects 
of PKD inhibition on further MMPs may show a similar pattern to gene 
silencing studies.  
 The effects of PKD1 gene silencing on signalling pathways activated by 
IL-1 and OSM alone would provide further insight into the mechanism by 
which PKD1 regulates collagenase gene expression in HAC.  
 The effect of PKD2 silencing on the expression of other MMP family 
members could also be studied. This would give further insight into the 
specificity of this isoform in the regulation of MMP gene expression.  
 To gain further insight into the regulation and phosphorylation of PKD, 
further gene silencing studies of all PKC isoforms could be performed. 
This would provide further information into the regulation of PKD activity 
via IL-1 and OSM stimulation in HAC.  
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 Each isoform of PKD was shown to regulate the phosphorylation of the 
MAPK pathways. The level at which each isoform of PKD regulates this 
phosphorylation still remains unclear within HAC. Phospho-MAP2K and 
phospho-MAP3K antibodies could be used to identify the level at which 
PKD regulates the MAPK pathways.  
 The effect of PKD1 gene silencing on the nuclear translocation of NFκB 
could be studied. This would give a greater understanding of the role of 
this transcription factor in the regulation of collagenase gene expression 
via PKD1 induction.  
 The effects of PKD1 silencing on post-AP-1 transcription factors could 
also be studied. If, as speculated, PKD1 modulates Jun expression, it 
would be interesting to understand whether PKD1 also modulates the 
expression of these transcription factors.  
 As previously mentioned ATF3 has been shown to induce the expression 
of RUNX2, a known MMP-13 gene expression regulator. PKD has also 
been implicated in regulation of RUNX2 gene expression. This suggests 
a potential mechanism by which PKD3 could modulate the expression of 
RUNX2 through inducing ATF3. The effects of PKD3 gene silencing on 
the expression of RUNX2 could therefore be studied. The time point at 
which RUNX2 expression occurred would also be of interest. If as 
expected the expression of this transcription factor is dependent on 
ATF3, this could help explain the temporal lag between AP-1 gene 
transcription and MMP gene expression.  
 To further confirm the data observed in HAC stimulated with IL-1 in 
combination with OSM and PKD, further pro-inflammatory cytokines seen 
to be elevated in arthritic disease, could be used to stimulate HAC and 
the assess the effects of PKD signalling. This would give further insight 
into the role of these proteins in the regulation of collagenase gene 
expression within a further arthritic context. These data would also give 
further insight into the usefulness of IL-1 in combination with OSM as a 
model to study the signalling pathways activated during inflammation 
during arthritic disease. 
 To fully understand the role of PKD in the regulation of collagenase gene 
expression within the joint, the role of each isoform of PKD in the 
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modulation of MMP gene expression could be studied in further cell 
types found within the joint. As cell-specific roles of PKD in the induction 
of MMPs are seen, this may indicate the impact of isoform specific 
inhibition of each isoform of PKD within the whole joint.  
6.7 Summary 
This study has demonstrated the individual roles of each isoform of PKD in the 
regulation of collagenase gene expression under the pro-inflammatory cytokine 
stimulus of IL-1 in combination with OSM in HAC. Each isoform has been 
shown to differentially regulate collagenase gene expression, with PKD1 
inhibiting MMP-1 and MMP-13 gene expression, PKD2 not being involved in 
their regulation and PKD3 promoting expression. Data have shown PKCι to 
regulate the phosphorylation of PKD in HAC stimulated with IL-1 in combination 
with OSM. This, to my knowledge, is the first example of this isoform of PKC 
regulating this phosphorylation.  
Using gene silencing the signalling events involved in the induction of 
collagenase gene expression were shown to be differentially regulated by each 
isoform of PKD under this pro-inflammatory stimulus. Data imply PKD1 inhibits 
the expression of MMP-1 and MMP-13 through the inhibition of STAT-1 
phosphorylation. This loss of phosphorylation may prevent the transcriptional 
activity of STAT-1. PKD1 also inhibits Akt signalling, which is a known regulator 
of collagenase gene expression under this stimulus; NFκB has the potential to 
be a downstream transcription factor involved in this process. Although PKD2 
regulated the serine phosphorylation of STAT-1 and STAT-3, the lack of 
modulation of the MAPKs, in IL-1 in combination with OSM stimulate cells, 
appears to prevent this isoform from regulating collagenase gene expression. 
PKD3 on the other hand induces collagenase gene expression through the 
induction of all three MAPK pathways, as well as priming STAT-1 and STAT-3 
for transcription through serine phosphorylation. These differences in the 
signalling pathways regulated may explain why only PKD3 regulated the 
expression of the key collagenase transcription factor AP-1, with the modulation 
of both the MAPKs and STAT pathway needed for significant changes in 
expression to be observed.  
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The potential mechanisms by which each isoform of PKD modulate MMP gene 
expression can be seen in Figure 6.1, Figure 6.2 and Figure 6.3. Overall, I have 
shown the importance of studying the individual isoforms of a kinase family 
within one cell type, with opposing effects being observed on gene expression 
under the same stimulus via closely related proteins.  
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Figure 6.1. Diagram summarising the potential signalling consequences of PKD1 in HAC 
stimulate with IL-1 in combination with OSM. PKD1 phosphorylates all three MAPK 
pathways, but this appears not to regulate collagenase gene expression. PKD1 signalling 
inhibits the phosphorylation of STAT-1 at its tyrosine and serine sites, while phosphorylating 
STAT-3 only at its serine site. PKD1 also inhibits Akt signalling, which may modulate 
collagenase gene expression via NFκB.  
 
? 
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Figure 6.2. Diagram summarising the potential signalling consequences of PKD2 in HAC 
stimulate with IL-1 in combination with OSM. PKD2 signalling inhibits the phosphorylation of 
p38 but no other MAPK; this inhibition appears to have no effect on collagenase gene 
expression. PKD2 signalling leads to the phosphorylation of STAT-1 and STAT-3 at their serine 
phosphorylation sites. This phosphorylation does not have any downstream transcriptional 
consequences in relation to MMP-1 or MMP-13.  
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Figure 6.3. Diagram summarising the potential signalling consequences of PKD3 in HAC 
stimulate with IL-1 in combination with OSM. PKD3 signalling phosphorylates all three 
MAPK, this has the potential to lead to the induction of c-fos and c-jun gene expression as well 
as increase the transcriptional activity of both c-Fos and c-Jun via their phosphorylation. PKD3 
also phosphorylates STAT-1 and STAT-3 at their serine phosphorylation sites. This 
phosphorylation may lead to the induction of c-fos gene expression via binding to the SIE 
element of the c-fos promoter. The induction of Fos and Jun may also increase the expression 
of many post-AP-1 transcription factors and cytokine, which can then induce the expression of 
MMP-1 and MMP-13. 
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7 Appendices 
7.1 The effect of the PKD inhibitor kb NB 142-70 on cell death in HAC 
 
 
 
 
 
 
 
 
 
Figure 7.1. The cytotoxic effects of the PKD inhibitor kb NB 142-70 on cell death in HAC. 
HAC plated into 96 well plates were grown to 70% confluency and then serum starved 
overnight. The following day, 1 hour prior to stimulation, cells were treated with either DMSO, 1, 
3, 5 μM of kb NB142-70. Cells were then stimulated with IL-1 (0.05 ng/ml) ± OSM (10 ng/ml) for 
24h. The following day half the media was extracted and the cells were freeze thawed 3 times 
to ensure complete lysis. The extracted and freeze thawed medium were then used in the toxi-
light assay as described in the Materials and Methods. Percentage of cell death of HAC treated 
with the inhibitor can then be calculated. These data are accumulative of two separate 
chondrocyte populations (each assayed in hextuplicate).  
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7.2 The effect of PKD1 over-expression in SW1353 cells on collagenase 
gene expression   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. The effect of PKD1 over-expression on collagenase expression in SW1353 
cells SW1353 cells in 96 well plates were transfected with pcDNA3-PKD1 or pcDNA3.1, and 
then serum starved overnight. The following day cells were stimulated with IL-1 (0.5 ng/ml) ± 
OSM (10 ng/ml) for 24 h. Cells were lysed and lysates reversed transcribed to cDNA. Real-time 
PCR was performed for (A) MMP-1 and (B) MMP-13, 48 h after start of transfection as 
described in the Materials and Methods. Data (mean ± S.E.M.) are accumulative of at least 
three separate chondrocyte populations (each assayed in hextuplicate) presented as relative 
expression levels normalised to 18S rRNA housekeeping gene. Comparisons shown are 
specific transfected PKD isoform versus control over-expression, where **, p≤0.01, ***, p≤0.001, 
vs transfected vector. 
 
A) 
B) 
Chapter 7. Appendices 
 
214 
 
7.3 The effect of PKD1 gene silencing in SW1353 cells on collagenase 
gene expression 
 
 
 
 
 
 
 
 
 
 
Figure 7.3. The effect of PKD1 gene silencing on collagenase expression in SW1353 cells. 
SW1353 cells were plated into 96 well plates and left over-night. The following day the medium 
was removed and replaced with viral supernatant containing either a shCON or PKD1 shRNA 
#2 at a MOI of 30, in a total volume of 1 ml SFM. Polybrene at a concentration of 8 μg/ml was 
also added. Supernatant was replenished with fresh serum containing medium after 24 hours. 
Cells were then visualised 72 hours post transduction to confirm shRNA expression. Cells were 
then serum starved over-night. The following day cells were stimulated with IL-1 (0.5 ng/ml) in 
combination with OSM (10 ng/ml) for 24 hours. Cells were lysed and lysates reversed 
transcribed to cDNA. Real-time PCR was performed for (A) MMP-1 and (B) MMP-13, 96 h after 
start of transduction as described in the Materials and Methods. Data (mean ± S.E.M.) are 
accumulative data of at least three separate chondrocyte populations (each assayed in 
hextuplicate) presented as relative expression levels normalised to 18S rRNA housekeeping 
gene. Comparisons shown are specific transduced PKD isoform versus control transduced, 
where **, p≤0.01 vs shCON. 
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7.4 The effect of PKD2 gene silencing in SW1353 cells on collagenase 
gene expression 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4. The effect of PKD2 gene silencing on collagenase expression in SW1353 cell 
line. Following transfection with siRNA specific to PKD2 or non-targeting siCON (100 nM) 
SW1353 cells were stimulated with IL-1 (0.5 ng/ml) ± OSM (10 ng/ml) for 24 h. Cells were lysed 
and lysates reversed transcribed to cDNA. Real-time PCR was performed for (A) MMP-1 and 
(B) MMP-13, 72 h after start of transfection as described in the Materials and Methods. Data 
(mean ± S.E.M.) are accumulative data of at least three separate chondrocyte populations 
(each assayed in hextuplicate) presented as relative expression levels normalised to 18S rRNA 
housekeeping gene. Comparisons shown are specific transfected PKD isoform versus control 
transfection, where **, p≤0.01 vs siCON. 
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7.5 The effect of the STAT-3 inhibitor S3I-201 on cell death in HAC 
 
 
 
 
 
 
 
 
 
Figure 7.5. The cytotoxic effects of the STAT-3 inhibitor, S3I-201, on cell death in HAC. 
HAC plated into 96 well plates were grown to 70% confluency and then serum starved 
overnight. The following day, 1 hour prior to stimulation, cells were treated with either DMSO, 
200, 100, 50 μM of S3I-201. Cells were then stimulated with IL-1 (0.05 ng/ml) ± OSM (10 ng/ml) 
for 24h. The following day half the media was extracted and the cells were freeze thawed 3 
times to ensure complete lysis. The extracted and freeze thawed medium were then used in the 
toxi-light assay as described in the Materials and Methods. Percentage of cell death of HAC 
treated with the inhibitor can then be calculated. These data are accumulative of two separate 
chondrocyte populations (each assayed in hextuplicate).  
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7.6 The effect of PKD3 silencing on MMP-9 gene expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 The effect of PKD3 gene silencing on MMP-9 gene expression in human 
chondrocytes. P0 HAC were trypsinised and plated into 96 well plates and left over-night. The 
following day cells were transfected with siRNA specific to PKD3 or siCON (100 nM). 48 hours 
later cells were serum starved over-night. The following day cells were stimulated with IL-1 (0.05 
ng/ml) ± OSM (10 ng/ml) for 24 h. Cells were lysed and lysates reversed transcribed to cDNA. 
Real-time PCR was performed for MMP-9, 72 h after start of transfection as described in the 
Materials and Methods. Data (mean ± S.E.M.) are accumulative data of at least three separate 
chondrocyte populations (each assayed in hextuplicate) presented as relative expression levels 
normalised to 18S rRNA housekeeping gene. Comparisons shown are specific transfected PKD 
isoform versus control transfection, where ***, p≤0.001, **, p≤0.01, *, p≤0.05 vs siCON. 
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7.7 The effect of PKD1 shRNA mediated gene silencing on interferon 
gene expression in HAC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7. The effect of PKD1 gene silencing on interferon expression in HAC. P0 HAC 
were trypsinised and plated into 96 well plates and left over-night. The following day the 
medium was removed and replaced with viral supernatant containing either a shCON or PKD1 
shRNA #2 at a MOI of 30, in a total volume of 1 ml SFM. Polybrene at a concentration of 8 
μg/ml was also added. Supernatant was replenished with fresh serum containing medium after 
24 hours. Cells were then visualised 72 hours post transduction to confirm shRNA expression. 
Cells were then serum starved over-night. The following day cells were stimulated with IL-1 
(0.05 ng/ml) in combination with OSM (10 ng/ml) for 24 hours. Cells were lysed and lysates 
reversed transcribed to cDNA. Real-time PCR was performed for (A) interferon-α and (B) 
interferon-ƴ, 96 h after start of transduction as described in the Materials and Methods. Data 
(mean ± S.E.M.) are accumulative data of at least three separate chondrocyte populations 
(each assayed in hextuplicate) presented as relative expression levels normalised to 18S rRNA 
housekeeping gene. Comparisons shown are specific transduced PKD isoform versus control 
transduced, where **, p≤0.01 vs shCON. 
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7.8 An example of a primer dissociation curve for the primers used for 
the quantification of lentiviral RNA 
 
 
 
 
 
 
 
 
 
Figure 7.8. Primer dissociation curve. An example of the dissociation curves observed for the 
primers used for the quantification of lentiviral RNA. The One peak with no smaller peaks either 
side indicates that there were no primer dimers or secondary non-specific PCR artefacts.  
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7.9 Lentiviral packaging, envelope, PKD1 over-expression and PKD1 
shRNA plasmid maps  
 
pCMV-dR8.91 packaging plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pMD2.G envelope plasmid 
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GIPZ shRNA plasmid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRIPZ shRNA plasmid 
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HA-tagged PKD1 over-expression plasmid 
 
 
 
Figure 7.9 Plasmid maps for all plasmids used in this thesis. Plasmid maps for pCMV-
dR8.91, pMD.2G and HA.PKD were all taken from www.addgene.org, where further information 
on these plasmids can be found. Plasmid maps for TRIPZ and GIPZ plasmids were taken from 
http://dharmacon.gelifesciences.com/shrna/tripz-lentiviral-shrna-libraries/ for TRIPZ plasmids 
http://dharmacon.gelifesciences.com/shrna/gipz-lentiviral-shrna-libraries/ for GIPZ plasmids, 
where further information on these plasmids can be found. All plasmids were transfected into 
cells using JetPEI transfection reagent as described in Material and methods.   
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